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Preface 
This PhD project was supported by the Belgian National Fund for Scientific Research (Grant 
F.R.S.-FNRS-Télévie 7.4.532.15.F.) thanks to the Télévie campaign, an operation begun in 1989 
to raise funds for scientific cancer research in children and adults. This work will therefore focus 
on cancer research and, especially, deal with the epigenetic therapy of cancer. This issue was 
first addressed during my master’s thesis at the University of Namur (UNamur) completed in 
2012 in the Laboratory of Structural Biological Chemistry directed by Professor Johan Wouters.  
Tumorigenesis and tumor maintenance are controlled by genetic events but also by 
epigenetic events. These events control the expression of genes by modifications on (“epi-”) 
DNA and histones (proteins wrapping DNA into nucleosomes). As these modifications are 
reversible, it is possible to revert the cell to a normal state leading to an inhibition of cancer cell 
growth. There is a plethora of proteins involved in the epigenetic regulation of gene expression 
which may be considered as epigenetic targets for chemotherapy. Among these, we focused 
our research on human DNA (cytosine-5) methyltransferases (DNMTs) which catalyze the 
methylation of cytosine nucleotide. This epigenetic modification, 5-methylcytosine, can lead to 
the development and progression of cancer and, therefore, the discovery and optimization of 
novel epi-drugs targeting DNMTs are needed.  
To this end, structural studies of complexes between DNMTs and non-nucleoside inhibitors, 
as well as an identified epigenetic mark guiding DNA methylation, were carried out. To achieve 
this goal, several techniques including, protein expression and purification, crystallography, 
molecular modeling and enzymology were used during this thesis. The following manuscript, 
containing results obtained during the four years of doctorate study, is presented as an article 
thesis. This consists of an introduction, three main chapters and a conclusion part including 
perspectives for future work.   
Here, I would especially like to thank the Télévie for the grant, all authors of publications 
and the different collaborators met to achieve the intended goals of my thesis research. 
I hope you enjoy your reading.                                        Grégoire Rondelet 
 
Namur, December 2016 
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Résumé 
Chez les eucaryotes, la méthylation de l’ADN est une importante modification épigénétique 
contrôlant l’expression des gènes. Cette réaction de méthylation est catalysée par des enzymes 
appelées « ADN (cytosine-5) méthyltransférases » (DNMTs). Dans les cellules normales, la 
méthylation de l’ADN est impliquée, entre autres, dans la différenciation cellulaire lors de 
l’embryogenèse, l’inactivation d’un des chromosomes X chez la femme et la stabilité 
chromosomique. Cependant, dans la plupart des cancers, ce processus de méthylation est 
dérégulé et conduit au développement et à la progression des cellules tumorales. Comme cette 
modification est réversible, il est possible de renverser le profil de méthylation en inhibant 
l’activité des DNMTs et, ainsi, arrêter la progression tumorale.  
Cette thèse porte sur l’étude structurale d’inhibiteurs non-nucléosidiques des DNMTs. En 
particulier, nous avons étudié des dérivés maléimides du RG108 (RG108-1 et RG119-1). Ces 
composés ont le potentiel de réactiver des « gènes suppresseurs de tumeurs » réduits au 
silence par méthylation de leur promoteur. Les résultats ont montré une corrélation entre la 
cytotoxicité sur des cellules de mésothéliome et leur puissance inhibitrice envers les DNMTs. 
Des études théoriques, appuyées par des études cristallographiques (apo structure de la 
M.HhaI) et de fluorimétrie à balayage différentiel, ont permis de déterminer leur mode 
d'action. Nous nous sommes également intéressés à une modification post-traductionnelle des 
histones, la triméthylation de la  lysine 36 de l’histone 3 (H3K36me3). Ce marqueur 
épigénétique permet le recrutement des DNMT3s, via leur domaine PWWP, à des régions 
génomiques impliquées dans l’oncogenèse. La résolution structurale de cette reconnaissance 
biologique (domaine PWWP de la DNMT3B avec le marqueur épigénétique H3K36me3) et la 
construction d’un modèle complet de la DNMT3A en complexe avec un dinucléosome nous ont 
permis de proposer un mécanisme de reconnaissance génomique des DNMT3s. À partir de ce 
complexe, nous avons pu développer des inhibiteurs potentiels pouvant perturber l’interaction 
entre le marqueur épigénétique H3K36me3 et le domaine PWWP des DNMT3s. L’inhibition de 
cette interaction protéine-protéine empêcherait la méthylation intragénique d’oncogènes, qui 
est responsable de leur transcription.  
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Abstract 
 In eukaryotes, DNA methylation is an important epigenetic modification involved in gene 
regulation. This methylation is catalyzed by DNA (cytosine-5) methyltransferases (DNMTs). In 
normal cells, DNA methylation is involved, inter alia, in cell differentiation, embryonic 
development, X-chromosome inactivation and maintenance of chromosomal stability. 
However, in most cancers, this methylation process is deregulated and leads to the 
development and progression of tumor cells. As this modification is a reversible process, 
inhibitors targeting DNMTs are promising anticancer agents to reverse the deregulated 
methylome to stop cancer proliferation. 
This thesis deals with the structural study of non-nucleoside inhibitors of DNMTs. In particular, 
we studied maleimide derivatives of RG108 (RG108-1 and RG119-1) which have the potential 
to reactivate tumor suppressor genes. Findings demonstrated a correlation between 
cytotoxicity on mesothelioma cells of these compounds and their inhibitory potency against 
DNMTs. Non-covalent and covalent docking studies, supported by crystallographic (apo 
structure of M.HhaI) and differential scanning fluorimetry assays, provided detailed insights 
into their mode of action and revealed essential residues for the stabilization of such 
compounds inside DNMTs. We were also interested in a post-translational modification of 
histones, the trimethylation of lysine 36 of histone 3 (H3K36me3). This epigenetic mark allows 
the recruitment of DNMT3s, via their PWWP domain, for intragenic methylation of oncogenes. 
The structural resolution of this biological system (DNMT3B PWWP/H3K36me3) and the 
construction of a complete model of the DNMT3A in complex with a dinucleosome allowed us 
to propose a genomic recognition mechanism for DNMT3s. This complex led us to identify new 
potential inhibitors disrupting the interaction between the histone mark H3K36me3 and the 
DNMT3s PWWP domain. The inhibition of this protein-protein interaction would prevent the 
intragenic methylation of oncogenes, which is responsible for their transcription. 
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Chapter 1. Human DNA (cytosine-5) methyltransferases: a functional and 
structural perspective for epigenetic cancer therapy 
Grégoire Rondelet* and Johan Wouters 
Department of Chemistry, NAmur MEdicine & Drug Innovation Center (NAMEDIC-NARILIS), University 
of Namur, 61 rue de Bruxelles, B-5000 Namur, Belgium 
*Corresponding author: gregoire.rondelet@unamur.be 
† In preparation 
Personal contribution: Performed literature search, generated figures and tables, and wrote 
the manuscript. 
Abstract 
Epigenetic modifications modulate chromatin states to regulate gene expression. Among 
them, DNA methylation and histone modifications play a crucial role in the establishment of 
the epigenome. In cancer, these epigenetic events may act in concert to repress tumor 
suppressor genes or promote transcription of oncogenes. In the context of cancer initiation 
and progression, recruitment of DNA (cytosine-5) methyltransferases to specific genomic 
regions is mediated by histone epigenetic marks, transcription factors and co-regulators. This 
introductory chapter will review these mechanisms and present state-of-the-art of DNA 
methylation, treatment and development of epigenetic cancer therapies targeting this 
epigenetic modification. 
Keywords: Cancer, DNA methylation, Promoter hypermethylation, Gene body methylation, 
DNMT, DNMT inhibitors, Epigenetic therapy 
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1.1 From genome to epigenome 
Initiated in 1990, the Human Genome Project finished sequencing and mapping all the genes 
of Homo sapiens in 2003 (Consortium, 2004). This complete genome, ~3.109 DNA base pairs 
distributed among 23 chromosome pairs, contains all the genetic information essential for 
human life. With the complete genome sequence as a powerful tool, research tends to 
understand cancer by discovering genetic mutations located in certain genomic regions and 
the functions of various genes in order to establish new treatment strategies. However, 
genome sequence is just a part of a more complex system involved in gene expression 
regulation.  
 Indeed, DNA is a dynamic molecule organized in chromatin structure in which 
nucleosomes (histone octamer core around which DNA is wrapped) are the basic units. These 
units can be arranged to give an open (euchromatin) or a closed (heterochromatin) form of 
chromatin in local regions (Fig. 1). Euchromatin is associated with transcriptional activation, 
whereas heterochromatin blocks DNA accessibility to transcription machinery and conducts 
to inactivation of gene expression (Keshet et al., 1986). This chromatin remodeling is 
controlled essentially by chemical modifications on DNA (DNA methylation) and histone tails 
(methylation and/or acetylation) which define the epigenome (Fig. 1).  
 
Figure 1. Representation of a local chromatin modification regulating gene expression. Depending 
on the cellular context, the epigenetic modifications, such as DNA methylation and histone 
modifications, will modulate the chromatin state to control gene expression. Euchromatin and 
heterochromatin result from these modifications and, consequently, are associated with distinct 
epigenomic patterns. Euchromatin is transcriptionally permissive, while heterochromatin is 
transcriptionally repressive.  
  Introduction | 1 
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These modifications, which occur without a change in DNA sequence, are heritable, 
reversible and response to external signals (Berger et al., 2009; Jaenisch and Bird, 2003; Wolffe 
and Matzke, 1999). Epigenetic events are essential for interpreting the genome in normal and 
abnormal cells. Recently, a great progress in the comprehensive analysis of the chromatin 
remodeling was reached with a paper published in PNAS (Almassalha et al., 2016). This study 
revealed a new imaging technique to study the chromatin dynamic and organization in real 
time from the nucleosomal (10 nm) to chromosomal (> 200 nm) length scales allowing, for 
example, to investigate the effect of a drug on cancer cells. As an overview, genome is the 
blueprint for coding proteins, and the epigenome controls the access to this genetic 
information. In 2008, an international project, named “Alliance for the Human Epigenome 
and Disease”, was set up to decode the human epigenome, just as the Human Genome 
Project, to have a better understanding of disease mechanisms with direct implications in 
prevention, diagnosis and treatment of human diseases (Jones et al., 2008). In this spirit, the 
US National Institutes of Health Roadmap Epigenomics Mapping Consortium produces a 
public resource of epigenome maps and proposes standardization of protocols for the 
research community (Bernstein et al., 2010). 
Modulation of local chromatin states to regulate gene expression is achieved by a 
plethora of chromatin-binding proteins assigned to different mechanisms such as editing the 
epigenome (writing or erasing it) or reading it. A nice example combining these mechanisms 
is the interplay between DNA methylation and histone modifications to silence genes: the 
“writers” DNA methyltransferases (DNMTs) deposit DNA methylation on cytosine in CpG 
(cytosine-phosphate-guanine) dinucleotides, then “readers” methyl-CpG-binding domain 
proteins (MBPs) recognise methylated DNA and recruit histone deacetylases (HDACs) as 
“erasers” of histone acetylation. Resulting hypoacetylated histones lead to chromatin 
condensation (heterochromatin), preventing DNA binding factors and, consequently, form a 
stable gene silencing (Fig. 1) (Bird, 2002; Klose and Bird, 2006).  
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1.2 Epigenome in diseases 
Epigenetic modifications control the precise expression of cell genes and are then crucial for 
cell differentiation, embryonic development, X-chromosome inactivation and maintenance of 
chromosomal stability (Fig. 2) (Mohn and Schübeler, 2009; Riggs, 1975; Wutz, 2011). However, 
epigenetic dysregulation occurs in multiple diseases, including diabetes, cardiopulmonary 
diseases, neurological disorders, imprinting disorders, autoimmune diseases and cancer 
(Esteller, 2008; Jones, 2012; Jones et al., 2008; Shirohzu et al., 2002; Tatton-Brown et al., 2014; 
Wang et al., 2008). As epigenetic modifications are heritable and reversible in somatic cells, 
epigenomic patterns could be reversed to a normal cell phenotype by drug treatments. In this 
sense, Epi-drugs (chromatin-modulating agents) targeting DNA methylation, histone 
deacetylation, methylation and demethylation, or histone readers are developed to treat 
cancer (Erdmann et al., 2015; Falkenberg and Johnstone, 2014; Miranda et al., 2009; Zhao et 
al., 2013).  
1.3 Cancer DNA methylome 
To introduce this part, the following timeline (Fig. 2) presents the fundamental findings of 
DNA methylation, which is one of the most important epigenetic modifications. 
 
Figure 2. Timeline of fundamental findings of DNA methylation. (Riggs, 1975): DNA methylation 
explains the initiation and maintenance of mammalian X inactivation. (Keshet et al., 1986): CpG 
methylation is linked with alterations in chromatin structure and gene silencing. DNA methylation 
affects interactions between DNA and nuclear proteins. (de Bustros et al., 1988): One of the first 
example of hypermethylation of tumor suppressor genes in a human cancer associated with gene 
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inactivation. (Eden et al., 1998): Proteins belong to the family of methyl-CpG-binding domain proteins 
(MBPs) recruit histone deacetylases (HDACs) to mediate transcriptional repression. (Okano et al., 
1999): DNMT3A and DNMT3B are required for de novo methylation. (Suetake et al., 2004): DNMT3L 
(DNA methyltransferase 3-like protein) stimulates the activity of DNMT3A and DNMT3B for maternal 
methylation imprinting. (Chodavarapu et al., 2010): DNMTs preferentially target nucleosome-bound 
DNA. (Yang et al., 2014): Gene body methylation is correlated with gene transcription and represents 
a new therapeutic target.   
DNA methylation occurs on cytosine at the C5 position (5-methylcytosine, 5-mC) of CpG 
(Cytosine-phosphate-Guanine) dinucleotides and is catalyzed by DNA methyltransferases 
(DNMTs) (Fig. 3) (Bestor, 2000).  
 
Figure 3. DNA methylation at the C5 position of cytosine catalyzed by DNMTs in the presence of the 
SAM cofactor as methyl group donor. SAM: S-adenosyl-L-methionine, SAH: S-adenosyl-L-homocysteine 
 The distribution of 5-methyl cytosine throughout the genome depends on the genomic 
and epigenomic contexts during development and disease (Hackett and Surani, 2013). As an 
important remark, the function of DNA methylation is related to CpG density and their 
localization on the genome. Thereby, methylation of promoter CpG islands (CGIs) is correlated 
with transcriptional silencing of the gene, whereas intragenic methylation, or so-called gene 
body methylation, at lower CpG density or certain CGIs is associated with gene expression (Fig. 
4) (Ball et al., 2009; Rakyan, 2008; Deaton et al., 2011; Meissner et al., 2008; Nguyen et al., 
2001; Weber et al., 2007).  
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Figure 4. Proposed model for dual function of DNA methylation in gene regulation. Promoter methylation (top): hypermethylation of CGIs in a gene promoter 
is associated with gene inactivation (de Bustros et al., 1988). Gene body methylation (bottom): In cancer, gene body CpGs are preferential sites for de novo 
methylation (Nguyen et al., 2001). This gene body methylation is associated with gene expression (Ball et al., 2009). Combination of permissive histone 
epigenetic marks H3K4me0 and H3K36me3 are necessary for gene body methylation (Stewart et al., 2015; Tomizawa et al., 2012). 
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 When DNA methylation is associated with transcriptional repression, the heterochromatin 
is formed and the compacted nucleosomes block RNA polymerase transcription (Jones and 
Liang, 2009). Conversely, gene body methylation promotes transcriptional elongation (Ball et 
al., 2009). Deregulation of these DNA methylation patterns contribute to tumorigenesis and 
tumor maintenance. Indeed, in cancer, promoter hypermethylation of CpG islands in tumor 
suppressor genes (TSGs) promoters (e.g., TP53 encoding p53 essential for apoptosis induction) 
leads to their inactivation (de Bustros et al., 1988; Hansen et al., 2011; Irizarry et al., 2009; 
Rideout et al., 1990). On the other hand, gene body methylation is associated with activation 
of oncoprotein-regulated genes as observed in colon cancer cell lines (Yang et al., 2014). 
1.4 Human DNA (cytosine-5) methyltransferases  
Human DNMTs are classified in two families (DNMT1 and DNMT3s) that are structurally and 
functionally distinct (Cheng and Blumenthal, 2008). DNMT3A and DNMT3B are de novo 
methyltransferases as they establish the initial CpG methylation pattern during 
embryogenesis (Li et al., 2007; Okano et al., 1999). They are coupled with the inactive DNMT3-
Like (DNMT3L) to stimulate their activity (Chédin et al., 2002; Jia et al., 2007). The pattern of 
methylation is then maintained during chromosome replication by DNMT1 (Chen and Li, 
2006).  
Structurally, these enzymes (DNMT1 and DNMT3s) possess a N-terminal regulatory 
domain and a C-terminal catalytic domain (Fig. 5) (Jeltsch, 2002; Jurkowska et al., 2011). In 
mammals, the N-terminal domain guides their localization to chromatin by interacting with 
other proteins and DNA, and regulates their intrinsic activity. The C-terminal catalytic domain 
has six highly conserved motifs involved in DNA binding and catalysis of methyl transfer. 
Residues in motifs I and X are involved in the cofactor binding, motifs IV, VI and VIII are 
responsible for the target-base binding and the catalysis, and motif IX is involved in DNA 
recognition (Fig. 5 and Fig. S4 in chapter 2). DNMT3L lacks essentials motifs for DNA and 
cofactor binding (IX and X) and is catalytically inactive (Bourc'his et al., 2001).
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Figure 5. Schematic representation of the domain structure of mammalian DNMT isoforms. Blue portions reveal domains structurally solved. I, IV, VI, IX and 
X are conserved motifs of the active C-terminal catalytic domain of DNMTs (red box). DNMT1 has a large regulatory domain comprising a DNA 
methyltransferase associated protein (DMAP), a nuclear localization signal (NLS), a replication foci targeting sequence (RFTS), a cysteine-rich (CXXC) DNA 
binding domain and bromo-adjacent homology domains 1 and 2 (BAH1 and BAH2). The autoinhibitory linker (Auto) between CXXC–BAH1 prevents de novo 
methylation (Song et al., 2011). N-terminal part of DNMT3A and DNMT3B have an ATRX–DNMT3–DNMT3L (ADD) domain and Pro–Trp–Trp–Pro (PWWP) 
domain for activity regulation and nucleosome recognition (Baubec et al., 2015; Guo et al., 2015). Catalytically inactive DNMT3L possesses only an ADD domain 
on the N-terminal part. This isoform stimulates the activity of DNMT3A and DNMT3B (Jia et al., 2007). 
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1.5 Bacterial DNA methyltransferases - Their use as model in cancer research 
Bacterial DNMTs possess only the C-terminal catalytic domain required for methyltransferase 
activity. In prokaryotes, DNA methylation (adenine or cytosine methylation) controls initiation 
of DNA replication, protects cells from foreign DNA through restriction-modification systems 
and plays an essential role in bacterial virulence (e.g., Mycobacterium tuberculosis and 
Brucella) (Low et al., 2001; Shell et al., 2013).   
 In cancer research, two C5-DNA methyltransferase bacteria (M.SssI from Spiroplasma and 
M.HhaI from Haemophilus haemolyticus) serve as model to investigate the inhibition 
mechanism of human DNMTs. Indeed, they share a high structural homology and sequence 
identity with human DNMTs for the conserved motifs involved in DNA binding and catalysis 
of methyl transfer (see Fig. S4 in chapter 2). M.SssI (376 aa) completely methylates CpG 
sequences in a processive manner and was validated for use in activity assays in epigenetic 
studies due to its high efficiency and fast reaction rate (Renbaum et al., 1990). Conversely, 
M.HhaI (325 aa) recognizes and methylates the sequence 5'-GCGC-3' in a non-processive 
manner but is largely studied in crystallography and constitutes an appropriate model to 
investigate the inhibition mechanism of human DNMTs.  
1.6 Current treatments targeting DNA methylome 
Actually, only two drugs received FDA (Food and Drug Administration) approval as 
demethylating agent for myelodysplastic syndromes, acute myeloid leukemia and chronic 
myelomonocytic leukemia: the cytosine analogs 5-azacytidine (Vidaza®) and decitabine 
(Dacogen®) (Fig. 6) (Christman, 2002a; Issa and Kantarjian, 2009; Jones and Taylor, 1980; 
Wijermans et al., 2008). An extension of the use of these drugs to the European market was 
applied in 2008 for Vidaza® and in 2012 for Dacogen® by the European Medicines Agency. 
These inhibitors are incorporated into the DNA, and they covalently trap DNMTs (Christman, 
2002a; Issa and Kantarjian, 2009; Jones and Taylor, 1980). However, due to their high toxicity, 
low specificity, chemical instability and poor bioavailability during cancer therapy, 
development of a new generation of nucleoside drugs is ongoing (Christman, 2002b; Lyko and 
Brown, 2005). Among these, the prodrug SGI-110 derived from decitabine presents 
improvement in pharmaceutical properties and is under investigation in phase 2 clinical trials 
for the treatment of myelodysplastic syndromes and acute myeloid leukemia (Fig. 6) (Chuang 
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et al., 2010; Issa et al., 2015). Combinatorial therapy approach using nucleoside analogs is 
also used in clinical trials. In epigenetic therapy, combination of Vidaza® and Entinostat® has 
a synergistic therapeutic effect on solid tumors and abolished chemoresistance in cancer cells 
(Clozel et al., 2013; Juergens et al., 2011).  
In parallel to these advances in research on nucleoside analogs, non-nucleoside 
compounds are developed to increase specificity and selectivity towards DNMTs, and less 
cytotoxicity by acting directly on DNMTs without incorporation into DNA. For example, drugs 
used for other indications (hydralazine (antihypertensive), procainamide (antiarrhythmic), 
and procaine (local anesthetic)), several natural compounds (parthenolide, nanaomycin A, (-
)-epigallocatechin-3-gallate (EGCG, a polyphenol from green tea leaves), curcumin, genistein 
and laccaic acid A) and inhibitors discovered from virtual screening campaigns (e.g., RG108) 
have been identified as DNMT inhibitors (Fig. 6) (Erdmann et al., 2015).  
As DNA methylation occurs in normal cells, selectivity towards DNMTs is a challenging 
task to personalize treatment for cancer, and so to decrease side effects. To achieve this goal, 
current studies tend to identify the contribution of each DNMT in various cancer cells. For 
example, DNMT3A mutations occur in acute myeloid leukemia (Ley et al., 2010; Shlush et al., 
2014) and this isoform is overexpressed in melanoma cell lines (Deng et al., 2009), while 
DNMT3B is overexpressed in breast and colorectal cancers (Nosho et al., 2009; Roll et al., 
2008). It was also shown that DNMT1 and DNMT3B cooperate to maintain gene silencing in 
cancer cells (Rhee et al., 2002). The development of selective inhibitors for a particular DNMT 
isoform is therefore an important issue. However, development of non-nucleoside compounds 
targeting the catalytic domain is slowed by lack of selectivity or structure−activity relationships 
information. The only complex reported so far is the one between bacterial C5-DNA 
methyltransferase M.HhaI and a nucleoside inhibitor, zebularine (PDB code: 1M0E) (Fig. 6) 
(Zhou et al., 2002). 
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Figure 6. Chemical structures of DNA methyltransferase inhibitors and JQ1 molecule as protein-
protein inhibitor example.  The first approved drugs for the treatment of myelodysplastic syndromes 
and acute myeloid leukemia are nucleoside analogs 5-azacytidine and Decitabine (orange top box). 
New studied non-nucleoside compounds (green bottom box) include drugs used for other indications, 
natural compounds and RG108, a compound identified from a virtual screening campaign.  
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1.7 Targeting transcription regulation in cancer: DNMTs cooperativity 
The following timeline (Fig. 7) presents all the different types of DNMTs complexes which will 
be discussed later (in parts 1.7.1 and 1.7.2). 
 
Figure 7. Timeline of known crystal complexes with DNMTs. (Klimasauskas et al., 1994): M.Hhal flips 
its target base out of the DNA helix (PDB code: 1MHT). (Zhou et al., 2002): First structure of M.HhaI in 
complex with a nucleoside inhibitor (PDB code: 1M0E). (Ooi et al., 2007): DNMT3L recognition of 
nucleosome via the ADD domain and the unmethylated histone H3K4 tail (PDB code: 2PVC). (Chang et 
al., 2011): chromodomain of MPP8 recognizes the methylated DNMT3A and the self-methylated GLP 
to form a repressive complex (PDB code: 3SW9 and 3SWC). (Estève et al., 2011): Lys142 methylation is 
a key signal for degradation of DNMT1 (PDB code: 3OS5). (Song et al., 2012): Structural insights of the 
mechanism of DNA methylation maintenance by DNMT1. (Guo et al., 2015): Regulation of DNMT3A 
activity by the unmethylated histone H3K4 tail and DNMT3L (PDB code: 4U7T and 4U7P). (Cheng et al., 
2015): USP7 (also known as HAUSP) interacts with DNMT1 and stimulates its activity (PDB code: 4YOC). 
(Rondelet et al., 2016):  DNMT3B PWWP recognizes the permissive histone epigenetic mark H3K36me3 
(PDB code: 5CIU).  
Current inhibitors targeting the catalytic domain of DNMTs induce DNA demethylation across 
genomic regions. Here we will show that protein-protein interactions are important 
mediators for DNA methylation in cancer and can be targeted selectively and specifically for 
cancer treatment depending on the epigenomic features.  
Transcription regulation is a complex process involving multiple proteins that target a 
specific gene. Indeed, synergistic mechanisms between epigenetic effectors conduct to the 
inactivation of tumor suppressor genes in cancers, and, therefore, their effective reactivation 
depends on inhibition of multiple epigenetic pathways. An important level of transcriptional 
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regulation is achieved through protein-protein interactions between transcription factors 
(e.g., c-Myc and UHRF1) and transcriptional co-regulators (e.g., DNMTs and HDACs) (Yan and 
Higgins, 2013). Another transcriptional control involves DNA methylation and/or histone 
modifications to recruit transcription factors/co-regulators or directly the regulators to the 
target gene. In cancers, this regulation controls the oncogenic pathway, and, therefore, 
transcription therapy targeting aberrant protein-protein interactions was proposed (Pandolfi, 
2001; White et al., 2008).  
We will review these different processes involving DNMTs recognition to regulate the 
transcription in the context of cancer initiation and progression. Understanding the 
recruitment mechanisms of DNMTs to specific genomic regions and identification of 
interaction sites between transcription factors/epigenome modifications and co-regulators 
will help future development of protein-protein interaction inhibitors targeting oncogenic 
pathways for personalized cancer therapeutics.  
1.7.1 Targeting de novo DNMT3s to gene bodies via specific histone 
epigenetic marks  
Among chromatin-binding proteins, several (e.g., PWWP, MBT, tudor, and PHD domains) are 
involved in protein-protein interactions with epigenetic marks deposited on histone or DNA. 
These epigenetic “readers” define potential druggable targets for developing selective 
protein-protein interaction inhibitors as a new promising strategy for chemotherapy (Cole, 
2008). The proof-of-concept was established in 2010 with the BET (bromodomain and 
extraterminal) protein BRD4. This oncoprotein, involved in transcriptional regulation, binds 
lysine-acetylated residues on histone tails (Filippakopoulos et al., 2010). The discovered small 
molecule JQ1 (Fig. 6) binds into the acetyl-lysine recognition motif of BRD4 preventing the 
binding to chromatin and leads to a specific antiproliferative effect (Fig. 8). 
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Figure 8. Human BRD4-JQ1 complex structure. Structural overview of the BRD4 domain structure with 
the JQ1 inhibitor. BRD4 domain is represented as a blue solid ribbon. JQ1 inhibitor is represented as 
green stick model. Residues of the binding site are represented as orange stick models.  
In cancer, promoter CpG hypermethylation is well known to silence tumor suppressor 
genes and is the target of current treatments. Recently, however, a novel therapeutic target 
of DNA methylation was proposed, the gene body methylation. Indeed, gene body 
methylation  mediates transcriptional activation of the potential oncogene ITPKA (Inositol-
trisphosphate 3-kinase A) and genes up-regulated by the oncogenic transcription factor c-Myc 
(Wang et al., 2016; Yang et al., 2014).  
Recently, regulatory mechanisms of gene body methylation were, in part, elucidated and 
require both de novo methyltransferase DNMT3B and the permissive histone epigenetic mark 
H3K36me3 (Baubec et al., 2015; Jin et al., 2012). More precisely, DNMT3B PWWP domain 
recognizes the trimethylation state of lysine 36 on histone H3 (H3K36me3) distributed within 
the gene body in a particular gene context (Figs. 4 and 9) (Baubec et al., 2015; Jin et al., 2012). 
Structure of DNMT3B PWWP domain in complex with the epigenetic mark H3K36me3 could 
lead to development of small-molecule inhibitors of this epigenetic complex (Fig. 9) (Rondelet 
et al., 2016). This will result in a DNA demethylation of gene bodies and a specific 
downregulation of oncogenic pathways as the small-molecule inhibitor JQ1 of BRD4 was 
proposed to target the c-Myc gene expression (Delmore et al., 2011; Filippakopoulos et al., 
2010; Yang et al., 2014). The selective recruitment of DNMT3B to gene bodies compared to 
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DNMT3A still remains to be explained as their PWWP domain share a high sequence identity 
(53% using blastp). This could be determined by the cellular context or the difference in 
protein-protein interactions with the N-terminal part and transcription factors for example 
(Baubec et al., 2015; Rondelet et al., 2016). The N-terminal part of DNMT3s (1-281 aa) seems 
also important for nucleosome binding, but no structural information is available to date (Fig. 
5) (Baubec et al., 2015; Jeong et al., 2009).  
 
Figure 9. Structural overview of the DNMT3B PWWP domain structure in complex with the 
H3K36me3 peptide. PWWP domain is represented as a green solid ribbon. Epigenetic mark H3K36me3 
peptide is represented as yellow stick models. Aromatic cage residues are represented as orange stick 
models. 
Another recognition mechanism of DNMT3s, is the interaction with the unmethylated 
histone tail (H3K4me0) on nucleosome via their ADD domain (Fig. 5) (Ooi et al., 2007). This 
domain plays an important regulatory role for de novo methylation. Indeed, the recognition 
of H3K4me0 with DNMT3A ADD domain permits to release the autoinhibition of DNMT3A by 
disrupting the interaction between the ADD and catalytic domains of DNMT3A (PDB code: 
4U7T) (Fig. 7) (Guo et al., 2015). 
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1.7.2 Targeting DNMTs to specific promoters via transcription factors and co-
regulators 
Transcription factors and co-regulators direct DNA methylation to specific promoters during 
cancerogenesis and tumor progression (Blattler and Farnham, 2013). These site-specific 
factors recruit, directly or indirectly, DNMTS to form a repressive complex and silence target 
genes. DNMTs can be also the scaffolds on DNA to recruit other repressor proteins.  
The following table (Table 1) is a summary of the main partners involved in the recruitment 
of DNMTs to specific gene region. Details of the various recruitment mechanisms are 
explained in the following paragraphs. 
Table 1. Partners of DNMTs associated to a particular cancer type.   
DNMTs Partners Cancer type References 
DNMT1 UHRF1- USP7 breast cancer 
(Felle et al., 2011; Qin et 
al., 2016) 
DNMT1 
DMAP1  - 
HDAC2 
Glioma (Rountree et al., 2000) 
DNMTs PML-RAR acute promyelocytic leukemia (Di Croce et al., 2002) 
DNMT3A/B EVI1 acute myeloid leukemia (Lugthart et al., 2011) 
DNMT3A c-Myc human astrocytoma 
(Brenner et al., 2005; 
Hervouet et al., 2009) 
DNMT3A/B DNMT3L- NFkB glioma cell lines (Pacaud et al., 2014) 
DNMT1 STAT3 
breast cancers; T-cell 
lymphoma 
(Lee et al., 2012) 
DNMT1 NF-κB breast cancer (Liu et al., 2012) 
DNMT3A SETDB1 
human breast adenocarcinoma 
cells 
(Li et al., 2006) 
DNMTs EZH2 
colon cancer and 
osteosarcoma cells 
(Viré et al., 2006) 
DNMTs CBX7 embryonal carcinoma (Mohammad et al., 2009) 
DNMT3A 
G9a/GLP - 
MPP8 
epithelial tumor cells (Chang et al., 2011) 
DNMT1 and 
DNMT3A 
SUV39H1 - 
HP1β 
cervical carcinoma 
(Fuks et al., 2003; 
Machado et al., 2010) 
DNMT3A 
CUL4B - 
SUV39H1/HP1 
cervical carcinoma (Yang et al., 2015) 
DNMT1 or 
DNMT3B 
NuRD colon cancers cells (Cai et al., 2014) 
DNMT3A ZN217/CoREST myelodysplastic syndromes 
(Thillainadesan et al., 
2012) 
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Colocalization of DNMT1 with an essential activator for maintenance methylation, UHRF1 
(E3 ubiquitin–protein ligase), is observed in late S phase (Bostick et al., 2007). UHRF1 
recognizes hemimethylated DNA and can recruit DNMT1 through its SRA (Set and Ring 
Associated) domain and the RFTS domain of DNMT1 (Fig. 5) (Achour et al., 2008; Bostick et 
al., 2007). UHRF1 could also relieve the DNA binding inhibition mediated by the acidic linker 
(Auto) between BAH1 and CXXC domains (Fig. 5) (observed in mouse DNMT1 in complex with 
DNA (PDB code: 3PT6)) (Syeda et al., 2011). UHRF1 is overexpressed in various cancers and 
maintains the repression of several TSGs (p16INK4A, p14ARF, hMLH1, BRCA1, RB1, FHIT, RARb, 
APC and DAPK) during cell proliferation (Alhosin et al., 2011; Unoki et al., 2009).  
 Recently, USP7 (also known as HAUSP) was identified as an important partner of DNMT1 
and UHRF1. Indeed, this partner interacts with DNMT1 and stimulates its activity, then this 
dimeric complex (DNMT1-USP7) is recruited by UHRF1 on chromatin to silence genes where 
USP7 stabilizes UHRF1 (Felle et al., 2011). If interaction between UHRF1/USP7 and DNMT1 
are disrupted, expression of the tumor suppressor genes can be triggered to cause apoptosis 
and cell cycle arrest. In this way, the structure of the DNMT1-USP7 complex with DNMT1 was 
recently solved and shows molecular interactions between the C-terminal domain of USP7 
and the RFTS domain of DNMT1 (PDB code: 4YOC) (Cheng et al., 2015). In another way, a team 
discovered recently small molecules binding the 5-methylcytosine pocket of UHRF1 to inhibit 
its recognition with the hemimethylated DNA (Myrianthopoulos et al., 2016).  
 In addition to its DNA methylation maintenance ability, DNMT1 forms different repressive 
transcription complexes during DNA replication at replication foci. DNMT1 can recruit both 
DMAP1 (via the first 120 aa - DMAP) and HDAC2 to deacetylate local chromatin. DMAP1 
further recruits the TSG101 (co-repressor) (Rountree et al., 2000). Crystal structure of the 
DMAP1 protein is known (PDB code: 4IEJ), but the structure of the DMAP1 domain of DNMT1, 
despite its important role to form a repressive transcription complex, still has not been solved 
(Fig. 5). Recently, inhibition of protein-protein interaction between DNMT1 and DMAP1 was 
proposed to sensitize cancer cells to chemotherapy (Cheray et al., 2013). 
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 The oncogenic transcription factor PML-RAR, found in acute promyelocytic leukemias, 
recruits DNMTs to target promoters for gene silencing (hypermethylation) (Di Croce et al., 
2002). As in acute myeloid leukemia, EVI1 (ecotropic viral integration site 1) directs promoter 
methylation by recruitment of de novo DNMT3A/B (Lugthart et al., 2011). Another oncogenic 
transcription factor, c-Myc, induces gene repression by recruitment of DNMT3A within the 
promoters of CDKN1a, CCND1, TIMP2 and p21Cip1 genes in human astrocytoma (Brenner et 
al., 2005; Hervouet et al., 2009).  
 The catalytically inactive DNMT3L interacts with a site-specific transcription factor, NFkB-
p65, to recruit de novo DNMT3A/B on the TRAF1 promoter in glioma cell lines (Pacaud et al., 
2014). DNMT3L has a dual function as it interacts with the catalytic domain for the 
recruitment and the enzymatic activity stimulation. The structure between DNMT3L and 
DNMT3A was previously solved (PDB code: 2QRV) (Jia et al., 2007).  
 Acetylation at Lys685 of the oncogenic transcription factor STAT3 (Signal transducer and 
activator of transcription 3) permits the binding of DNMT1 to promoters in several cancers 
(e.g., breast cancers and T-cell lymphoma) (Lee et al., 2012). The mutation of Lys685 (K685R) 
disrupts DNMT1-STAT3 complex providing evidence of a focus region (“hot spot”) for small 
protein-protein interaction inhibitors development. Phosphorylated RelA/p65, the subunit of 
NF-κB, functions as an active transcriptional repressor via a direct recruitment of DNMT1 to 
BRMS1 (breast cancer metastasis suppressor 1) promoter (Liu et al., 2012). Inhibition of this 
protein-protein interaction with protein transduction domain (PTD) peptide (PTD-RelA/p65 
peptide) resulted in an abrogation of BRMS1 methylation and the transcriptional repression.    
 In addition to transcription factors that interact directly with DNMTs, indirect 
recruitments to specific promoters involve repressive histone modifications complexes. H3K9 
methyltransferase SETDB1 interacts with DNMT3A to form a complex localized at promoters 
of the endogenous p53BP2 gene (encoding the tumor suppressor p53-binding protein 2) in 
HeLa cells and the RASSF1A gene (encoding the Ras association domain-containing protein 1) 
in human breast adenocarcinoma cells to silence their expression (Li et al., 2006).  H3K27 
methyltransferase EZH2 (Enhancer of Zeste homolog 2) which catalyzes trimethylation of 
histone H3 lysine 27 is a component of the Polycomb Repressive Complexes 2 and 3 (PRC2/3) 
and can recruit, via its N-terminal domain, DNMTs to silence genes (Viré et al., 2006). In colon 
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cancer and osteosarcoma cells, this Polycomb complex mediated de novo methylation and 
plays an important part in carcinogenesis (Schlesinger et al., 2007; Viré et al., 2006). In an 
identical manner, another component, the CBX7 (Chromobox protein homolog 7), targets 
DNMTs to gene promoters in cancer (Mohammad et al., 2009).  
 The Polycomb Repressive Complex 2 can also be regulated by G9a (histone-lysine N-
methyltransferase 2) and GLP (G9a-like protein) which deposit the repressive epigenetic mark 
H3K9me1 and H3K9me2 observed in colorectal and breast cancer cells (McGarvey et al., 2006; 
Mozzetta et al., 2014; Tachibana et al., 2005; Wozniak et al., 2007). More interestingly, 
G9a/GLP interact with MPP8 (M-phase phosphoprotein 8) and DNMT3A to silence tumor 
suppressor E-cadherin gene in epithelial tumor cells (Kokura et al., 2010). In 2011, the 
mechanism of formation of this repressive complex was established (Chang et al., 2011). First, 
G9a or GLP dimethylate the N-terminal lysine 44 of mouse DNMT3A (K47 for human 
DNMT3A). Then, the chromodomain of MPP8 recognizes the methylated DNMT3A and the 
self-methylated GLP to form a repressive complex on the promoter of E-cadherin gene. In 
addition, structure between GLP and DNMT3AK44me0/2 peptide (PDB code: 3SW9 and 
3SWC) were solved as well as the MPP8-DNMT3AK47me2 (PDB code: 3SVM) peptide complex 
(Fig. 7). As MPP8 and G9a/GLP direct de novo methylation for tumor progression in epithelial 
tumor cells, future protein-protein interaction inhibitors targeting these complexes could 
lead to the reexpression of the cell-adhesion molecule E-cadherin. For the repression of E-
cadherin gene transcription in breast cancer cells, the transcription factor ZEB1 (δEF1) recruits 
DNMT1 through its Smad-binding domain (SBD).  
 The histone-lysine N-methyltransferase, SUV39H1 (Su(var)3-9 homolog 1), is targeted to 
histone H3 for the repressive H3K9 methylation on major satellite repeats at pericentric 
heterochromatin (Lehnertz et al., 2003). HP1β chromodomain (Heterochromatin Protein 1) 
binds the methylated histone H3K9me3 and can recruit DNMT1 and DNMT3A to direct DNA 
methylation (Fuks et al., 2003; Machado et al., 2010). In cervical carcinoma, CUL4B (Cullin 4B), 
coordinates the function of this repressive complex (SUV39H1/HP1/DNMT3A) to repress 
tumor suppressor IGFBP3 by catalysing H2AK119 mono-ubiquitination (Yang et al., 2015). This 
interplay between histone ubiquitination/methylation and DNA methylation to repress TSGs 
in cervical carcinoma represents an important target for cancer therapy.  
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 Finally, NuRD and ZN217/CoREST chromatin remodeling complex cooperate with DNMTs 
to maintain silencing of TSGs in human cancers. NuRD complex (also known as Mi-2) 
cooperates with DNMT1 or DNMT3B to silence tumor suppressor genes in colon cancers cells 
whereas ZN217/CoREST complex cooperates with DNMT3A for repression of the p15ink4b gene 
in myelodysplastic syndromes (Cai et al., 2014; Thillainadesan et al., 2012).  
1.8 Conclusion 
Nucleoside analogs targeting DNMTs are used as chemotherapeutic agents in the treatment 
of myelodysplastic syndromes and acute myeloid leukemia. However, these compounds are 
not selective for isoforms of DNMTs, have a poor bioavailability and a high toxicity. To address 
these limitations, development of nonnucleoside compounds acting directly on the catalytic 
domain of DNMTs has progressed despite low cellular activities compared to nucleoside 
analogs. Over the last two decades, and in parallel to this development, DNMT-interacting 
partners were described in various cancers to regulate gene expression. These novel 
mechanistic insights provide new epigenetic therapy strategies for cancer as exemplified by 
the combination treatment targeting the catalytic functions of multiprotein complexes to 
induce a synergistic cytotoxicity effect. Here, we reviewed these molecular machineries 
involving DNMTs and propose a new approach to increase therapeutic efficacy and specificity 
by designing protein-protein inhibitors of DNMT-interacting partners. Some structural studies 
of recognition systems described in the present review await further biochemical 
characterization for the development of a new generation of DNMT inhibitors based on this 
approach. 
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Research Aims and Methods 
The motivations and objectives of the presented thesis are detailed and integrated in the 
epigenetic cancer therapy research. In addition, a brief description through the different 
chapters will be provide.  
Background: Epigenetic modifications control chromatin state and, therefore, regulate gene 
expression. These events occur in normal cells, but, in cancer cells, their deregulations 
conduct to the repression of tumor suppressor genes and the activation of oncogenic 
pathways. Among these epigenetic modifications, DNA methylation contributes to 
transcriptional regulation and is catalyzed by DNA (cytosine-5) methyltransferases (DNMTs). 
These DNMTs are targeted to specific regions of the genome to repress tumor suppressor genes 
by hypermethylation of their promoters. Alternatively, they mediate the transcription of 
oncoprotein-regulated genes by gene body methylation. As DNA methylation is a reversible 
process, treatment with demethylating agents could revert the epigenome cancer cell to stop 
cancer progression. Current treatments against DNMTs use nucleoside analogs for the 
treatment of myelodysplastic syndromes and acute myeloid leukemia.  
Problem definition: Nucleoside analogs are not selective for isoforms of DNMTs, have a poor 
bioavailability and a high toxicity. To address these limitations, development of non-nucleoside 
compounds acting directly in the catalytic domain of DNMTs has progressed. However, the 
mode of action of these compounds remains unclear and their cellular activities are still low 
when compared with nucleoside analogs. Furthermore, the efficacy of these compounds 
appears to be compromised by their lack of specificity. Therefore, the mode of action of 
current non-nucleoside DNMT inhibitors has to be investigated.  
Aims & Methods: The first aim of this research was to rationalize the catalytic inhibition of 
DNMTs by maleimide derivatives (RG108-1 and RG119-1) of RG108 (N-phthaloyl-L-tryptophan) 
(Fig.1). This was achieved by enzymatic and cellular assays, differential scanning fluorimetry 
assays, crystallographic studies and molecular docking. The related work is discussed in 
chapter 2, entitled “Rationalization of the inhibition of DNA (cytosine-5) methyltransferases 
by maleimide derivatives of RG108 as non-nucleoside inhibitors”.  
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Figure 1. Chemical structures of the non-nucleoside DNA methylation inhibitor RG108 and its 
maleimide derivatives. 
To enhance selectivity and specificity against DNMTs, a new strategy is proposed and is based 
on the specific gene body methylation associated with DNMT3B. DNMT3B recognizes, via its 
PWWP domain, the permissive histone epigenetic mark H3K36me3 for gene body 
methylation in cancer cells. The disruption of this protein-protein interaction could 
downregulate expression of oncogenes and oncoprotein-regulated genes. 
 Chapter 3 details the complex structure between DNMT3B PWWP domain and H3K36me3 
peptide (see introduction Fig. 9). Molecular modeling was also performed to propose a model 
of DNMT3A in a nucleosomal context. The related work is discussed in chapter 3, entitled 
“Structural basis for recognition of histone H3K36me3 nucleosome by human de novo DNA 
methyltransferases 3A and 3B”.  
 Based on the results of chapter 3, the third aim of this work was to develop and identify 
potential protein-protein interaction inhibitors of the PWWP DNMT3B-H3K36me3 complex. 
To this end, a similarity-based virtual screening was performed using the bis-tris molecule, 
identified from a complex with DNMT3B PWWP domain (PDB code: 3QKJ), and H3K36me3 
epigenetic mark as both chemical references. The hits identified were co-crystallized with the 
DNMT3B PWWP domain to generate in fine a pharmacophore model. Other virtual screenings 
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were performed to identify potential protein-protein interaction inhibitors targeting the 
DNMT3B PWWP domain. The related work is discussed in chapter 4, entitled “Targeting 
PWWP domain of DNA methyltransferase 3B for epigenetic cancer therapy: Identification and 
structural characterization of new potential protein-protein interaction inhibitors”. 
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Abstract 
DNA methyltransferases (DNMTs) are important drug targets for epigenetic therapy of 
cancer. Identification of novel non-nucleoside inhibitors are needed to decrease side effects 
and increase selectivity against DNMTs. Among these inhibitors, maleimide derivatives of 
RG108 seem promising compounds to improve inhibitory potency and selectivity for DNMTs. 
RG119-1 was found to be 10-fold more potent (IC50 values in the low micromolar range) than 
RG108-1 against DNMT3A and M.SssI. While RG119-1 was active against DNMT1, RG108-1 
showed no inhibition. This was reflected in the cytotoxicity activity of RG119-1 on the 
mesothelioma cells line with TC50 values in the low micromolar range. In order to understand 
the difference of activity against DNMTs isoforms, crystallographic assays were performed 
and conducted to the first apo structure of M.HhaI. This structure reveals that the S-adenosyl-L-
methionine (SAM) cofactor does not affect the cofactor binding site conformation. Finally, a 
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new docking protocol was proposed based on differential scanning fluorimetry results, 
crystallographic studies and the mechanism of methylation of DNMTs. Covalent docking 
studies were also performed with RG108-1 and RG119-1 on DNMTs, and revealed essential 
residues for the stabilization of such compounds. 
Keywords: DNA methylation, DNA methyltransferases, Covalent inhibitors, Michael acceptor, 
DNMT3A, DNMT1, M.HhaI, M.SssI, Apoenzyme crystal structure 
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2.1 Introduction 
In mammalian cells, DNA methylation is an important epigenetic modification involved in 
physiological events like embryonic development, genomic imprinting, X-chromosome 
inactivation, maintenance of chromosomal stability and gene silencing (Wutz, 2011). In cancers, 
hypermethylation of CpG islands of tumor suppressor genes (TSGs) promoters leads to their 
inactivation and, consequently, induces tumorigenesis and tumor maintenance (Esteller, 2008; 
Jones, 2012). This covalent epigenetic modification, which occurs at the C5 position of cytosine 
(5-methylcytosine, 5-mC), in CpG dinucleotides is catalyzed by C5-DNA methyltransferases 
(DNMTs) in the presence of the S-adenosyl-L-methionine (AdoMet or SAM) cofactor as methyl 
group donor (Bestor, 2000). Based on crystallographic and enzymatic studies, mostly conducted 
with bacterial C5-DNA methyltransferase M.HhaI, a mechanism of DNA cytosine-C5 
methylation involving the nucleophilic addition of a cysteine to the cytosine prior to 
methylation was proposed (Fig. S1) (Bestor and Verdine, 1994; Goll and Bestor, 2005). 
As DNA methylation is a reversible process, DNMTs are targeted for epigenetic therapy to 
re-express tumor suppressor genes leading to proliferation arrest and apoptosis in cancer cells 
(Goll and Bestor, 2005; Gros et al., 2012; Mai and Altucci, 2009). In 2004 and 2006, two 
nucleoside analogs of cytosine, namely 5-azacytidine (azacitidine, Vidaza®) and 5-aza-
deoxycytidine (decitabine, Dacogen®) (see Fig. 6 in chapter 1), have been approved by FDA for 
myelodysplastic syndromes, acute myeloid leukemia and chronic myelomonocytic leukemia 
(Christman, 2002; Issa and Kantarjian, 2009; Jones and Taylor, 1980; Wijermans et al., 2008). 
These drugs are incorporated into DNA instead of deoxycytidine, the -elimination reaction 
(releasing normally the 5-methylcytosine (Fig. S1)) cannot occur and thus irreversibly trap 
DNMT. This results in a degradation of DNMTs and a methylation marks depletion during DNA 
replication (Stresemann and Lyko, 2008). However, these nucleoside analogs are also 
associated with significant toxicity, low specificity, strong side effects, chemical instability and 
poor bioavailability (Lyko and Brown, 2005).  
During the last decade, an attractive and novel alternative for epigenetic cancer therapy 
tends to develop more specific and selective DNMTis such as non-nucleoside compounds. 
These compounds act directly on DNMTs without incorporation into DNA expecting lower 
cytotoxicity and better selectivity. With this approach, there is an increasing number of non-
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nucleoside analogs with various chemical structures and different expected modes of action 
targeting, inter alia, cofactor and/or substrate pockets (Erdmann et al., 2015a). Despite the 
fact that in vitro inhibitory activity increased for the new generation, development of non-
nucleoside compounds is currently slowed by the lack of structural information of DNMTs in 
complex with these compounds, their low selectivity for DNMTs, the lack of information 
about their mechanism of inhibition and the low inhibitory activity in cells. Therefore, there 
is a need to understand the mode of action of current non-nucleoside DNMT inhibitors.  
To this end, we focused our research on maleimide derivatives of the most studied 
compound, the RG108 (N-phthaloyl-L-tryptophan) (Fig. 1) (Brueckner et al., 2005). Since its 
discovery, several studies reported a weak inhibitory activity of RG108 and its demethylating 
activity remains controversial. However, this compound present interesting features and 
pharmacomodulations of RG108 were performed in different studies to increase its potency. 
In 2010, novel DNMTis derived from RG108 and characterized by the replacement of 
phthalimide group with a maleimide group were identified (Suzuki et al., 2010). Among these, 
RG108-1 (Fig. 1) was found to be the most potent DNMT1 inhibitor (60% inhibition at 10 µM), 
having a better inhibitory effect than RG108. Recently, a systematic structure-activity 
relationship (SAR) study on the RG108 and its analogs was performed to understand the role 
of the different moieties and to increase its activity, leading to the thionitropyridine analog, 
which presents an IC50 value of 20 µM against DNMT1 (Fig. 1) (Asgatay et al., 2014). In the 
same study, authors showed that the carboxylate anion of RG108 does not influence its 
inhibitory activity.  
Based on these results, we decided to study the RG108-1 and RG119-1 (a tryptamine 
derivative lacking carboxylate functionality) (Fig. 1) (Suzuki et al., 2010). These compounds 
are expected to target directly DNMTs by covalent bonding with the catalytic cysteine residue 
without incorporation into DNA unlike nucleoside inhibitors. To decrease the toxicity of such 
compounds caused by the off target effects, specific non-covalent interactions with the 
scaffold of the compound are important. This will stabilize the compound inside the binding 
site and preferentially orientate the warhead relative to the cysteine, the electrophile moiety, 
to increase the rate, the selectivity and the potency of covalent bond formation (London et 
al., 2014). The challenge is to develop a covalent non-nucleoside inhibitor combining a scaffold 
for non-covalent interaction and an electrophilic warhead capable to covalently link the sulfur 
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atom of the key cysteine residue on the catalytic loop (Fig. S1). Selective inhibition of DNMTs 
will be based on the structural differences between isoforms of DNMTs (Erdmann et al., 
2015b). Designing compounds with both specific non-covalent interactions and covalent 
binding will minimize off-target reactivity and ameliorate safety concerns (Zhu et al., 2014). 
The objective of the present study is to rationalize the inhibition of DNMTs by RG108-1 and 
RG119-1 as the binding mode of such inhibitors remains to be explored. Thereto, both 
compounds were analyzed in enzymatic and cellular assays. Crystallographic studies were also 
conducted leading to the first apo structure of M.HhaI. Finally, a new docking protocol 
(including covalent docking) was proposed based on differential scanning fluorimetry (DSF) 
assays, crystallographic studies and the mechanism of methylation of DNMTs.  
 
Figure 1. Chemical structures of the non-nucleoside DNA methylation inhibitor RG108 and its 
analogs. RG108-1 and RG119-1 are the compounds studied in this work. The compounds are named 
according to the corresponding articles.  
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2.2 Results and discussion  
The reference RG108 compound (Fig. 1) was discovered by virtual screening using the National 
Cancer Institute (NCI) database and a homology model of human DNMT1 (Brueckner et al., 
2005; Siedlecki et al., 2006). Authors reported an IC50 value of 0.6 µM against M.SssI DNA 
methyltransferase and the reactivation of tumor suppressor genes, SFRP1 and p16Ink4a, in 
colon cancer cells (Brueckner et al., 2005; Siedlecki et al., 2006). Nevertheless, other studies 
reported a weak activity of this compound toward DNMT1 (IC50 value of 390 µM) and murine 
DNMT3A (IC50 value >500 µM), reconsidering its selectivity and potency toward DNMTs 
(Asgatay et al., 2014; Ceccaldi et al., 2011; Suzuki et al., 2010). In 2010, novel DNMTis derived 
from RG108 and characterized by a maleimide scaffold were identified and presented a better  
inhibitory effect than RG108 (Fig. 1) (Suzuki et al., 2010).  
So, we conducted this study on maleimide derivatives as their potential use as therapeutic 
agents recently emerged to treat cancer (Cashman et al., 2010), Alzheimer (Halim et al., 2007; 
Sivaprakasam et al., 2006), bacterial infection (López et al., 2003) and inflammatory diseases 
(Mahle et al., 2010; Matuszak et al., 2009). Covalent inhibitors can form a covalent bond with 
their target protein assisted by non-covalent interactions to improve selectivity, potency and 
be used for biological studies. We can cite as potential covalent non-nucleoside inhibitors of 
DNMTs, natural compounds parthenolide (IC50 of 3.5 µM against DNMT1), nanaomycin A 
(IC50 of 0.5 µM against DNMT3B) and curcumin (IC50 of 30nM against M.SssI) (see Fig. 6 in 
chapter 1) (Kuck et al., 2010; Liu et al., 2009a; Liu et al., 2009b; Merfort, 2011). Such 
compounds are useful pharmacological tools for understanding the mechanisms of DNA 
methylation and links with other epigenetic modulations as exemplified by the recent probe 
develop for activity-based protein profiling technology based on the RG108-1 (Fig.1) (London 
et al., 2014; Zhu et al., 2015). These compounds are the basis for the design of new inhibitors 
of DNMTs. We evaluated also the activity of RG119-1 (Fig. 2), a tryptamine derivative, on 
DNMTs and compared it to RG108-1 as the presence of the carboxylate moiety does not seem 
necessary to improve the activity of such compound (Asgatay et al., 2014).  
For the different studies (in vitro and crystallographic assays), our sample of RG108-1 was 
purchased in racemic form. Indeed, in the first report of RG108 study, the inhibitory activity 
was determined with the racemate (NSC401077) (Siedlecki et al., 2006). Furthermore, a study 
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of how the chirality of RG108 affects the activity was previously reported and showed no 
significant difference of activity between the enantiomers (Asgatay et al., 2014). Finally, our 
docking studies show that the binding poses of the two enantiomers are equivalent and form 
the same interactions with residues in the binding site (Fig. S2). RG119-1 was synthesized 
based on a previously described procedure and its structure was confirmed by X-ray 
diffraction (Dubois et al., 2016). 
2.2.1 Inhibition of human DNMT1, human DNMT3A and bacterial M.SssI by 
RG108-1 and RG119-1 
Enzymatic assays were developed for human DNMT1, human DNMT3A and bacterial M.SssI 
(Ceccaldi et al., 2011; Gros et al., 2013; Rilova et al., 2014). Dose-dependent inhibitions were 
observed and IC50 values were determined for RG108-1 and RG119-1 against those DNMTs 
(Table 1). RG119-1 showed a better inhibitory effect than RG108-1 against all DNMTs. For 
human DNMT3A and bacterial M.SssI, RG119-1 has similar activities with IC50 values of 3.1 
µM and 3.9 µM, respectively, and is 10-fold more potent than RG108-1 (Table 1). However, 
the inhibitory activity of RG119-1 against DNMT1 (IC50 value of 45 µM) is much better than 
RG108-1 (IC50 value in the millimolar range). The ability for RG108-1 to inhibit preferentially 
human DNMT3A can be exploited to develop a selective inhibitor. 
Table 1. Inhibition of human DNMT1, human DNMT3A and bacterial M.SssI. 
 
 
DNMT1 DNMT3A M.SssI 
IC50 95% CI IC50 95% CI IC50 95% CI 
RG108-1 (µM) >1000 27 17-42 37 16-87 
RG119-1 (µM) 45 12-174 3.1 2.0-4.8 3.9 2.5-6.0 
IC50, 50% inhibitory concentration in DNMTs assay; 95% CI, 95% confidence interval. 
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2.2.2 Cytotoxic effect of RG108-1 and RG119-1 in mesothelioma cell lines 
(M14K and H28) 
In this study, we evaluated also the cytotoxic effects of RG108-1 and RG119-1 on 
mesothelioma cell lines M14K and H28 (Fig. S3). M14K cell line is more sensitive compared to 
the more chemoresistant H28. These cell lines were chosen as hypermethylation of tumor 
suppressor genes was reported in malignant pleural mesothelioma (Batra et al., 2006). Results 
from cytotoxic assays show that RG108-1 has a weak activity, while RG119-1 is the most active 
compound (Table 1). Interestingly, their cytotoxicity activities are related to their inhibitory 
activities toward DNMT1 (Table 1 and Table 2). In mesothelioma cells, this enzyme represents 
more than 90% of total DNMTs expressed compared to the other isoforms (Amatori et al., 
2009). RG119-1 has an IC50 value of 45 µM against DNMT1 and presents TC50 values in the 
low micromolar range (TC50H28= 6.2 µM; TC50M14K= 5.4 µM).  
Table 2. Cytotoxic effect of RG108-1 and RG119-1 in M14K and H28 cell lines. 
 
 
H28 M14K 
TC50 95% CI TC50 95% CI 
RG108-1 (µM) >1000 >1000 
RG119-1 (µM) 6.2 3.9-9.6 5.4 3.2-9.2 
TC50, 50% inhibitory concentration in cytotoxicity; 95% CI, 95% confidence interval. 
2.2.3 Apo structure of M.HhaI  
In order to understand the mechanism of molecular recognition of RG108-1 and RG119-1 by 
DNMTs, crystallographic studies were performed using the bacterial C5-DNA methyltransferase 
from haemophilus haemolyticus, M.HhaI. This enzyme is the smallest DNMT (327 aa), is largely 
studied and serves as a model to investigate the inhibition mechanism of human DNMTs due 
to its high structural homology and sequence identity for the conserved motifs with human 
DNMTs (Figs. S4 and S5). 
In 1993, the first crystal structure of M.HhaI with SAM was determined (PDB code: 1HMY) 
(Cheng et al., 1993). Since then, different ternary complexes of M.HhaI complexed with SAM 
cofactor or SAH product and DNA, containing methylated, mismatched target base or 
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nucleoside inhibitor were determined (Klimasauskas et al., 1994; Sheikhnejad et al., 1999; 
Zhou et al., 2002). However, no complex of DNMTs with any non-nucleoside inhibitors has 
been reported in the literature to date.  
Prior to crystallization trials, differential scanning fluorimetry (DSF) assays were 
conducted to study the stabilizing effect of RG108-1 and RG119-1 with human DNMT1 alone, 
in presence of DNA and/or SAM. DSF is a highly sensitive method used to measure the thermal 
stability of a protein given by its melting temperature (Tm). If a compound stabilizes a protein, 
the free energy of unfolding (ΔGu) increases and so does the Tm (Niesen et al., 2007). The 
stability of the protein-ligand complex is therefore reflected by the difference in Tm (ΔTm) in 
the presence and absence of the ligand. In this study, RG108-1 does not appear to stabilize 
DNMT1 in any form (Table 3), an observation that can be correlated with the low in vitro 
inhibitory activity toward DNMT1 (Table 1). In contrast, RG119-1 induces a pronounced 
thermal shift (ΔTmDNMT1 = ~2.8°C) in presence of DNA. We can interpret this result in the 
following way: as DNA binding stabilizes the closed form of the catalytic loop, which is the 
active conformation of DNMTs, interactions engaged by RG119-1 should be more favourable 
(Song et al., 2012). This hypothesis is reinforced by the fact that without DNA, we observe a 
slight stabilization of the DNMT1 enzyme alone and no stabilization in presence of cofactor 
SAM (Table 3). In presence of DNA and SAM, RG119-1 caused a smaller thermal shift 
(ΔTmDNMT1 = ~1.3°C) than DNMT1-DNA system. It is difficult to interpret this difference, but it 
could be caused by a competition of RG119-1 with the SAM cofactor as previously reported 
for RG108 (Asgatay et al., 2014).  
Table 3. Results of DSF (ΔTm [°C]) against DNMT1 alone, in presence of DNA and/or SAM a. 
 DNMT1 DNMT1-SAM DNMT1-DNA DNMT1-DNA-SAM 
RG108-1 0.0 -0.3 -0.2 -0.8 
RG119-1 0.3 -0.4 2.8 1.3 
aCompound concentration, 200 μM; protein concentration, 2.5 μM; SAM cofactor concentration, 5 
µM ; DNA duplex concentration, 5 µM. Experiments were carried out in duplicate; average values are 
reported. Heat map shows relative ΔTm; red is for the largest ΔTm and blue indicates small ΔTm.  
Based on these results, we tried to obtain a crystal structure of the ternary complex of 
M.HhaI with DNA and RG108-1 or RG119-1 by co-crystallization or crystal-soaking using crystal 
Chapter 2 
46 
 
ternary complex (M.HhaI-SAH-DNA) but without success. Crystallization trials were also conducted 
in the absence of DNA in the hope to obtain a crystal structure complex of M.HhaI with RG108-1 or 
RG119-1 with no more success. However, we obtained the first crystal structure of the apoenzyme 
of M.HhaI despite a strong and stable association between the cofactor and M.HhaI, even after 
several purification steps (Kumar et al., 1992) and several dialysis (complex of M.HhaI-SAM 
obtained without addition of exogenous SAM).    
Apo crystals of M.HhaI were obtained using two different methodologies. After a dialysis 
to decrease the concentration of endogenous SAM, the purified M.HhaI was crystallized by 
hanging-drop vapor-diffusion method in the presence of RG108-1 or RG119-1. For the second 
method, cocrystals of M.HhaI with exogenous SAM were soaked with RG108-1 or RG119-1. 
In both cases, we obtained apo crystals of M.HhaI crystallizing in the monoclinic space group 
P 1 21 1 (Table 4) as the previous binary complex of M.HhaI, with two molecules of M.HhaI in 
the asymmetric unit (O'Gara et al., 1999).  
This crystal structure (Fig. 2) displays a vacant SAM-binding pocket with slight backbone 
displacement for key residues Glu40, Trp41, Asp60 and Ile 61 (Fig. 3a). These residues, except 
for Trp41, are conserved among DNMTs and mediate interactions with the cofactor (Fig. S6). 
In addition to these movements of the backbone, the most significant side chain 
conformational changes compared to the binary complex (M.HhaI-SAM, PDB code: 2HMY) 
(O'Gara et al., 1999) are found for residues Phe18 and Trp41 (Fig. 3b). These two residues 
interact normally with the adenine ring of the SAM, the Phe18 by π-π T-shaped interaction 
and the Trp41 by parallel π-π stacking interaction (Fig. S6). These observations indicate that 
the cofactor does not affect the cofactor binding site conformation of M.HhaI. More 
interestingly, RG119-1 seems to compete against SAM binding by displacing the cofactor from 
the binary complex as observed for the RG108 on the murine catalytic domain of DNMT3A 
(Asgatay et al., 2014). Unfortunately, RG119-1 was not observed in the electron density map 
probably reflecting high mobility and a low occupancy of the inhibitor in the active site. This 
also could be connected with our DSF results. Indeed, RG119-1 better stabilizes DNMT1 in 
presence of DNA than with DNMT1 alone, and it would probably be difficult to get a complex 
with the inhibitor in the absence of DNA.  
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Figure 2. Structure of the M.HhaI apoenzyme. Solid Ribbon representation of cofactor binding site 
with 2Fo-Fc electron density map contoured at 1.0 σ for residues (orange mesh) normally involved in 
cofactor interaction and a Fo-Fc omit map contoured at 2.0 σ (green mesh) near the cofactor-binding 
site.  
 
Figure 3. Superposition of binary complex M.HhaI-SAM cofactor (orange) (O'Gara et al., 1999) (PDB 
code: 2HMY) with the apoenzyme (blue). Amino acid residues of the binding site are rendered as stick 
models while rest of the protein backbone is displayed as line ribbon. SAM cofactor is rendered as green 
stick model. (a) Slight backbone displacement for residues Glu40, Trp41, Asp60, and Ile 61 and (b) 
conformational side-chain rearrangements for residues Phe18 and Trp41 when cofactor binds to 
M.HhaI.  
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Table 4. Data collection and refinement statistics. 
 Apoenzyme M.HhaI 
Data collection  
Space group P 1 21 1 (No. 4) 
Cell dimensions  
a, b, c (Å) 53.0, 70.0, 87.8 
,,() 90.0, 101.3, 90.0 
Resolution (Å) 41.73 - 1.90 (1.97  - 1.90) * 
Rsym or Rmerge (%) 5.8 (42.9) 
I /I 12.42 (2.77) 
Completeness (%) 99.61 (99.74) 
Redundancy 3.68 (3.57) 
  
Refinement  
Resolution (Å) 41.73 - 1.9 
No. reflections 49517 
Rwork / Rfree (%) 17.84/21.94 
No. atoms  
    Protein 5122 
    Ligand/ion 25 (sulfate) 
    Water 246 
B-factors  
    Protein 34.27 
    Ligand/ion 40.63 
    Water 39.54 
R.m.s. deviations  
    Bond lengths (Å) 0.007 
    Bond angles () 1.08 
*Values in parentheses are for highest-resolution shell. 
2.2.4 Molecular docking of RG108-1 and RG119-1 into DNMTs 
To investigate the mode of interaction of RG108-1 and RG119-1 with DNMTs, we performed 
non-covalent docking followed by covalent docking. Firstly, we studied by non-covalent 
docking the conformation of RG108-1 and RG119-1 inside the active site, and the orientation 
of the maleimide moiety relative to the catalytic cysteine to perform the covalent binding. 
Secondly, we examined by covalent docking the conserved interactions and the ones newly 
formed to maintain and stabilize this complex during the reaction process.  
Based on the results of the DSF experiments with DNMT1, crystallographic studies and 
the mechanism of methylation of DNMTs, we propose here a new docking protocol. Several 
structures of DNMTs are available in the PDB (Protein Data Bank) (Berman et al., 2000) either 
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in complex with the SAM cofactor, in complex with a DNA probe and SAH, or alone. 
Crystallographic structures of mouse DNMT1 (PDB code: 4DA4, 2.6 Å) (Song et al., 2012) and 
M.HhaI (PDB code: 1M0E, 2.5 Å) (Zhou et al., 2002) both in ternary complex with SAH and 
DNA were used for both non-covalent and covalent docking. Indeed, the conformation of 
DNMTs approaches the active conformation as the DNA stabilizes the closed form of the 
catalytic loop which covers the active site. This effect is especially pronounced for the 
bacterial M.HhaI (Fig. S7). When DNA binds to M.HhaI, the catalytic loop undergoes a major 
conformational change (2.5 nm) to close the catalytic site (Sankpal and Rao, 2002). This ensures 
that the nucleophilic catalytic Cys81 is close to the target cytosine and allows a direct attack at 
the C6 position.  
Docking simulations reported in the literature with DNMTs were conducted with the 
active conformation of the catalytic domain taken from the ternary complex by removing the 
DNA duplex and cofactor (Rilova et al., 2014; Suzuki et al., 2010), with the  binary complex by 
removing the cofactor (Valente et al., 2014) and homology models (Kuck et al., 2010; Yoo and 
Medina-Franco, 2011). In our study, we decided to keep the DNA double-helical structure 
during docking simulations as this partner permits to close the loop for M.HhaI and to change 
the conformation of side-chain residues by steric effects into the active form for human DNMTs 
(Fig. S5). Furthermore, based on our DSF experiments, we conclude that RG119-1 stabilizes 
more the DNMT1 in presence of the DNA. However, to study the substrate pocket in the active 
form, we extracted the flipped substrate as the base flipping is a reversible process. DNMTs, as 
explained in the methylation mechanism (Fig. S1), flip the deoxycytidine out of the DNA helix 
into the catalytic pocket. The kinetic scheme proposed for M.HhaI includes first the binding of 
DNA, followed by the binding of the cofactor, the loop closing and the base flipping occurring 
almost simultaneously (Gerasimaitė et al., 2011; Kurkcuoglu et al., 2012). All these elements 
led us to keep the DNA during the docking simulations.  
The docking protocol was first validated by docking the SAH inside the DNMTs. The 
proposed binding mode for the cofactor within the active site superimposed well with M.HhaI 
and DNMT1 with a RMSD of 0.89 Å and 1.34 Å, respectively (<2 Å) (Fig. S8). Binding of RG108-
1 and RG119-1 was then explored inside the cofactor-binding site and the catalytic cavity, where 
the cytosine binds (Fig. S5), in order to model competition with the cofactor and DNA substrate, 
respectively. The SAM binding pocket is highly conserved among DNMTs with residues 
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forming hydrogen bond interactions and surrounding the adenine ring of cofactor with a 
hydrophobic pocket (Fig. S6). However, Trp41 in M.HhaI is replaced by Met1172 in DNMT1 
and Val661 in DNMT3A.  
Our non-covalent docking simulations of RG108-1 and RG119-1 on bacterial M.HhaI and 
mouse DNMT1 (Fig. 4) suggest that the indole ring of both ligands, like the adenine ring of the 
cofactor, occupies a hydrophobic pocket surrounded by residues Phe18, Trp41, Ile61 and 
Leu100 for M.HhaI, and residues Phe1148, Met1172 and Leu1250 for DNMT1 (Fig. 4c and d). 
Furthermore, this moiety superimposes well with the adenine ring of SAH and forms similar 
interactions with the cofactor site (Fig. S9). The indole ring of RG108-1 and RG119-1 is 
involved in π-π T-shaped interaction with the phenylalanine residue and parallel π-π stacking 
interaction with Trp41 for M.HhaI and π-sulfur interaction with Met1172 for DNMT1. Such 
aromatic interactions seem important as derivatives lacking the indole moiety of RG108 are 
inactive and its bioisosteric replacement by a benzothiophene, containing a sulfur atom in 
place of the nitrogen atom, increases its inhibitory potency by two (Asgatay et al., 2014). 
Moreover, the donor NH group from the indole ring does not interact with any surrounding 
residue.  
For M.HhaI, maleimide ring of both compounds is directed to the substrate pocket and 
mediates, via a carbonyl group, a moderate hydrogen interaction (DA-B= 3.0 Å) with Gln82 
residue. This residue seems required for the preferential orientation of the warhead of 
RG108-1 and RG119-1 directed to the catalytic cysteine. Interestingly, for DNMT1, only 
RG119-1 forms a hydrogen bond with Gln1230 via the carbonyl group (DA-B= 3.1 Å). For 
RG108-1, the maleimide ring (warhead) seems not stabilized by hydrogen bonding as reflected 
by the multiple conformations of the top docking solutions for this moiety.  
In addition, the carboxylate makes a salt bridge with Lys1247 (D = 2.8 Å) and a hydrogen 
bond with Gln1230 (DA-B= 3.1 Å) which could prevent the RG108-1 to react with the catalytic 
cysteine by blocking the compound. This could explain the relatively low inhibitory activity of 
RG108-1 against DNMT1. In the case of human DNMT3A and M.HhaI, the lysine residue 
(Lys1247) is replaced by a threonine residue (Thr727) and an arginine residue (Arg97), 
respectively. However, it is unlikely that Arg97 from M.HhaI interacts with the carboxylate of 
RG108-1 as it is engaged in a bidentate interaction with a phosphate group of the DNA 
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backbone and is apart from the binding site. Additionally, a π-sulfur interaction is formed also 
between the maleimide group of both compounds and the catalytic cysteine (Cys81 residue 
for M.HhaI and Cys1229 for DNMT1).  
 
Figure 4. Non-covalent docking of RG108-1 (a,c) and RG119-1 (b,d) into bacterial M.HhaI (top) and 
mouse DNMT1 (bottom). Ligands and amino acid residues of the binding site are rendered as stick 
models while rest of the protein backbone is displayed as line ribbon. DNA backbone is displayed as 
purple tube model. Zebularine and 5-Fluorocytosine, removed prior to docking simulations, were added 
for final visualization. Molecular interactions are shown in dotted lines with the following color codes: 
green for conventional hydrogen bond, yellow for π-sulfur interaction, orange for salt bridge, purple 
for π-sigma interaction, light pink for π-alkyl interaction and pink for π-π stacking interaction. (a and 
b) Details of the binding mode of RG108-1 (a; green; docking pose) and RG119-1 (b; purple; docking 
pose) to M.HhaI (orange; PDB code: 1M0E). RG108-1 and RG119-1 both interact with M.HhaI via 
hydrogen bond involving Gln82, van der Waals interaction involving Pro80 and Leu100, π-π T-shaped 
interaction involving Phe18, parallel π-π stacking interaction involving Trp41 and π-sulfur interaction 
involving Cys81. RG108-1 makes an additional interaction with Trp41 by hydrogen bonding. (c and d) 
Details of the binding mode of RG108-1 (c; green; docking pose) and RG119-1 (d; purple; docking pose) 
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to DNMT1 (blue; PDB code: 4DA4). RG108-1 and RG119-1 both interact with DNMT1 via van der Waals 
interaction involving Pro1128 and Leu1250 and π-sulfur interaction involving Cys1229. Carboxylate of 
RG108-1 interacts with Gln1230 via a hydrogen bond and Lys1247 via a salt bridge. RG119-1 interacts 
with Gln1230 via the carbonyl group. 
Based on this non-covalent docking study, we propose that RG108-1 and RG119-1 
preferentially occupy the cofactor pocket and could act as inhibitors competitive to the SAM. 
This hypothesis was verified with RG108 on the murine catalytic domain of DNMT3A by 
conducting a WaterLOGSY (water-ligand observed via gradient spectroscopy) (Asgatay et al., 
2014). The same hypothesis was proposed from previous reported docking studies but with 
different binding mode as these simulations were performed without DNA duplex (Suzuki et 
al., 2010; Yoo and Medina-Franco, 2011). In these studies, the carboxylate group of RG108-1 
interacts with arginine residues normally involved in DNA binding. Interestingly, the 
maleimide moiety of each compound points into the cytosine cavity close to the catalytic 
cysteine. 
Concerning the catalytic domain of mouse DNMT3A in complex with C-terminal DNMT3L 
(PDB code: 2QRV) (Jia et al., 2007), no preferential docking pose was obtained despite a good 
conformation of the active site loop stabilized by the DNMT3L. After analysis of structural 
alignment between ternary complexes of DNMT1 and M.HhaI with DNMT3A, it appears that 
the residue Asn707 in DNMT3A possesses a different conformation (flip of 90°) compared to 
Gln1230 for DNMT1 and Gln82 for M.HhaI. In our results, this residue mediates a moderate 
hydrogen bonding with a carbonyl group of the maleimide ring. 
These non-covalent interactions could assist covalent bond formation, and we further 
performed a covalent docking simulation to investigate this complex formation. The role of 
the α,β-unsaturated ketone seems important for the formation of a Michael-type adduct with 
the sulfhydryl group of the conserved catalytic cysteine in DNMTs, as the replacement of the 
maleimide group of RG108-1 by a succinimide group conducts to an inactive compound 
(Suzuki et al., 2010). The covalent binding was then modelled using GOLD Suite software 
(v5.2.2, CCDC, Cambridge, UK) by forcing the ligand link atom to occupy the same steric 
volume as the DNMT sulfur atom. Recently, It was suggested that deprotonation of the 
catalytic cysteine residue occurs after DNA binding (Aranda et al., 2016). The unprotonated 
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cysteine facilitates the nucleophilic attack onto the 6-position of cytosine and the transition 
state is stabilized by hydrogen bond interactions with protonated Glu119 (Fig. S1). 
For M.HhaI, aromatic interactions are maintained after covalent binding and Pro80 
interacts at present with the indole ring (Fig. 5a and b) as observed for DNMT1 (Fig. 5c and 
d), but not for the Met1172 residue. However, interaction of maleimide group with Gln82 is 
lost, but the protonation state of Glu119 permits to form a moderate hydrogen bond (DA-B = 
3.2 Å) with the opposite carbonyl moiety. The same observation is made for Glu1269 of 
DNMT1 (DA-B = 2.9 Å for RG108-1 and DA-B = 2.6 Å for RG119-1) (Fig 5c and d). The carboxylate 
group of RG108-1 does not interact with any residue of M.HhaI and DNMT1 (Fig 5a and c). 
The contribution of the negative charge was recently experienced by replacing the carboxylate 
anion with a neutral isosteric moiety (Asgatay et al., 2014). Replacement of the carboxylate 
group did not change the inhibitory activity of this compound leading to reassess the role of 
this moiety for RG108 and RG108-1. Interestingly, for DNMT1, indole group of RG119-1 
maintains π-π T-shaped interaction with Phe1148 and makes an additional interaction with 
Glu1171 (as observed for M.HhaI) with a strong hydrogen bonding interaction (DA-B = 2.5 Å) 
(Fig 5d), while indole ring of RG108-1 is only surrounded by Pro1128 for DNMT1 (Fig 5c). 
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Figure 5. Covalent docking of RG108-1 and RG119-1 into bacterial M.HhaI and mouse DNMT1. 
Ligands and amino acid residues of the binding site are rendered as stick models, while the rest of the 
protein backbone is displayed as line ribbon. DNA backbone is displayed as purple tube model. 
Zebularine and 5-Fluorocytosine, removed prior to docking simulations, were added for final 
visualization. Molecular interactions are shown in dotted lines with the following color codes: green 
for conventional hydrogen bond, yellow for π-sulfur interaction, purple for π-sigma interaction, light 
pink for π-alkyl interaction and pink for π-π stacking interaction. (a and b) Details of the binding mode 
of RG108-1 (a; green; docking pose) and RG119-1 (b; purple; docking pose) to M.HhaI (orange; PDB 
code: 1M0E). RG108-1 and RG119-1 both interact with M.HhaI via hydrogen bond involving Glu119, 
van der Waals interaction involving Pro80, π-π T-shaped interaction involving Phe18 and parallel π-π 
stacking interaction involving Trp41. RG119-1 makes an additional interaction with Glu40 by hydrogen 
bonding. (c and d) Details of the binding mode of RG108-1 (c; green; docking pose) and RG119-1 (d; 
purple; docking pose) to DNMT1 (blue; PDB code: 4DA4). RG108-1 and RG119-1 both interact with 
DNMT1 via hydrogen bond involving Glu1269, and van der Waals interaction involving Pro1128. Indole 
group of RG119-1 makes additional π-π T-shaped interaction with Phe1148 and with Glu1171 by 
hydrogen bonding. 
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2.3 Conclusion 
DNA methyltransferases (DNMTs) are highly studied because of their role in epigenetic 
regulation leading to the silencing of tumor suppressor genes during oncogenesis. 
Accordingly, identification of novel non-nucleoside DNMT inhibitors acting directly on DNMTs 
without incorporation into DNA are necessary to decrease side effects of current treatments 
and increase selectivity against DNMTs for personal cancer therapy.  
In this study, we selected two maleimide derivatives of RG108 (RG108-1 and RG119-1) to 
rationalize their mode of action against DNMTs. From enzymatic assays, in vitro inhibitory 
activities of RG119-1 are slightly better than those of RG108-1 on DNMT3A and M.SssI (by a 
factor of 10), but much better against DNMT1 (IC50 value of 45 µM). Therefore, RG108-1 
seems to be selective for DNMT3A (IC50 value of 27 µM), since no activity against DNMT1 was 
observed. Interestingly, this weak activity of RG108-1 toward DNMT1 is reflected in the 
cytotoxicity on mesothelioma cells while RG119-1 demonstrates potent inhibition of cell 
proliferation. This difference in activity can be explained by the high expression of DNMT1 in 
mesothelioma cells versus other isoforms.  
The weak activity of RG108-1 towards DNMT1 is still difficult to explain, but could be 
related to the additional interactions of the carboxylate with Lys1247 (salt bridge) and 
Gln1230 (hydrogen bond) that could block RG108-1 in this conformation which does not allow 
covalent reaction with the catalytic cysteine of DNMT1. Furthermore, our non-covalent 
docking shows that the maleimide ring of RG108-1 makes no significant interactions. In 
addition, if a covalent complex is formed, the carboxylate group of RG108-1 does not interact 
with any residue of M.HhaI and DNMT1. Therefore, this moiety does not appear to participate 
in the stabilization of the covalent complex. Docking analysis suggests that RG108-1 and 
RG119-1 inhibit DNMTs activity by competition with both cytosine substrate and SAM 
cofactor. In the non-covalent docking analysis, the maleimide moiety of each inhibitor points 
into the cytosine cavity and could form a covalent bond with the catalytic cysteine. The 
covalent docking reveals a certain conservation of the non-covalent interactions after 
reaction and highlights essential residues for the stabilization of the inhibitors.  
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Crystallization trials did not allow to observe a complex of M.HhaI with RG108-1 and RG119-1 
but the presence of the inhibitors conducted to the first apo structure of M.HhaI. This reveals that 
the SAM cofactor does not affect the cofactor binding site conformation of DNMTs and that it 
is probably displaced by our inhibitors, suggesting a competitive mode of action. Covalent 
inhibitors can improve selectivity, potency and be used for biological studies. Indeed, such 
compounds are useful pharmacological tools for understanding the mechanisms of DNA 
methylation and links with other epigenetic modulations and the basis for the design of 
inhibitors of DNMTs.  
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2.4 Materials and methods 
General 
All commercially available reagents and solvents were purchased from Sigma-Aldrich, 
VWR France, radioactive [methyl-3H] SAM from Perkin-Elmer. 10 mM stock solutions of 
chemicals were prepared in DMSO and aliquoted.  
2.4.1 Chemistry 
The racemic mixture of RG108-1 was purchased from Enamine (Kiev, Ukraine). Synthesis 
of RG119-1 (1-[2-(1H-Indol-3-yl)-ethyl]-pyrrole-2,5-dione) was adapted from previous work 
(Casimir et al., 2002) and the structure was confirmed by X-ray diffraction (Dubois et al., 
2016). 
2.4.2 Enzyme production  
Full length human DNMT1 (182 kDa, histidine-tagged) was produced and purified 
according to Lee et al. (2005). Catalytic human DNMT3Acat (623-908 a.a.) was produced and 
purified according to Gros et al. (2013). The SssI methyltransferase (M.SssI) was obtained 
from New England Biolabs (France). Overexpression of M.HhaI in E. coli strain ER1727 
containing the pUHE25HhaIM plasmid (provided by Dr. S. Kumar, New England Biolabs) and 
purification were performed according to previous work (Kumar et al., 1992; Rondelet et al., 
2016). 
2.4.3 DNMT inhibition assays 
DNMT1 inhibition assay was developed and described in Gros et al. (2013), DNMT3Acat 
inhibition assay was described in Rilova et al. (2014) and M.SssI inhibition assay was described 
in Ceccaldi et al. (2011). The concentration at which 50 % of inhibition is observed (IC50) was 
determined by analysis of a concentration range of the tested compound in duplicate. The 
negative and positive controls were defined as points without enzyme and points without any 
compound, respectively. The percentages of inhibition (%I) were calculated as following: %I = 
100-100x(cpmi-cpmneg)/(cpmpos-cpmneg), where cpmi is the inhibitor signal, cpmneg the 
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negative control signal and cpmpos the positive control signal. The non-linear regression 
fittings with sigmoidal dose-response (variable slope) were performed with GraphPad Prism 
4.03 (GraphPad Software). SGI-1027 was used as a reference inhibitor (IC50DNMT3A = 0.9 µM 
and IC50DNMT1 = 10 µM) (Erdmann et al., 2015b). 
2.4.4 Differential Scanning Fluorimetry assay  
Experiments were conducted using a CFX384TM Real-Time System (C1000 Thermal cycler, 
Bio-Rad CFX Manager 2.0 Software, Bio-Rad, USA). The samples were heated at 0.5°C/s, from 
10 to 80°C. The fluorescence intensity was plotted as a function of the temperature. T1/2 was 
given by the inflection point of the fluorescence curve. ∆T1/2 were calculated by subtracting 
the T1/2 in the absence of the compound to the T1/2 in the presence of the compound in the 
same condition (i.e., in the presence of other partners DNA and/or SAM).  
The protein was scanned to assess suitability of the method and the lowest concentration 
of DNMT1 protein needed to generate a strong signal was determined to be 2.5 µM. 
Compound concentration was 200 µM. The DNA duplex used in the enzymatic assays was 
chosen and added at 5 µM. The SAM cofactor was added or not in a final concentration of 5 
µM. The Sypro orange dye (Invitrogen) was diluted to 1/400th in each sample. Each 
experiment was repeated for at least two times in duplicate. 
2.4.5 Cell viability assays  
 M14K and H28 mesothelioma cell lines were maintained in Dulbecco’s Modified Eagle 
Medium-High glucose with L-glutamine (DMEM-HG, Lonza, Westburg, Leusden, Netherlands) 
supplemented with 10% of fetal bovine serum (FBS, Gibco) and penicillin-streptomycine 10% 
(v/v) (Vandermeers et al., 2013). Cells were grown at 37 °C in a humidified atmosphere 
containing 5% CO2. Cells were seeded and incubated in 96-well plates (3.103 cells per well) for 
4 hours prior to treatment with the drugs. Drugs were suspended in DMSO and prepared to 
achieve a concentration range of 0 to 10 mM for RG108-1 and 0 to 1 mM for RG119-1. The 
final concentration of DMSO in the wells was 1% (v/v). After drugs treatment, the cells were 
maintained in culture for 72 h. Then, cell viability was determined using the CellTiter 96® 
AQueous Non-Radioactive Cell Proliferation Assay Kit (Promega). For that, 20 µL of a reagent 
mix (MTS tetrazolium/phenazine methosulfate) was added to 100 µL media per well. After 1 
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h incubation at 37°C, the absorbance of the formazan product in the 96-well plates was 
measured at a wavelength of 490 nm on a Wallac 1420 Victor2 Microplate Reader 
(PerkinElmer Life Sciences). Data are normalized to the control condition. The non-linear 
regression fittings with sigmoidal dose-response (variable slope) were performed with 
GraphPad Prism 5.0 (GraphPad Software). Experiments were repeated two times in triplicate. 
2.4.6 Crystallization and structure determination of the apoenzyme form of 
M.HhaI 
Crystallization conditions for the binary complex (M.HhaI-SAM) were previously reported 
(Kumar et al., 1992) and crystallization assays to obtain the ternary complex (M.HhaI-DNA-
Inhibitors) were based and adapted from previously published data (O'Gara et al., 1996; 
O'Gara et al., 1998). Apo crystals of M.HhaI were obtained following two different 
methodologies. In the first place, dialysis is performed at 4 °C overnight to decrease the 
concentration of endogenous SAM after the final step of purification. Co-crystallization assays 
of M.HhaI (10 mg/mL) and RG108-1 or RG119-1 were carried out with a molar ratio of 1:3 
using the hanging-drop vapor-diffusion method at room temperature. Drops consisted of 1 μL 
of mixture plus 1 μL of reservoir solution equilibrated against a reservoir volume of 700 μL. 
Crystals were grown against a reservoir solution consisting of 50 mM ammonium sulfate, 100 
mM citrate buffer at pH 6.0-6.6, and 22-32% (w/v) PEG-4000. For the second method, 
cocrystals of M.HhaI with exogenous SAM (Sigma Aldrich) obtained with a molar ratio of 1:2 
were soaked with a concentration range of 0.5-5 mM of RG108-1 or RG119-1 for 10-30 min. 
Single crystals were flash-cooled in liquid nitrogen and data sets were collected at SOLEIL 
Synchrotron, Gif-sur-Yvette, France on beamline PROXIMA 2 (PX2-A) using ADSC Q315r 
detector at a wavelength of 0.9801 Å. The select crystal diffracts up to 1.9 Å resolution and 
was used for structure determination. The data were processed using XDS/XSCALE (Kabsch, 
2010). A summary of the data-collection and refinement statistics is presented in Table 4. 
Initial phases were calculated by molecular replacement using the program PHASER in PHENIX 
(Adams et al., 2010; McCoy et al., 2007) with experimental reflection data set (Fo) and the 
search model (Fc) solved at 2.6 Å resolution (PDB code: 2HMY) (O'Gara et al., 1999). The 
complex was built using the Coot program (Emsley et al., 2010) and refined with the program 
PHENIX (Adams et al., 2010). Ramachandran plot for the final model shows 97.5% residues in 
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favoured regions, 2.2% in allowed regions and 0.3% in disallowed regions. Figures were drawn 
using both Pymol (DeLano, 2002) and Discovery Studio (BIOVIA, 2015). 
2.4.7 Molecular docking 
Ligand preparation  
Non-covalent: RG108-1 (R and S) and RG119-1 were prepared by using the “Prepare 
Ligands” tool in Discovery Studio protocols. The pH was set to 7.4 to calculate the degree of 
ionization of compounds and the other parameters were turned to “False”. A minimization 
procedure was applied to the molecules with MMFF (Merck molecular force field) force field 
(Halgren, 1996) and the conjugate gradient algorithm with a convergence criteria of 0.01 
kcal.mol-1.Å-1.  
Covalent: Based on the non-covalent docking and the identification of the bond-forming 
group, ligands were changed for covalent docking. Structure of the ligands contains the 
succinimide group and the link atom with a free valence (here the sulfur atom of cysteine) 
which was also specify for the protein. The covalent link between the succinimide group of 
ligands and the sulfur atom of the catalytic cysteine (Cys81 for M.HhaI and Cys1229 for mouse 
DNMT1) was specified in GOLD.  
Protein preparation 
 Ternary complex of mouse DNMT (DNMT1-SAH-hemimethylated CpG duplex, PDB code: 
4DA4, 2.6 Å) and ternary complex DNA of methyltransferase HhaI (M.HhaI-SAH-DNA, PDB 
code: 1M0E, 2.5 Å) were used for both non-covalent and covalent docking. Binary complex of 
human DNMT3A (DNMT3A-SAH, PDB code: 2QRV, 2.9 Å) was used for non-covalent docking. 
The binding site was defined as a sphere of 15 Å radius centered on the sulfur atom of SAH 
including both the cofactor and cytosine binding pockets. Cofactor product SAH found in all 
structures studied, 5-fluorocytosine from mouse DNMT1 (5-FC) and Zebularine from bacterial 
M.HhaI complex were extracted prior to docking simulations. DNA double-helical structure 
was kept during docking simulations. Rotamers of asparagine and glutamine residues were 
checked and corrected (e.g., Gln1230) using NQ-Flipper (Weichenberger and Sippl, 2006). 
Proteins were prepared for docking by using the “Prepare Protein” tool in Discovery Studio 
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protocols. This procedure permits to adjust the pH to 7.4, add missing hydrogens, fixe the 
missing side chains and assign atom types (corrected connectivity and bond orders) by 
applying CHARMm (Chemistry at HARvard Macromolecular mechanics) force field (version 
c36b2) (Brooks et al., 1983).  
Docking Simulations 
RG108-1 and RG119-1 were docked within the defined binding site of each protein using 
GOLD 5.3.0 docking software tool (Jones et al., 1997). Number of genetic algorithm (GA) 
iterations was changed to 100 and the top 20 docking poses were generated for every ligand. 
Final poses were scored with ChemPLP fitness function (Korb et al., 2009). In each cluster of 
20 conformations generated, conformational analysis was performed to select the most 
representative conformation with the highest score. Images were generated using Discovery 
Studio (BIOVIA, 2015). 
Data deposition 
Coordinates and diffraction data for the apo structure of M.HhaI have been deposited in the 
Protein Data Bank with accession code 5LOD. 
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"Consortium des Équipements de Calcul Intensif (CÉCI)" (http://www.ceci-hpc.be). 
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2.6 Supplementary Data 
 
 
Supplementary Figure S1: Proposed mechanism of cytosine methylation catalyzed by DNMTs based 
on M.HhaI studies (Bestor and Verdine, 1994; Goll and Bestor, 2005). The catalytic mechanism 
involves first the binding of DNMT to the target DNA. Then, the cytosine flips out of the double helix (base-
flipping) to be localized in the active site. Glu119 acts as a hydrogen donor to the N3 atom of the 
cytosine allowing the nucleophilic addition of the unprotonated Cys81 which is situated on the catalytic 
loop (I). This leads to the formation of a covalent intermediate. The 5-position of the cytosine is activated 
and then accepts the methyl group from SAM (or AdoMet) to form the 5-methyl covalent adduct and 
SAH (or AdoHcy) (II). Subsequently, the covalent complex between the DNA methyltransferase and the 
methylated cytosine is released by β-elimination (III). 
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Supplementary Figure S2: Solutions of the docking simulations of RG108-1 with M.HhaI. Zebularine, 
removed prior to docking simulations, was added for final visualization. (a) Superimposition of non-
covalent docking poses of RG108-1 (S) and RG108-1 (R) (green, pink sticks, respectively). (b) 
Superimposition of covalent docking poses of RG108-1 (S) and RG108-1 (R) (green, pink sticks, 
respectively). The carboxylate anions of both enantiomers overlap well and binding poses of the two 
enantiomers are the same. They formed same interactions with residues in the binding site for non-
covalent docking simulation.   
 
Supplementary Figure S3: Determination of the half maximal toxic concentration (TC50) of RG119-1 
and RG108-1. (a) Evaluation of the TC50 of RG119-1. H28 and M14K cells were incubated 72 h with 
the indicated concentrations of RG119-1 (n=6). Data are normalized to the control condition. RG119-1 
has a TC50 of 5.4 µM and 6.2 µM against M14K and H28, respectively. (b) Evaluation of the TC50 of 
RG108-1. H28 and M14K cells were incubated 72 h with the indicated concentrations of RG108-1 (n=6). 
Data are normalized to the control condition. RG108-1 has no marked inhibitory effect on H28 and 
M14K cells.
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
Supplementary Figure S4: Structure-based sequence alignment of DNMTs. Alignment of catalytic domain of human DNMT1 (uniprotkb:P26358), mouse DNMT1 
(uniprotkb:P13864), human DNMT3A (uniprotkb:Q9Y6K1), mouse DNMT3A (uniprotkb:O88508), bacterial M.HhaI (uniprotkb:P05102) and bacterial M.SssI 
(uniprotkb:P15840). Identical residues are indicated with a red background while similar residues are boxed in blue. Conserved motifs are underlined in green and 
numbered according to (Gowher et al., 2006). This multiple structure and sequence alignments was performed with PROMALS3D (Pei et al., 2008) and formatted 
with Espript (Gouet et al., 1999).
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Supplementary Figure S5: Conformation of M.HhaI, and by extension DNMT1, used for non-covalent 
and covalent docking simulations. Zebularine and cofactor are represented as sticks models in green. 
M.HhaI is displayed in solid ribbon: green for the large catalytic domain, red for the small regulation 
and blue for the hinge region connecting the two domains. Three-dimensional structure of catalytic 
domain of DNMTs is schematically divided into three parts: a pocket to bind the adenosyl group of 
SAM, another to bind the amino acid of SAM, and a pocket to bind the flipped out cytosine of the DNA 
double helix (Rilova et al., 2014). In the ternary complex, the catalytic loop is in a conformation allowing 
the cysteine to carry out the nucleophilic attack on cytosine. SAH and Zebularine (5-fluorocytosine for 
DNMT1) were extracted prior to docking simulations, and DNA double helical structure was kept during 
docking simulations. For docking simulation, we chose the eukaryotic mouse DNMT1 in the active form 
bound with hemimethylated CpG duplex (PDB code: 4DA4) (Song et al., 2012). Indeed, the published 
crystal structure of human DNMT1 (PDB code: 3PTA) (Song et al., 2011) bound with an unmethylated 
CpG duplex shows an autoinhibitory mechanism. In this conformation, the catalytic loop does not cover 
the active site, putting the catalytic cysteine far away from its active conformation (8 Å). This crystal 
structure does not possess the active conformation for the catalytic mechanism of DNA methylation. 
Moreover, the catalytic domain of mouse and human DNMT1 share a high sequence identity (92%, 
BLAST). For bacterial M.SssI, since no structural information is available in the PDB, we conducted 
docking studies on M.HhaI since the catalytic pocket is well conserved among the bacterial DNMTs.  
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Supplementary Figure S6: Cofactor binding site of mouse DNMT1 (a; blue; PDB code: 4DA4) (Song et 
al., 2012), human DNMT3A (b; pink; PDB code: 2QRV) (O'Gara et al., 1999) and M.HhaI (c; orange; 
PDB code: 1M0E) (Zhou et al., 2002) in complex with SAH cofactor (green). Key interactions between 
SAH cofactor and DNMTs are mediated through conserved residues. Adenine ring of the cofactor is 
stabilized in a conserved hydrophobic pocket. Trp41 in M.HhaI is replaced by Met1172 in DNMT1 and 
Val661 in DNMT3A. Hydroxyl groups of ribose form hydrogen bonds with a conserved glutamate. 
Different residues are engaged in interaction with the carboxylate group of SAH methionine.  
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Supplementary Figure S7: Mechanism of base flipping and catalytic loop closure adapted from 
Gerasimaitė et al. (2011). During the formation of the ternary complex (M.HhaI-SAM-DNA), the 
cytosine flips out of the DNA duplex and  the catalytic loop (residues 81-100) undergoes a 
conformational change (2.5 nm) to close the catalytic site (Sankpal and Rao, 2002). This active 
conformation permits the nucleophilic attack of Cys81 (red balls) at the C6 position of cytosine. 
 
 
 
Supplementary Figure S8: Docking validation of the new proposed protocol. (a) Superimposition of 
the crystal structure of M.HhaI (orange, solid ribbon) (PDB code: 1M0E) (O'Gara et al., 1999) in complex 
with the cofactor SAH (green) and the top docking solution of SAH in M.HhaI model (purple) (RMSDSAM 
crystal-SAM model of 0.89 Å). (B) Superimposition of the crystal structure of DNMT1 (blue, solid ribbon) (PDB 
code: 4DA4) (Song et al., 2012) in complex with the cofactor SAH (green) and the top docking solution 
of SAH in DNMT1 model (purple) (RMSDSAM crystal-SAM model of 1.34 Å).  
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Supplementary Figure S9: Solutions of the non-covalent docking simulations. Zebularine and 5-
Fluorocytosine, removed prior to docking simulations, were added for final visualization. (a) 
Superimposition of non-covalent docking poses of RG108-1 and RG119-1 (green, purple sticks, 
respectively) with cofactor SAH inside M.HhaI. (b) Superimposition of non-covalent docking poses of 
RG108-1 and RG119-1 (green, purple sticks, respectively) with cofactor SAH inside DNMT1. Indole ring 
of RG108-1 and RG119-1 superimposed well with adenine ring of SAH interacting with the same 
aromatic interactions. Maleimide ring is directed to the cytosine substrate pocket and is stabilized by 
the same interactions for M.HhaI and DNMT1.  
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Abstract 
DNA methylation is an important epigenetic modification involved in chromatin organization 
and gene expression. The function of DNA methylation depends on cell context and is 
correlated with histone modification patterns. In particular, trimethylation of Lys36 on 
histone H3 tail (H3K36me3) is associated with DNA methylation and elongation phase of 
transcription. PWWP domains of the de novo DNA methyltransferases DNMT3A and DNMT3B 
read this epigenetic mark to guide DNA methylation. Here we report the first crystal structure 
of the DNMT3B PWWP domain-H3K36me3 complex. Based on this structure, we propose a 
model of the DNMT3A PWWP domain-H3K36me3 complex and build a model of DNMT3A 
(PWWP-ADD-CD domains) in a nucleosomal context. The trimethylated side chain of Lys36 
(H3K36me3) is inserted into an aromatic cage similar to the “Royal” superfamily domains 
known to bind methylated histones. A key interaction between trimethylated Lys36 and a 
conserved water molecule stabilized by Ser270 explains the lack of affinity of mutated 
DNMT3B (S270P) for the H3K36me3 epigenetic mark in the ICF (Immunodeficiency, 
Centromeric instability and Facial abnormalities) syndrome. The model of the DNMT3A-
DNMT3L heterotetramer in complex with a dinucleosome highlights the mechanism for 
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recognition of nucleosome by DNMT3s and explains the periodicity of de novo DNA 
methylation. 
Keywords: DNA methylation, Methyltransferases, M.HhaI, DNMT3A, DNMT3B, PWWP, 
H3K36me3, Structure, Nucleosome 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Molecular basis of histone H3K36me3 recognition by the PWWP domain of DNMT3s | 3 
81 
 
3.1 Introduction 
DNA methylation occurs at CpG dinucleotides in mammalian cells and is catalyzed by DNA 
methyltransferases (DNMTs). DNMT3A and DNMT3B are both involved in de novo 
methylation establishing the methylation pattern in genome during embryogenesis while 
DNMT1 maintains the pattern during chromosome replication. DNA methylation is essential 
for cell differentiation and development but is also involved in pathologies like cancer (Bird, 
2002). The function of DNA methylation depends on cell context and is correlated with 
histone modification patterns (Jones, 2012). In particular, trimethylation of Lys36 on histone 
H3 tail (H3K36me3) is associated with gene body methylation in embryonic stem (ES) cells 
and elongation phase of transcription (Baubec et al., 2015; Hahn et al., 2011; Lee and 
Shilatifard, 2007). Both DNMT3A and DNMT3B PWWP domains read H3 tails containing 
H3K36me3 to guide DNA methylation (Baubec et al., 2015; Dhayalan et al., 2010). A point 
mutation in the DNMT3B PWWP domain (S270P) leads to loss of recognition with H3K36me3-
modified nucleosome (Baubec et al., 2015; Ge et al., 2004) and a decrease in DNA methylation 
at pericentromeric satellite repeat II as observed for ICF syndrome (Chen et al., 2004; Shirohzu 
et al., 2002). 
DNMT3A and DNMT3B possess a C-terminal catalytic domain (CD) and an N-terminal part 
with a regulatory function mediated by the ADD (ATRX–DNMT3–DNMT3L) domain and a 
nucleosome recognition PWWP fold. Similar to the chromodomain, MBT and Tudor domains, 
the PWWP domain is a member of the “Royal” superfamily domains which recognize 
methylated histone tails through a conserved aromatic cage (Qin and Min, 2014). The 
H3K36me3-binding ability was established for the PWWP domains of BRPF1 (Vezzoli et al., 
2010), DNMT3A (Dhayalan et al., 2010), DNMT3B (Baubec et al., 2015), PSIP1, MSH6, 
ZMYND11 + H3.3K36me3 (Qin and Min, 2014), LEDGF (Pradeepa et al., 2012), and Tudor 
domains of PHF1 and PHF19 (Ballaré et al., 2012; Musselman et al., 2012). The PWWP domain 
contains an anti-parallel β-barrel-like fold formed by five β-strands (β1–β5) (Fig. 1a), where a 
short 310 helix is found between β4 and β5 (η2), an insertion motif of different lengths 
between β2 and β3 (η1) and a C-terminal helix bundle of 1-6 α-helices (Qiu et al., 2002). 
PWWP domains of DNMT3A and DNMT3B are characterized by a short motif insertion (η1) 
and five α-helices following the β-barrel. The conserved Pro-Trp-Trp-Pro (PWWP) motif 
becomes SWWP and is found in the β2 strand. DNMT3A and DNMT3B PWWP domains would 
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synergistically bind both histone and DNA through their conserved aromatic cage for the 
recognition of H3K36me3 epigenetic mark, and a positively charged surface that interacts 
with DNA (Qin and Min, 2014; Qiu et al., 2002). Recently, DNMT3B was shown to be involved 
in the selective targeting of transcribed genes in mouse stem cells (Baubec et al., 2015). This 
association occurs through the binding of DNMT3B PWWP domain to trimethylated lysine 36 
on histone H3. 
Here we report the first crystal structure of the DNMT3B PWWP domain in complex with 
histone H3K36me3. Based on this structure, we propose a model for the DNMT3A PWWP 
domain-H3K36me3 complex and predict a structure of DNMT3A in a nucleosomal context to 
propose a mechanism of nucleosome recognition and de novo DNA methylation. 
3.2 Results and discussion 
3.2.1 Structure of the DNMT3B PWWP domain in complex with histone 
H3K36me3 
We determined the crystal structure of the DNMT3B PWWP domain in complex with the 
epigenetic mark H3K36me3 (H332–38K36me3) to gain structural insight into this recognition 
(Fig. 1a-d).  
Compared to the open form (Qiu et al., 2002), the loop between the β1 and β2 strand 
undergoes an induced fit that closes the aromatic cage in order to enhance recognition of this 
epigenetic mark (see Fig. 6 in chapter 4). The histone peptide occupies a surface groove 
formed by the β1 strand, the loop between β1 and β2, and the β4 strand (Fig. 1a and b). The 
trimethylated side chain of Lys36 is well resolved in the density map and is inserted into the 
aromatic cage formed by the three aromatic residues Phe236, Trp239 (β2 strand) and Trp263 
(β3 strand) (Fig. 1c). The trimethyl-ammonium group forms interaction with this aromatic 
cage by van der Waals and π-cation interactions with aromatic side chains of Phe236, Trp239 
and Trp263, and electrostatic–cation interaction with the carboxylate group of Asp266 
(Fig. 1d). These interactions are common to different chromatin-binding proteins in complex 
with the H3K36me3 peptide (Qin and Min, 2014). Another important common feature of 
“Royal” superfamily domains for binding preferentially H3K36me3 involves hydrophobic 
contacts surrounding the trimethylated lysine 36.  
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In our complex, Pro38 is involved in a hydrophobic contact with the side chain of Ile233 
as observed for the PHF1 Tudor domain (Cai et al., 2013; Musselman et al., 2012) and Val35 
for the PWWP domain of BRPF1 (Vezzoli et al., 2010; Wu et al., 2011). For complex between 
epigenetic marks H3K4me3, H3K9me3, and H3K27me3, and other chromatin-binding 
proteins, we observe polar contacts in this surface area (Cheng et al., 2013; Pena et al., 2006; 
Sanulli et al., 2015). Besides that, an additional key interaction involved the CO main chain 
group of trimethylated Lys36 with a conserved water molecule stabilized by the oxygen atom 
of the lateral chain of Ser270. The loss of this last strong hydrogen bond (DA–B = 2.41 Å in chain 
C and 2.59 Å in chain D) in the ICF syndrome (S270P) explains the lack of methyltransferase 
recognition and activity on nucleosomal substrates (Baubec et al., 2015; Dhayalan et al., 
2010; Shirohzu et al., 2002). The rest of the modified peptide is involved in intermolecular 
hydrogen-bonds with backbone amino and carbonyl groups: CO of Thr32 and conserved 
waters stabilized by CO of Asp266, CO of Gly34 and NH of Phe269, and NH of trimethylated 
Lys36 and CO of Phe269. The previously discussed intermolecular interactions between 
DNMT3B PWWP domain and H3K36me3 peptide are presented in Table S2. Some of these 
observed interactions can be related to previous mutational studies. Mutations among 
conserved residues of DNMT3A and DNMT3B PWWP domains were performed in the β-barrel 
(for DNMT3B: W239P240-ST; D266-A) and led to the loss of ability of both DNMT3A and DNMT3B 
to bind to H3K36me3 modified nucleosomes (Baubec et al., 2015; Chen et al., 2004; Dhayalan 
et al., 2010; Ge et al., 2004). As observed for other H3K36me3 binding domains, van der Waals 
and electrostatic interactions contribute to a specific association of DNMT3B PWWP domain 
with H3K36me3 peptide. 
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Figure 1. Structure of the DNMT3B PWWP domain in complex with H3K36me3 peptide. (a) Solid 
ribbon representation of the crystal structure of the complex between the DNMT3B PWWP domain 
and the H3K36me3 peptide. The anti-parallel β-barrel-like is colored in green, the insertion motif η1 in 
grey and the C-terminal helix bundle in blue. (b) DNMT3B PWWP domain surface colored by 
electrostatic potential of the residues (red: negatively charged area and blue: positively charged area) 
with the peptide represented in stick. (c) 2Fo-Fc electron density map contoured at 1.0 σ for the 
H3K36me3 peptide (blue mesh) with the stick representation of the residues of the aromatic cage: 
Phe236, Trp263, Asp266 and Trp239. (d) Selected intermolecular interactions of the peptide with the 
DNMT3B PWWP domain (Table S2). 
One additional observation is that the trimethylated lysine can be engaged differently as 
observed for the PHF1 and PHF19 Tudor domains (Fig. 2a). We observed a flip of 180 °C as 
these domains lack the α-helix bundle and interact with another surface of the nucleosome-
core. H3K36me3 peptide adopts the same binding mode with both DNMT3B PWWP and 
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BRPF1 (Fig. 2b) (Vezzoli et al., 2010). However, the β-β-α insertion motif of the BRPF1 
interacts with peptide residues preceding the trimethylated Lys36 compared to the DNMT3B 
PWWP exhibiting a short α-helix motif (η1 insertion motif). 
 
Figure 2. Different orientations and interactions of H3K36me3 peptide observed among the “Royal” 
superfamily. (a) Superposition of the DNMT3B PWWP domain (gray) – H3K36me3 (yellow) complex 
with the PHF1 (green) – H3K36me3 (orange) complex (Musselman et al., 2012) (PDB code: 4HCZ). The 
absence of a helix bundle for the PHF1 allows the H3K36me3 to be engaged differently than with 
DNMT3B PWWP. (b) Superposition of the DNMT3B PWWP domain (gray) – H3K36me3 (yellow) 
complex with the BRPF1 (purple) – H3K36me3 (orange) complex (Vezzoli et al., 2010) (PDB 
code: 2X4W). 
Experiments to confirm binding of the H3K36me3 peptide to the DNMT3B PWWP 
domain in vitro were attempted, so far without success. In particular, due to unanticipated 
technical problems inherent to the system under study (precipitation and non-specific 
binding), we were not able to confirm the interaction using different biophysical approaches 
(ITC, DSF, and Bio-layer interferometry). 
 
a b 
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Table 1. Data Collection and Refinement Statistics. 
 DNMT3B PWWP-H3K36me3 M.HhaI-DNA-SAH 
Data collection   
Space group P 32 2 1 (No. 154) H 3 2 (No. 155) 
Cell dimensions   
a, b, c (Å) 73.44, 73.44, 158.20 95.33, 95.33, 314.69 
,,() 90, 90, 120 90, 90, 120 
Resolution (Å) 50.0 - 2.24 (2.32  - 2.24) * 47.7-1.59 (1.65  - 1.59) * 
Rsym or Rmerge (%) 6.2 (63.3) 4.5 (69.4) 
I /I 18.50 (3.19) 24.96 (1.71) 
Completeness (%) 99.74 (99.96) 98.50 (90.27) 
Redundancy 6.9 (7.0) 6.6 (3.2) 
   
Refinement   
Resolution (Å) 36.72  - 2.24 36.55  - 1.59 
No. reflections 24436 72699 
Rwork / Rfree (%) 22.4/25.9 16.5/18.8 
No. atoms   
    Protein 1997 2606 
    Peptide/DNA 100 (peptide) 484 (DNA) 
    Ligand/ion 6 (citrate) 26 (SAH); 40 (sulfate) 
    Water 163 634 
B-factors   
    Protein 45.90 16.81 
    Peptide/DNA 52.60 (peptide) 23.20 (DNA) 
    Ligand/ion 55.14 (citrate) 27.74 (SO4) 
    Water 49.30 30.70 
R.m.s. deviations   
    Bond lengths (Å) 0.009 0.006 
    Bond angles () 1.20 1.16 
*Values in parentheses are for highest-resolution shell. 
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3.2.2 Modeling of the DNMT3A PWWP domain in complex with histone 
H3K36me3 
As we were not able to crystallize the complex between the DNMT3A PWWP domain and 
H3K36me3 peptide, we performed a protein-peptide docking based on our structural study. 
DNMT3A and DNMT3B PWWP domains are small domains of ∼150 residues very similar in 
structural organization and amino acid sequence (Fig. S1). They share 53% of identity in 
sequence and 67% of similarity using blastp.  
Based on our crystal structure (DNMT3B PWWP-H3K36me3) and the high structural 
similarity between the two domains, we decided to dock this short peptide (H332–38K36me3) 
inside the DNMT3A PWWP domain (Wu et al., 2011) (PDB code: 3LLR). We used for this the 
Rosetta FlexPepDock protocol introduced for the refinement of coarse starting structure of 
peptide-protein complex into high-resolution models (Raveh et al., 2010). The proposed 
model provides a binding mode of the H3K36me3 peptide similar to the one observed in the 
crystallographic complex with the DNMT3B PWWP domain (Fig. 3a and b). Residues 
interacting with the H3K36me3 peptide are conserved among DNMT3A and DNMT3B PWWP 
domains (Fig. 4 and Tables S1 and S3). The trimethyl-ammonium group is stabilized into the 
cage formed by Phe303, Trp306, Trp330, and Asp333 (Phe236, Trp239, Trp263 and Asp266 
for DNMT3B). The backbone of the peptide is involved in intermolecular hydrogen-bonding 
interactions with Phe336 (Phe2693B) and Ser337 (Ser2703B). A hydrophobic contact is 
observed between Pro38 and the isopropyl-group of Leu300 (Ile2333B). 
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Figure 3. Molecular modeling of interactions between the DNMT3A PWWP domain and H3K36me3 
peptide (H332–38K36me3). (a) Intermolecular interactions of the top scoring model of the DNMT3A 
PWWP domain in complex with the H3K36me3 peptide. (b) DNMT3A PWWP domain surface colored 
by electrostatic potential of the residues (red: negatively charged area and blue: positively charged 
area) with the peptide represented in stick. 
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Figure 4. Structure-based sequence alignment of homologous PWWP domains reveals conserved residues involved in nucleosomal DNA binding. This 
multiple structure and sequence alignments of homologous PWWP domains was performed with PROMALS3D (Pei et al., 2008) and formatted with Espript 
(Gouet et al., 1999). In the family of PWWP domains, a hydrophobic interface interacts with the histone tail and an adjacent more basic surface interacts with 
the negative phosphate backbone of the DNA in order to increase selectivity and affinity with the nucleosome. Residues involved in the H3K36me3 peptide 
binding:  DNA-binding residues: . For LEDGF protein, residues Lys16 (↓) and Lys73 (↓) have a large contribution to the intermolecular energy (van Nuland 
et al., 2013); they correspond to Arg301 and Lys361 in DNMT3A, and Lys234 and Lys294 in DNMT3B. 
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3.2.3 DNMT3A/3B PWWP domains in complex with the histone H3K36me3 
nucleosome core particle 
In addition to their histone tail binding abilities, PWWP domains of DNMT3A and DNMT3B 
interact non-specifically with DNA through a basic surface adjacent to the histone binding site 
(Fig. 1b) (Purdy et al., 2010; Qiu et al., 2002). Individually, different PWWP domains bind free 
DNA in the μM range and H3K36me3 peptide in the μM–mM range which is quite low (Lukasik 
et al., 2006, Qiu et al., 2002; Yu et al., 2012). However, the cooperative binding of these 
partners can increase the binding affinity up to 104-fold and enhance specificity of PWWP 
domains for H3K36me3-NCP (nucleosome core particle) (Musselman et al., 2012; Wang et al., 
2014). This seems to be a general property of PWWP modules and involves conserved 
interactions at the same interface (Eidahl et al., 2013; Qin and Min, 2014; van Nuland et al., 
2013). Indeed, multiple structure and sequence alignments of homologous PWWP domains 
(Fig. 4) show that these domains present the same aromatic cage to bind the histone tail and 
the basic surface have conserved residues to interact with the nucleosomal DNA.  
The question remains how the DNMT3A and DNMT3B PWWP domains bind the 
H3K36me3 epigenetic mark which is near the nucleosome core. To investigate this 
mechanism of recognition, we superimposed the DNMT3A and DNMT3B PWWP domains with 
the previously studied LEDGF PWWP domain (provided by Prof. Mamuka Kvaratskhelia), 
sharing high structural similarity, bound to H3K36me3-NCP (Eidahl et al., 2013). We observe 
that the basic surface is positioned on the DNA wrapped around histone core and is likely to 
interact with the phosphate backbone of DNA through the same conserved residues as those 
of LEDGF PWWP domain (Figs. 4 and 5A, B). DNMT3A and DNMT3B PWWP domains are 
situated between two DNA duplexes from where the epigenetic mark H3K36me3 emerges to 
interact with them (Figs. 5A and 6C). The selectivity of DNMT3A and DNMT3B for the 
H3K36me3-NCP is then mediated by interactions of the PWWP domain through the aromatic 
cage for H3K36me3 recognition and the basic surface which could bind two DNA duplexes of 
the nucleosome. Experiments showing this direct interaction between the PWWP domain and 
H3K36me3 nucleosomes were performed in previous studies for both DNMT3A and DNMT3B 
by GST pull-down assays (Baubec et al., 2015; Dhayalan et al., 2010). These interactions are 
  Molecular basis of histone H3K36me3 recognition by the PWWP domain of DNMT3s | 3  
 
91 
 
disrupted by different point mutations (as mentioned earlier in the description of the complex 
between the DNMT3B PWWP domain and histone H3K36me3). 
 
Figure 5. PWWP domains in complex with H3K36me3-NCP. (a) HADDOCK model of the complex 
between the LEDGF PWWP (green) domain and H3K36me3-NCP (Eidahl et al., 2013) superimposed 
with DNMT3A (orange) (RMSD of 1.9 Å) and DNMT3B (gray) (RMSD of 1.9 Å) PWWP domains. (b) 
PWWP domains surface colored by electrostatic potential of the residues (red: negatively charged area 
and blue: positively charged area). The positively charged surface is positioned between two DNA 
strands and contains the following residues for the DNMT3A PWWP domain: Lys299, Arg301, Lys343 
and Lys 361. These residues correspond to Lys232, Lys 234, Lys276, and Lys 294 in the DNMT3B PWWP 
domain. They are situated on β1, on the loop between β1 and β2, between β4 and β5 (n2), on the loop 
between α2 and α3, and on helix α3. 
3.2.4 DNMT3A (PWWP-ADD-CD domains) in a nucleosomal context 
DNA methylation functions in specific cellular and genomic contexts. For example, DNA 
methylation is dependant of a number of post-translational modifications on histones to 
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recruit and activate the de novo DNA methylation complex. DNMT3L, which lacks the PWWP 
domain and the catalytic domain, recognizes specifically the unmethylated histone H3 tail 
(H3K4me0) through the ADD domain (Table S1) (Eustermann et al., 2011; Ooi et al., 
2007; Otani et al., 2009). This protein is expressed especially in oocytes to stabilize the 
conformation of the active loop and stimulates the activity of DNMT3A and DNMT3B for the 
establishment of the genomic imprinting (Jia et al., 2007; Smallwood et al., 2011; Suetake et 
al., 2004). The epigenetic mark H3K4me0 is also bound by DNMT3A via the same ADD domain 
to allosterically activates the DNMT3A (Guo et al., 2014; Li et al., 2011; Otani et al., 2009). 
Without this recognition, the ADD domain interacts specifically with the catalytic domain and 
prevents interaction with the DNA substrate inhibiting the activity. Binding of this epigenetic 
mark H3K4me0 to the ADD domain disrupts this autoinhibitory structure and an important 
conformational change permits to the catalytic domain to recognize the DNA. The ADD 
domain of DNMT3B binds the H3K4me0 (1–19) with the same affinity as DNMT3A suggesting 
a similar mechanism (Table S1) (Zhang et al., 2010). H3K36me3 epigenetic mark, as explained 
before, is read by both DNMT3A and DNMT3B PWWP domains to recruit these enzymes on 
the nucleosomal DNA in the pericentromeric heterochromatin regions and gene bodies 
(Bachman et al., 2001; Baubec et al., 2015; Chen et al., 2004; Dhayalan et al., 2010). The 
combination of histone modifications permissive unmethylated H3K4me0 and trimethylated 
H3K36me3 seems therefore necessary for the DNMT3A and DNMT3B to access and methylate 
DNA (Stewart et al., 2015; Tomizawa et al., 2012). 
Different structural and biophysical data are available for separated domains of DNMT3s 
with individual parts of nucleosome. However, no structural information is available for the 
recognition of DNMT3s with the integral nucleosome. In this regard, we propose here a model 
of the DNMT3A (PWWP-ADD-CD) in a nucleosomal context. The crystal structure of the active 
complex of DNMT3A (ADD-CD)-DNMT3L-H3K4me0 peptide has recently been solved without 
the PWWP domain (Guo et al., 2014) (PDB code: 4U7T). Based on this structure, we predict 
the DNMT3A (PWWP-ADD-CD) structure including the missing PWWP domain by using three 
protein–protein docking servers emerging from the CAPRI experiment (Janin et al., 2003).  
This reconstructed DNMT3A structure (Fig. 6a) shows that the β-strands, β2 and β3, and 
the insertion motif η1 (α-helix motif) of the PWWP domain are positioned at the interface 
with the ADD domain (Figs. 6A and S3). The PWWP and the ADD domains are associated by 
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strong electrostatic interactions and diverse hydrogen bonds. In addition, due to the high 
structural and sequence similarity of the catalytic domain of DNMT3A and the M.HhaI, a 
bacterial DNMT we solved in complex with a short DNA duplex, we superimposed these 
domains (root-mean-square deviation of 1.2 Å). The short oligonucleotide is in the continuity 
of the nucleosomal DNA and can be connected easily to the border of the nucleosome to form 
a contiguous DNA segment (Fig. 6b and c).  
This approach yields a complete structural model of the H3K36me3-nucleosome-DNMT3A 
complex which can explain DNMT3A recruitment to a genomic site (Fig. 6c). The PWWP 
domain specifically binds the H3K36me3-NCP followed by an activation of the catalytic 
domain through the binding of the H3K4me0 with the ADD domain to methylate the nearby 
cytosine (Fig. 8a). We also introduced in this study, the DNMT3L from the active complex of 
DNMT3A (ADD-CD)-DNMT3L-H3K4me0 peptide (Guo et al., 2014) and the dimerization of 
DNMT3A through the catalytic domain (Chodavarapu et al., 2010; Jia et al., 2007; Yazdi et al., 
2015). This gives a heterotetramer (DNMT3L-DNMT3A-DNMT3A-DNMT3L) in complex with a 
dinucleosome exhibiting a bent linker DNA (Figs. 7 and 8B). The DNMT3A-DNMT3A dimer is 
responsible for methylation of DNA in a periodic pattern of ∼10-bp between two CpG sites 
corresponding to a helical turn as previously demonstrated (Jia et al., 2007; Lister et al., 
2009; Smallwood et al., 2011). Moreover, this model highlights, as described in the literature, 
that de novo DNA methylation occurs on the linker DNA region between nucleosomes and at 
the border of the nucleosome (Baubec et al., 2015; Felle et al., 2011; Morselli et al., 
2015; Takeshima et al., 2008). Indeed, DNMT3A and DNMT3B prefer to target the 
nucleosome-bound DNA through a synergetic effect to methylate the linker DNA region 
between two nucleosomes which is more accessible (Felle et al., 2011, Morselli et al., 
2015; Zhang et al., 2010). Furthermore, the nucleosomes are more regularly connected in the 
pericentromeric heterochromatin regions with a linker DNA of ∼30-bp which corresponds to 
the linker DNA size of our model (Chodavarapu et al., 2010). The four ADD domains present 
in the heterotetrameric complex (DNMT3L-DNMT3A-DNMT3A-DNMT3L) could read the 
H3K4me0 state for the DNA methylation establishment. The question may be asked whether 
DNMT3L could interact with the second copy of H3 tail of the histone octamer from adjacent 
nucleosomes. This could lead to a synergistic effect of binding proteins on nucleosome. This 
model needs further testing to answer these questions, nevertheless taken together our 
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observations emphasize the functional importance of the combination of histone tail 
modification status for the formation of a stable de novo methylation complex to methylate 
DNA in a periodic pattern. 
 
Figure 6. Construction of the complete DNMT3A (PWWP-ADD-CD domains) in a nucleosomal 
context. (a) Cartoon view of the complete reconstructed DNMT3A (PWWP-ADD-CD domains). (b) The 
bacterial M.HhaI (a DNA (cytosine-5) methyltransferase from Haemophilus haemolyticus) in complex 
with DNA and SAH (S-adenosyl-l-homocysteine). 2Fo-Fc electron density map contoured at 1.0 σ for 
short oligonucleotide (orange mesh), SAH (pink mesh) and selected residues interacting with DNA (blue 
mesh). (c) Structural model of the DNMT3A in complex with H3K36me3 nucleosome core particle.
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Figure 7. Structural model of DNMT3A (PWWP-ADD-CD domains)-DNMT3L heterotetramer in complex with H3K36me3-modified dinucleosome. Two active 
sites of distinct DNMT3A (green solid ribbon) are located on the linker DNA region between and at the border of the nucleosomes. The length of the linker DNA 
is ∼30-bp and corresponds to the average length in the pericentromeric heterochromatin regions (Chodavarapu et al., 2010). The center-to-center distance 
between the core particles is 20 nm. The model is available online: http://dx.doi.org/10.1016/j.jsb.2016.03.013  
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Figure 8. Proposed mechanism for recognition of nucleosome and DNA methylation by DNMT3A (for 
clarity, the DNMT3L was removed). (a) Sequential recognition mechanism of DNMT3A for nucleosome 
and methylation activation with H3 tail: 1-Nucleosome recognition by PWWP domain through 
interaction with methylated histone H3 tail (H3K36me3). 2- Histone H3 tail (H3K4me0) allosterically 
activates DNMT3A through binding with ADD domain. ADD domain of DNMT3A interacts with the 
catalytic domain and inhibits its activity by preventing it to interact with the DNA. (b) Periodicity in de 
novo methylation patterns of ∼10-bp between two CpG sites.  
It is still difficult to understand the difference of methylation activity between DNMT3A 
and DNMT3B. Indeed, as for DNMT3A, DNMT3B methylates the linker DNA with a periodicity 
of 10-bp and a periodicity corresponding to the nucleosome repeat length of ∼180 bp 
(nucleosomal DNA (147-bp) + linker DNA (∼30-bp)) (Baubec et al., 2015; Cokus et al., 
2008; Morselli et al., 2015). DNMT3B binding to nucleosome is also guided by the presence 
of two epigenetic marks, the H3K4me0 and the H3K36me3 peptides (Baubec et al., 
2015; Morselli et al., 2015). DNMT3A and DNMT3B act in a same nucleosome context in terms 
of organization of chromatin but methylate different regions of the genome. DNMT3B is 
however more enriched within gene bodies (Baubec et al., 2015; Jin et al., 2012). DNMT3A 
and DNMT3B are also distributed differently across the genome and this depends on the 
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cellular context (Jin et al., 2012). The mechanism of DNMT3s targeting to specific site of 
methylation throughout the genome is actually more complex and involves a series of events 
including the timing of expression (Lees-Murdock et al., 2005). The differences of recruitment 
of DNMT3s across the genome may be influenced by other specific histone tail modifications. 
Their distinct biological functions can be explained by the N-terminal sequence which shares 
very low sequence identity (10.9% using the EMBOSS needle program) between the two 
DNMT3s (Fig. S1). In our model we do not present this N-terminal part of DNMT3A (amino 
acids 1–281) as no structural information is available for neither DNMT3A nor DNMT3B. This 
N-terminal part of both DNMT3A/3B seems important for anchoring to nucleosomes (Baubec 
et al., 2015; Jeong et al., 2009). Indeed, based on multiple sequence alignments including this 
sequence, we found relate domains involved in DNA binding including the PDS5 homolog B 
protein (uniprotkb:Q6TRW4). This protein is a regulator which stabilizes cohesion complex 
association with chromatin suggesting that the N-terminal part of the DNMT3A could interact 
with DNA through its 21 arginines and 22 lysines (Fig. S1). Furthermore, this N-terminal part 
of both DNMT3A/3B could be important to mediate protein–protein interactions to 
discriminate the recruitment of these two enzymes on the nucleosomal-DNA (Geiman et al., 
2004; Li et al., 2006; Rigbolt et al., 2011; Sarraf and Stancheva, 2004; Velasco et al., 2010). 
3.3 Conclusion 
Here, we report the crystal structure of the de novo DNA methyltransferase DNMT3B PWWP 
domain in complex with the epigenetic mark H332–38K36me3. This structure emphasizes that a 
conserved water molecule mediates strong hydrogen bonding with the epigenetic mark 
explaining the loss of affinity in the ICF syndrome with the mutated DNMT3B PWWP domain 
(S270P). Based on this structure and the docked structure DNMT3A PWWP-H3K36me3, a 
structural model highlights interactions between PWWP domains of DNMT3s and a 
nucleosome core particle. PWWP domains, situated between two DNA duplexes, engage the 
same binding surface and residues to interact with the H3K36me3 nucleosome. Finally, the 
complete model structure of the DNMT3A-DNMT3L heterotetramer in complex with a 
dinucleosome provides structural information about DNA methylation on the linker DNA 
region of nucleosomes and the de novo DNA methylation patterns in agreement with the 
findings of the literature.  
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3.4 Materials and methods 
3.4.1 Cloning, expression and purification of DNMT3B PWWP domain 
The plasmid coding for the N-terminal human PWWP domain of DNMT3B was obtained 
from Addgene (plasmid 32044, C. Arrowsmith) as a bacterial stab culture. The plasmid 
containing the pET28-MHL vector codes for an N-terminal His6-tagged fusion protein with 
integrated TEV protease site. Plasmids were recovered from kanamycin-resistant colonies and 
purified following the Addgene protocol. Plasmid was sent for sequencing to Beckman Coulter 
Genomics (Hope end, Takeley CM22 6TA, Essex United Kingdom). Plasmid was transformed 
into Escherichia coli strain Rosetta™ 2 (DE3) competent cells (Novagen®). Cells were grown in 
TB medium containing 50 μg/ml kanamycin and 34 μg/ml chloramphenicol at 37 °C. When 
the OD 600 nm was about 1.5, the temperature was reduced to 18 °C and expression of 
PWWP domain was induced with 1 mM IPTG overnight. The cells were recovered by 
centrifugation at 7000 rpm for 30 min at 4 °C. The harvested cells were resuspended in ice-
cold lysis buffer (50 mM HEPES, pH 7.4, 500 mM NaCl, 2 mM β-mercaptoethanol, 5% glycerol, 
0,1% CHAPS) with protease inhibitor cocktail (Complete Mini EDTA-Free, 1 tablet for 10 mL of 
solution, Roche). Cells were lysed on ice by sonication using a cell disrupter. Crude extract 
were centrifuged at 9000 rpm for 30 min at 4 °C to recover the lysate. The supernatant was 
filtered through a 0.2 μm filter (Whatman® FP 30/0.2, GE Healthcare) and loaded onto a 5 ml 
HisTrap™ FF crude Ni-Chelating column (GE Healthcare) equilibrated with 20 mM HEPES, pH 
7.4, 500 mM NaCl, 5% glycerol, 50 mM imidazole. The charged column was washed with the 
equilibration buffer until a stable baseline was attained and the elution of PWWP domain of 
DNMT3B was performed with a linear gradient from 50 mM to 1 M imidazole over a total 
volume of 50 ml. After pooling the appropriate fractions, the solution was dialyzed overnight 
against 20 mM HEPES, pH 7.4 and 250 mM NaCl in presence of TEV protease (50 μg/mg of 
protein) to cleave the His-tag. After this, the solution was reloaded onto a 5 ml HiTrap™ IMAC 
FF Ni-Chelating column (GE Healthcare) and the column was washed with 10 column volumes 
of 20 mM HEPES, pH 7.4, 500 mM NaCl, 5% glycerol and 50 mM imidazole to elute the cleaved 
protein. Then, the protein was dialyzed against equilibration buffer (20 mM PIPES, pH 6.5). 
The sample was filtered through a 0.2 μm filter (Whatman® FP 30/0.2, GE Healthcare) and 
was loaded into an AKTA FPLC system (GE-Amersham Biosciences) with a cation exchange 
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column (1 ml, Resource™ S, GE Healthcare) to purify to homogeneity. The charged column 
was washed with the equilibration buffer until a stable baseline was attained and the elution 
of the protein was performed with a linear gradient of NaCl up to 1 M concentration over a 
total volume of 20 ml. The solution was concentrated in a stirred cell using a 5 kDa MWCO 
membrane (Vivaspin 15R; Sartorius Stedim Biotech GmbH, Göttingen, Germany) up to 
22 mg/mL prior to crystallization. All the different stages of expression and purification were 
followed by SDS–PAGE. 
3.4.2 H3K36me3 peptide production and purification 
H3K36me3 peptide (SAPATGGV{K(Me3)}KPHRYR) 28–42 was purchased from GenScript 
(Piscataway, NJ, USA) with a purity up to 95% using reverse-phase HPLC. 
3.4.3 Crystallization and structure determination of DNMT3B PWWP domain 
in complex with histone H3K36me3 
Crystallization trials were performed using the Hampton Research Crystal Screen kits 1–2 
and the sitting-drop vapor-diffusion method in 96-well plates at room temperature. Drops 
consisted of 1 μl of DNMT3B PWWP domain at 22 mg/ml – peptide mixture (1:5 M ratio) plus 
1 μl of reservoir solution equilibrated against a reservoir volume of 50 μl. Crystals of complex 
between DNMT3B PWWP domain and H3K36me3 peptide were grown against a reservoir 
consisting of 1.6 M Sodium citrate tribasic pH 6.5 (Hampton Research Crystal Screen 2 No. 
28). A single-crystal (crystal size: 0.45 mm × 0.4 mm) was cryoprotected in 20% glycerol and 
flash-cooled in liquid nitrogen. Data set was collected at SOLEIL Synchrotron, Gif-sur-Yvette, 
France on beamline PROXIMA 2 (PX2-A) using ADSC Q315 detector at a wavelength of 0.9801 
Å. The data were processed using XDS/XSCALE (Kabsch, 2010). Initial phases were calculated 
by molecular replacement using the program PHASER in PHENIX (Adams et al., 2010; McCoy 
et al., 2007) with experimental reflection data set (Fo) and the search model (Fc) DNMT3B 
PWWP domain in complex with bis–tris ligand solved at 2.0 Å resolution (Wu et al., 2011) 
(PDB code: 3QKJ). The complex was built using the Coot program (Emsley et al., 2010) and 
refined with the program PHENIX (Adams et al., 2010). Single group occupancy of the peptide 
was set to 0.5 on both monomers and refined. After refinement, occupancy of 0.8 for each 
peptide was retained and gave good agreement with B values of surrounding residues. A 
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summary of the data-collection and refinement statistics is presented in Table 1. 
Ramachandran plot for the final model shows 93.92% residues in favored regions and 6.08% 
in allowed regions. Figures were drawn using both Pymol (DeLano, 2002) and Discovery Studio 
(Visualizer, 2013). 
3.4.4 Modeling of the DNMT3A PWWP domain in complex with histone 
H3K36me3 
First, we validated the method by docking the H3K36me3 peptide into the DNMT3B 
PWWP domain (PDB code: 5CIU). For the validation procedure, the assessment of model 
quality was evaluated by the backbone RMSD (RMSBB) between the crystallographic 
structure and the peptide model. Flexpepdock retrieved the same binding mode and 
backbone positioning for eight models among the ten top scoring models, and the RMSBB of 
the best peptide model with the native peptide was 1.0 Å (<2 Å) (Fig. S2a). To model the 
H3K36me3 peptide (H332–38K36me3)-DNMT3A PWWP domain complex, we created an initial 
starting structure of the H3K36me3 peptide within the aromatic cage of DNMT3A PWWP 
domain by superposition with the DNMT3B PWWP domain–H3K36me3 structure, expecting 
the peptide to be in the correct binding site. We merged the estimated conformation for the 
H3K36me3 peptide with the DNMT3A PWWP domain receptor into an input PDB file for 
FlexPepDock refinement on the server. We also provided a Rosetta atom-pair constraints file 
to fix the trimethyl-ammonium group of Lys36 inside the aromatic cage during the simulation. 
The new structure was then refined in 600 independent FlexPepDock simulations. 300 
simulations were performed in high-resolution mode (full-atom mode) and, in order to 
increase samples of the conformational space, 300 simulations including a low-resolution pre-
optimization step (centroid-based optimization) prior to the high-resolution refinement were 
performed. After a prepacking to remove internal clashes, FlexPepDock applied a Monte Carlo 
minimization to iteratively (ten iterative cycles) optimize the rigid body orientation, the 
backbone and side chain flexibility of the peptide. During this minimization, side chain 
flexibility of protein receptor was also considered. The total 600 models were ranked based 
on the Rosetta full-atom energy score (Rohl et al., 2004). Among the ten top scoring models, 
nine were found to have the same binding mode and backbone positioning (Fig. S2b). 
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3.4.5 Construction of the DNMT3A (PWWP-ADD-CD) structure 
We selected as input structures the opened form and catalytically active structure for CD-
ADD of DNMT3A with H3K4me0 epigenetic mark (Guo et al., 2014) (PDB code: 4U7T) and the 
DNMT3A PWWP domain (Wu et al., 2011) (PDB code: 3LLR). The docking servers Cluspro 2.0 
(Comeau et al., 2004a; Comeau et al., 2004b; Kozakov et al., 2006; Kozakov et al., 2013) and 
Zdock 3.0.2 (Pierce et al., 2014) served to identify the interface interaction and the 
conformation of the complex. These servers perform both an automated rigid-body docking 
by using the fast Fourier transform correlation method and explore all the different binding 
modes by combination of translation and rotation of the ligand. Cluspro clusters the low-
energy docked conformations based on the RMSD and classify the clusters according to their 
size. Zdock uses an energy-based scoring function to evaluate each pose. For the calculations, 
known binding sites of the DNMT3A as the DNMT3L-DNMT3A (catalytic domain) interface and 
the DNA binding site of the PWWP domain were not considered. After calculations, we get 
the same conformation for the lowest scoring function value for Zdock and Cluspro and 
identified a common binding interface between the ADD domain and the PWWP domain (Fig. 
S3). Moreover, the obtained conformation was retrieved seven times among the ten top 
scoring models of Zdock. The resulting models from Zdock and Cluspro were then subjected 
to rigid-body minimization and side-chain conformation optimization using the “docking-
local-refine” on the RosettaDock server (Chaudhury et al., 2011; Lyskov and Gray, 
2008; Lyskov et al., 2013). The lowest RosettaDock binding score model (ROSETTADOCK 
binding score was −522.4 for Zdock and −534.8 for Cluspro) shown in orange in Fig. 6a was 
selected for structural analysis with the nucleosome (Figs. 6c and 7). 
3.4.6 Expression and purification of M.HhaI 
LB medium containing 100 μg/ml ampicillin was inoculated with Escherichia coli K-12 
strain ER1727 containing the pUHE25HhaI plasmid. When the OD600 nm reached 0.6, 
expression of M.HhaI was induced with 1 mM IPTG. After 3 h of induction at 37 °C, the cells 
were collected by centrifugation at 4000 rpm for 30 min at 4 °C. The cell paste was 
resuspended in ice-cold lysis buffer (10 mM Hepes (pH 7.0), 5 mM EDTA, 10% (v/v) glycerol, 
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0.1% (v/v) β-mercaptoethanol). Cells were lysed on ice by sonication using a cell disrupter. 
After centrifugation at 4000 rpm for 1 h at 4 °C, the supernatant was discarded and the pellet 
was resuspended in a high-salt buffer (10 mM Tris, 5 mM EDTA (pH 7.5), 10% (v/v) glycerol, 
0.1% (v/v) β-mercaptoethanol, 500 mM NaCl) to re-solubilize the protein. The high-salt 
suspension was centrifuged at 14000 rpm for 1 h at 4 °C, the supernatant was kept and the 
pellet undergoing the same processing with high-salt buffer. Precipitation of nucleic acids 
from the supernatant was performed by progressive addition of a half volume of protamine 
sulfate solution (10 mg/ml, solubilized in high-salt buffer). After incubation at room 
temperature for 5 min, the solution was centrifuged at 14000 rpm for 40 min at 4 °C and the 
supernatant dialyzed against 50 mM Tris (pH 6.7), 5 mM EDTA, 10% (v/v) glycerol, 0.1% (v/v) 
β-mercaptoethanol, 100 mM NaCl. All the following steps of purification were performed at 
4 °C. The sample was filtered through a 0.2 μm filter (Whatman® FP 30/0.2, GE Healthcare) 
and loaded onto a cation exchange column (1 ml, HiTrap™ SP FF, GE Healthcare). The charged 
column was washed with the equilibration buffer (50 mM Tris (pH 6.7), 5 mM EDTA, 10% (v/v) 
glycerol, 0.1% (v/v) β-mercaptoethanol, 100 mM NaCl) until a stable baseline was attained 
and the elution of the M.HhaI was realized with a linear gradient from 100 mM to 500 mM 
NaCl over a total volume of 50 ml. After pooling the appropriate fractions, the solution was 
concentrated in a stirred cell using a 10 kDa MWCO membrane (Vivaspin 15R; Sartorius 
Stedim Biotech GmbH, Göttingen, Germany) until ∼5 ml and dialyzed against 50 mM Tris (pH 
7.4), 5 mM EDTA, 10% (v/v) glycerol, 0.1% (v/v) β-mercaptoethanol, 100 mM NaCl. The 
sample was filtered through a 0.2 μm filter (Whatman® FP 30/0.2, GE Healthcare) and was 
injected into an AKTA FPLC system (GE-Amersham Biosciences) with an anion exchange 
column (1 ml, Mono-Q HR 5/5, GE Healthcare) equilibrated with 50 mM Tris (pH 7.4), 5 mM 
EDTA, 10% (v/v) glycerol, 0.1% (v/v) β-mercaptoethanol, 100 mM NaCl. The charged column 
was washed with the equilibration buffer until a stable baseline was attained. The collected 
flow-through fractions containing the purified M.HhaI were pooled and concentrated up to 
10 mg/mL concentration prior to crystallization. All the different stages of expression and 
purification were followed by SDS–PAGE. 
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3.4.7 Crystallization and structure determination of M.HhaI in complex with 
SAH and a short DNA duplex 
The crystallization conditions were based and adapted from previously published data 
(O’Gara et al., 1996; O’Gara et al., 1998). The oligonucleotides used to form the 12 bp duplex 
were purchased from Eurogentec (Seraing, Belgium). 
5′-T-C-C-A-T-G-C-G-C-T-G-A-C- -3′ 
3′- -G-G-T-A-C-G-X-G-A-C-T-G-T-5′ 
These two synthetic complementary strands of oligonucleotides were designed with a 
single 5′ thymidine (T)-overhangs at both ends and an abasic residue was incorporated with 
a dSpacer (X) at the target base pair (GC → GX). The two strands were hybridized in TE buffer 
at 90 °C for 5 min, followed by room temperature incubation for 1 h. Crystallization trials were 
performed using the hanging-drop vapor-diffusion method at room temperature with 
purified M.HhaI concentrated at 10 mg/ml, SAH (dissolved in water) and DNA with following 
molar ratio: 1:3:1.3. Drops consisted of 2 μl of M.HhaI-SAH-DNA mixture plus 2 μl of reservoir 
solution equilibrated against a reservoir volume of 700 μl. Crystals of complex between 
M.HhaI, SAH and DNA were grown against a reservoir consisting of 50 mM Citrate pH 5.6 and 
1.8 M ammonium sulfate. A single-crystal (crystal size: 0.3 mm × 0.2 mm) was cryoprotected 
in 20% glycerol and flash-cooled in liquid nitrogen. Data set was collected at SOLEIL 
Synchrotron, Gif sur Yvette, France on beamline PROXIMA 2 (PX2-A) using an ADSC Q315r 
detector at a wavelength of 0.9801 Å. The data were processed using XDS/XSCALE (Kabsch, 
2010). A summary of the data-collection and refinement statistics is presented in Table 1. 
Initial phases were calculated by molecular replacement using the program PHASER in PHENIX 
(Adams et al., 2010; McCoy et al., 2007) with experimental reflection data set (Fo) and the 
search model (Fc) solved at 2.4 Å resolution (O’Gara et al., 1998) (PDB code: 9MHT). The 
complex was built using the Coot program (Emsley et al., 2010) and refined with the program 
PHENIX (Adams et al., 2010). Ramachandran plot for the final model shows 97.85% residues 
in favored regions, 1.85% in allowed regions and 0.31% in disallowed regions. Figures were 
drawn using both Pymol (DeLano, 2002) and Discovery Studio (Visualizer, 2013). 
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Data deposition 
Coordinates and diffraction data for the structures of DNMT3B PWWP-H3K36me3 and 
M.HhaI-DNA-SAH have been deposited in the Protein Data Bank with accession codes 5CIU 
and 5CIY, respectively. 
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3.6 Supplementary Data 
Supplementary Table S1: Residues of DNMT3A and DNMT3B involved in the interaction between 
domains (CD-ADD-PWWP), DNMT3L and epigenetic marks H3K4me0 and H3K36me3. The residues 
involved in interactions, identified from the literature and in our study, are highlighted in green. These 
residues between DNMT3A and DNMT3B are highly conserved (highlight in red for identical residues 
and orange for similar residues).   
 
 DNMT3A 
residues 
DNMT3B 
residues 
DNMT3A-DNMT3L Arg729 Arg670 
(Guo et al., 2014; Jia et al., 2007) Phe732 Phe673 
 Glu733 Glu674 
 Tyr735 Tyr676 
 Arg771 Arg712 
 Glu774 Glu715 
DNMT3A-DNMT3A interface His873 His814 
(Guo et al., 2014; Jia et al., 2007) Asp876 Asp817 
 Arg885 Arg826 
DNMT3A ADD-CD active form Asp530 Asp476 
(Guo et al., 2014) Arg556 Arg503 
 Arg899 Arg846 
 Glu907 Asp854 
DNMT3A ADD-H3K4me0 Asp529 Asp475 
(Guo et al., 2014) Asp531 Asp477 
 Tyr536 Tyr482 
DNMT3B PWWP-H3K36me3 Leu300 Ile233 
(our study) Phe303 Phe236 
 Trp306 Trp236 
 Trp330 Trp239 
 Asp333 Asp266 
 Ser337 Ser270 
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Supplementary Table S2: Intermolecular interactions between DNMT3B PWWP domain and 
H3K36me3 peptide. 
 
Types Donor atom Acceptor atom 
Distance 
(Å) 
Electrostatic M3L36:NZ ASP266:OD2 4.04 
Electrostatic M3L36:NZ PHE236 (centroid) 4.28 
Electrostatic M3L36:NZ TRP239 (centroid of the pyrrole ring) 4.17 
Electrostatic M3L36:NZ TRP239 (centroid of the benzene ring) 4.30 
Electrostatic M3L36:NZ TRP263 (centroid of the pyrrole ring) 4.64 
Electrostatic M3L36:NZ TRP263 (centroid of the benzene ring) 4.98 
Hydrogen Bond W4d:O M3L36:O 2.59 
Hydrogen Bond PHE269:N GLY34:O 2.96 
Hydrogen Bond M3L36:N PHE269:O 2.99 
Hydrogen Bond W1d:O THR32:O 3.28 
Hydrogen Bond W9d:O THR32:O 2.66 
Hydrophobic PRO38 ILE233 5.12 
 
 
 
Supplementary Table S3: Intermolecular interactions between DNMT3A PWWP domain and 
H3K36me3 peptide. 
 
Types H3K36me3 DNMT3A PWWP 
Electrostatic M3L36 ASP253 
Hydrogen Bond GLY34 PHE256 
Hydrogen Bond M3L36 SER257 
Hydrogen Bond M3L36 PHE256 
Electrostatic M3L36 PHE223 
Electrostatic M3L36 TRP226 
Electrostatic M3L36 TRP250 
Hydrophobic PRO38 LEU220 
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Supplementary Figure S1: Sequence alignment of DNMT3s. Alignment of Human DNMT3A (uniprotkb:Q9Y6K1), mouse DNMT3A (uniprotkb:O88508), human 
DNMT3B (uniprotkb:Q9UBC3) and mouse DNMT3B (uniprotkb:O88509). Identical residues are indicated with a red background while similar residues are boxed 
in blue. This multiple structure and sequence alignments was performed with PROMALS3D (Pei et al., 2008) and formatted with Espript (Gouet et al., 1999). 
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Supplementary Figure S2: Modeling of H3K36me3 peptide-DNMT3A PWWP interactions. (a) 
Validation of the procedure: superposition of the native H3K36me3 peptide (yellow) in complex with 
the DNMT3B PWWP domain (PDB code: 5CIU) with the H3K36me3 peptide model (green) after 
docking. (b) Starting model (purple) and the ten top scoring models (yellow) after docking with the 
DNMT3A PWWP domain. 
  
Supplementary Figure S3: Complete reconstructed DNMT3A (PWWP-ADD-CD domains). Best 
solutions of protein-protein docking of Zdock (PWWP in red) and Cluspro (PWWP in purple).  
 
Chapter 3  
116 
 
3.7 Supplemental References 
Gouet, P., Courcelle, E., Stuart, D.I., 1999. ESPript: analysis of multiple sequence alignments 
in PostScript. Bioinformatics 15, 305-308. 
Guo, X., Wang, L., Li, J., Ding, Z., Xiao, J., Yin, X., He, S., Shi, P., Dong, L., Li, G., 2014. Structural 
insight into autoinhibition and histone H3-induced activation of DNMT3A. Nature 517, 
640-644. 
Jia, D., Jurkowska, R.Z., Zhang, X., Jeltsch, A., Cheng, X., 2007. Structure of Dnmt3a bound to 
Dnmt3L suggests a model for de novo DNA methylation. Nature 449, 248-251. 
Pei, J., Kim, B.-H., Grishin, N.V., 2008. PROMALS3D: a tool for multiple protein sequence and 
structure alignments. Nucleic acids research 36, 2295-2300. 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
CHAPTER 4 
                                   Protein-protein inhibitors of the DNMT3B PWWP-H3K36me3 complex | 4 
117 
 
Chapter 4. Targeting PWWP domain of DNA methyltransferase 3B for 
epigenetic cancer therapy: Identification and structural characterization of 
new potential protein-protein interaction inhibitors 
Grégoire Rondelet*, Thomas Dal Maso, Antonin Maniquet, Quentin Thémans, and Johan 
Wouters 
Department of Chemistry, University of Namur, 61 rue de Bruxelles, B-5000 Namur, Belgium 
*Corresponding author: gregoire.rondelet@unamur.be 
† In preparation 
Personal contribution: Participated in research design, conducted experiments (molecular 
similarity searching, docking simulations, pharmacophore generation, virtual screening, 
protein production, protein crystallization, structure determination and docking simulations), 
performed data analysis and literature search, generated figures and tables, and wrote the 
manuscript. 
Abstract 
PWWP domain of de novo DNA methyltransferase DNMT3B interacts with both DNA and the 
permissive epigenetic histone mark H3K36me3 to guide DNA methylation in intragenic 
regions. In cancer, gene body methylation mediates transcriptional activation of oncoprotein-
regulated genes and oncogenes. Therefore, DNMT3B PWWP domain represents a novel 
target for epigenetic therapy cancer. To identify protein-protein interaction inhibitors of the 
DNMT3B PWWP-H3K36me3 complex, we performed a similarity-based virtual screening 
based on the recently solved crystal structures of DNMT3B PWWP domain in complex with 
H3K36me3 and a bis-tris molecule. The top hits identified were co-crystallized with the 
DNMT3B PWWP domain in order to gain structural insight into their binding mode. 
Pharmacophore model was constructed using these complexes and a pharmacophore virtual 
screening was then performed against ZINC database. Finally, molecular docking simulations 
were carried out with new hits to identify and explore chemical diversity for development of 
protein-protein interaction inhibitors of DNMT3B PWWP domain. 
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4.1 Introduction 
Epigenetic modifications control gene regulation through modulation of the chromatin 
structure without changes in DNA sequence. For example, histone proteins can be modified 
at their tails to change nucleosomes organization state, and so the gene expression pattern.  
Another important epigenetic modification regulating gene expression is the DNA 
methylation. DNA methylation occurs on cytosine bases and is catalyzed by DNA 
methyltransferases (DNMTs). 
In cancer, promoter hypermethylation of tumor suppressor genes conducts to their 
repression preventing normal cell function and apoptosis induction, if necessary. Inhibition of 
DNMTs is promising since DNA methylation is a reversible process. For a decade, two 
nucleoside analogs of cytosine (5-azacytidine (Vidaza®) and decitabine (Dacogen®)) are used 
as therapeutic treatment for myelodysplastic syndromes and acute myeloid leukemia. They act 
by covalently trapping DNMTs at their catalytic domain (Christman, 2002; Issa and Kantarjian, 
2009; Jones and Taylor, 1980). These treatments lead to demethylation and reactivation of 
tumor suppressor genes, and, consequently, proliferation arrest and apoptosis of cancer cells 
(Goll and Bestor, 2005; Mai and Altucci, 2009). Current studies develop non-nucleoside analogs 
targeting directly the catalytic domain of DNMTs without incorporation into DNA, in contrast 
to nucleoside analogs, in order to decrease side effects (Erdmann et al., 2015). However, their 
selectivity towards DNMTs must be further improved.  
In the family of the DNA methyltransferases, DNMT3A and DNMT3B have a C-terminal 
catalytic domain and a N-terminal regulatory part containing PWWP and ADD (ATRX–DNMT3–
DNMT3L)  domains which interact with nucleosomes (Cheng and Blumenthal, 2008; Goll and 
Bestor, 2005; Hermann et al., 2004; Jeong et al., 2009). The unique recognition PWWP domain 
interacts with the extremity of histone 3 tail containing the trimethylated lysine 36 
(H3K36me3) epigenetic mark (Baubec et al., 2015; Dhayalan et al., 2010; Rondelet et al., 
2016). This result is related with the importance of PWWP domain in the methylation activity 
of DNMTs on nucleosomal DNA (Chen et al., 2004). Furthermore, the catalytic domain binds 
to CpG DNA sites and interacts with DNMT3L and other proteins to be recruited on specific 
genomic regions (Gopalakrishnan et al., 2009; Jia et al., 2007; Jurkowska et al., 2008; Ooi et 
al., 2007). Indeed, depending on cellular differentiation status, DNMT1, DNMT3A and 
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DNMT3B have different distribution across histone modification patterns (Jin et al., 2012; 
Jones, 2012).  
Recently, gene body methylation was shown to be associated with pluripotent human 
embryonic carcinoma and transcriptional activation of oncogenes as ITPKA and genes up-
regulated by the oncogenic transcription factor c-Myc (Jin et al., 2012; Yang et al., 2014; Wang 
et al., 2016). Interestingly, the permissive epigenetic mark H3K36me3 is necessary for gene 
body methylation and permits the specific recruitment of DNMT3B by association with its 
PWWP domain (Baubec et al., 2015; Jin et al., 2012; Yang et al., 2014). Therefore, DNMT3B 
PWWP domain represents a novel target for epigenetic cancer therapy. Research of small-
molecule inhibitors targeting this epigenetic complex (DNMT3B PWWP-H3K36me3) will 
downregulate oncogenic pathways and arrest cancer progression (Yang et al., 2014). 
Nowadays, number of detrimental protein-protein interactions (PPIs) have been 
identified as potential treatment targets for cancer therapy (White et al., 2008). For a while, 
research in this field has slowly emerged. Indeed, interaction regions in these systems were 
thought relatively large and represented a high challenge for the development of molecules 
inhibiting PPIs (Lyne, 2002). But since 2004, targeting PPIs in drug research for cancer therapy 
was reconsidered with the discovery of small-molecules inhibiting the p53-MDM2 (a p53 
negative regulator) interaction (Vassilev et al., 2004). In addition, a study showed that, for 
most of the PPIs, only certain residues were responsible for the binding affinity in a focus 
region, called “hot spot” (Lipinski et al., 2012). These hot spots have the size of small organic 
molecules and are defined as druggable binding sites. Identification of small molecules that 
disrupt specific PPIs is therefore important for developing anticancer agents. PPIs are 
attractive drug targets and the proof-of-concept was established in 2010 for epigenetic 
readers (e.g., PWWP domains) with BET bromodomains (Filippakopoulos et al., 2010). 
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Figure 1. Superimposition of complex structures of DNMT3B PWWP-H3K36me3 (PDB code: 5CIU) 
with DNMT3B PWWP-bis-tris (PDB code: 3QKJ). Epigenetic mark H3K36me3 and bis-tris compound 
are shown as yellow and pink stick representation, respectively. (a) Structural overview of the DNMT3B 
PWWP domain structure (solid Ribbon representation) with the superposition of H3K36me3 peptide 
and bis-tris compound. (b) Zoom on the aromatic binding site of DNMT3B PWWP domain. Bis-tris 
molecule is bound at the same position as the trimethyl-ammonium group of epigenetic mark 
H3K36me3. 
The aim of the present work is the identification and characterization of ligands for the 
PWWP regulatory domain of human DNA methyltransferase 3B. In 2011, a team solved for 
the first time the structure of the complex of DNMT3B PWWP domain with a ligand, the bis-
tris molecule, at a resolution of 2.0 Å (PDB code: 3QKJ) (Wu et al., 2011). The bis-tris binds 
into the aromatic cage of DNMT3B PWWP at the same position as the trimethyl-ammonium 
group of lysine of histone 3 (H3K36me3) (PDB code: 5CIU) (Fig. 1) (For the related result, see 
Chapter 3) (Rondelet et al., 2016). To identify novel potential PPIs, we performed a similarity-
based virtual screening using bis-tris molecule and H3K36me3 epigenetic mark as both 
chemical references. Several crystallographic complexes of DNMT3B PWWP domain with the 
best hits were obtained and used for building a pharmacophore model. This pharmacophore 
model was screened against ZINC database. Finally, new identified compounds which fit the 
pharmacophore model were subject to docking simulations in order to discover more potent 
Chapter 4 
122 
 
small orthosteric inhibitors showing chemical diversity. The flowchart for identification of new 
ligands of DNMT3B PWWP domain is shown in Figure 2. These compounds could inhibit the 
protein-protein interaction between DNMT3B PWWP domain and the H3K36me3 epigenetic 
mark.  
4.2 Results and discussion  
Structural studies of DNMT3B PWWP domain revealed a small contact surface between 
binding site and H3K36me3 epigenetic mark (see chap. 2) (Rondelet et al., 2016). The key 
residue of the peptide is the trimethylated Lys36 which is inserted into the concave aromatic 
surface formed by three aromatic residues (Phe236, Trp239 and Trp263) (Fig. 1) and forms 
van der Waals and π-cation interactions with these residues and electrostatic–cation 
interaction with the carboxylate group of Asp266. DNMT3B PWWP domain binds this short 
peptide and could therefore bind small molecules as shown for bromodomains (Cierpicki and 
Grembecka, 2015; Filippakopoulos and Knapp, 2014). The key hot spot is localized in the 
conserved aromatic cage where the bis-tris molecule and trimethyl-ammonium group of 
lysine of histone 3 (H3K36me3) are bound. To identify new potential protein-protein 
inhibitors of this epigenetic complex, we identified, firstly, lead compounds by similarity-
based virtual screening using the bis-tris compound and H3K36me3 epigenetic mark as both 
chemical references. 
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Figure 2. Overall workflow for the identification of potential protein-protein interaction inhibitors 
of DNMT3B PWWP domain.  
4.2.1 Molecular similarity searching - libraries of drug candidates 
The similar property principle (SPP) in drug discovery postulates that structurally similar 
compounds are assumed to exhibit similar physicochemical properties and/or biological 
activities (Zhang et al., 2010). In addition, molecular similarity is one of the most used 
concepts in computer-aided drug design (Goll and Bestor, 2005). There are many types of 
structural similarity search procedures presented in the literature (Gopalakrishnan et al., 
2009; Ooi et al., 2007; Otani et al., 2009), but the method of choice for computing the 
similarity between a query structure and each molecule of the database is based on the 2D 
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fingerprints. This similarity measure includes binary fingerprints for the characterization of 
the molecular structures being compared, a weighting of representation features. So, 
molecular similarity searching of the commercial Sigma-Aldrich library (~200.000 compounds) 
was carried out using 2D fingerprints and the Tanimoto coefficient (threshold = 0.6) (Fig. S1) 
to identify new compounds structurally similar to the bis-tris compound and trimethyl-
ammonium group of lysine of histone. Molecules in the database were ranked according to 
their computed similarity to both query molecules. We identified for bis-tris and trimethyl-
ammonium group, 163 and 133 hits respectively.  
4.2.2 ADMET prediction 
After identification of similar compounds using the 2D method and prior to in silico screening 
stage of these compounds into the receptor-binding site of DNMT3B PWWP domain, an 
ADME-Tox (Absorption, Distribution, Metabolism, Excretion and Toxicity) filter was applied to 
the selected library with the FAF-Drugs3 tool (Lagorce et al., 2008a). These properties are 
considered and evaluated in early stage of drug discovery process to discard compounds with 
poor ADME properties and containing toxic groups (Lyne, 2002; Selick et al., 2002). Indeed, 
compounds with inadequate properties increase development costs, prolong development 
timelines and poorly water-soluble drugs need to be administered to patients at a higher dose 
and/or intravenously (Kerns and Di, 2010).  
 This evaluation was performed based on Lipinski rule which takes into account these 
properties: the number of H-bond donors (HBD) and acceptors (HBA), the molecular weight 
(MW) and the logP (Lipinski et al., 2012). Compounds properties are evaluated to classify 
those with a lead-like or drug-like profile by applying “rule of 5” (Lipinski et al., 2012; Lyne, 
2002; Oprea et al., 2001; Teague et al., 1999). Since then, different additional rules were 
proposed by combination with the original “rule of 5” (Veber et al., 2002). In the present 
study, both Drug-Like Soft and Lead-Like Soft filters (Table S1) available in FAF-Drugs2 were 
used. The Drug-Like Soft filter was established by analyzing the descriptors values of 916 FDA 
oral drugs. The Lead-Like Soft filter thresholds were combined partially with the Drug-Like 
Soft filter and properties (e.g., molecular weight, logP, HBD and HBA) to allow addition of 
moieties in order to increase the affinity without decreasing the proper ADMET properties. 
After application of these filters, we found 83 drug-like compounds and 29 lead-like 
                                   Protein-protein inhibitors of the DNMT3B PWWP-H3K36me3 complex | 4 
125 
 
compounds similar to bis-tris molecule, and 39 drug-like compounds and 14 lead-like 
compounds similar to trimethyl-ammonium group of lysine of histone. 
4.2.3 Docking screen against DNMT3B PWWP domain 
In order to validate our molecular modeling procedure with GOLD Suite software (v5.2.2, 
CCDC, Cambridge, UK), docking of the bis-tris into the binding site of DNMT3B PWWP domain 
(PDB code: 3QKJ) was performed. Docking results show that bis-tris exhibits similar 
interactions as those observed experimentally in the crystal structure (Fig. S2). In addition, 
the crystallographic structures were aligned with the best pose prediction to predict the root-
mean-square deviation of heavy atom positions. Results was 0.98 Å RMSD for DNMT3B 
PWWP domain (3QKJ) which is much less than 2.0 Å, the usually accepted threshold for a 
docking accuracy success (Fig. S2) (Gohlke et al., 2000). We will use this method for the 
docking screening study.  
The virtual screening allowed the identification of new compounds similar to bis-tris (from 
101 to 292 MW, bis-tris 209) and trimethyl lysine group (from 101 to 442 MW). As the bis-tris 
and trimethyl lysine compounds are the starting lead-like compounds, we want to measure 
the drug-likeness of the new identified compounds, their potential to become a drug. This 
approach is dependent on the interpretation of the ranking scores. If the compounds having 
a different molecular weight are classified according to their dock scores, the selection of high 
MW compounds will be favored as the contribution of the internal energy to the total dock 
energy score dominates. Moreover, the energy score includes additionally the energy of 
interaction, sum of the van der Waals energy and electrostatic energy, between the ligand 
and the binding site, so the bigger the molecule is the more interactions it may form. In order 
to eliminate molecular size bias in the final ranking, one of the strategies of energy score 
normalization is based on the number of heavy atoms (non-hydrogen atoms) in the ligands 
(Pan et al., 2003). So, the score of the best pose for each ligand is divided by the number of 
heavy atoms, N, and leads to selected compounds with molecular weight distributions lower 
(≤ 300 daltons) than the original database with similarly good interactions. These compounds 
are potentially the best candidates selected as lead-like compounds. Indeed, this size-
normalization procedure is motivated by a search for molecules with low molecular weight 
having an enhanced absorption rate and being more suitable for structural optimization. As 
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the aim of our study is the identification of drug-like compounds, the normalization was 
performed by dividing energy score of rescoring (Table 1) for each ligand by the cube root of 
the number of non-hydrogen atoms, N1/3 (based on empirical considerations) (Oprea et al., 
2001; Pan et al., 2003). Rescoring of docked ligands has a favourable impact on the overall 
rank ordering of ligands in virtual screening. We explored the chemical space defined by 
protein-protein interaction complex of DNMT3B PWWP domain with H3K36me3 with 
screening of small analogs of both bis-tris molecule and H3K36me3 epigenetic mark (Table 1 
and Fig. 3).  
Among all the analogs, 6-dipropylamino-1-hexanol showed the best chemscore (29.87) 
and binding energy (-30.96 kcal.mol-1) values, even after normalization (Table 1). This 
approach gives multiple hits presenting a better affinity for DNMT3B PWWP domain than the 
chemical references as exhibited by the lowest binding energy of bis-tris (-14.88 kcal.mol-1). 
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Figure 3. Identified compounds after similarity-based virtual screening. bis-tris compound (pink) and 
H3K36me3 epigenetic mark (orange) defined as both chemical references (blue top box). Structure of 
analogs (orange bottom box) identified after virtual screening against DNMT3B PWWP domain. Bis-
tris and H3K36me3 epigenetic mark analogs are represented in pink and orange, respectively. 
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Table 1. Physicochemical descriptors and normalized scores of virtual screening hits. Bis-tris and H3K36me3 epigenetic mark analogs are represented in 
pink and orange, respectively.  
ID Name 
MW 
(g.mol-1) 
logP logD 
tPSA  
(Å²) 
Heavy 
Atoms  
(N) 
Solub. pH 7.4 
(mg/ml) 
Rescoring  
(ChemScore) 
ΔG 
(kcal/mol) 
Normalized Score 
(ChemScore/N 1/3) 
A 6-dipropylamino-1-hexanol 202.36 2.80 -0.42 24.67 14 22.45 29.87 -30.96 12.39 
B N1-(2-hydroxyethyl)-2-methyl-1,2-propanediamine 134.22 -1.21 -3.82 64.48 9 191.26 25.35 -25.51 12.19 
C Choline  104.17 -3.70 -4.66 20.00 7 500.00 21.76 -22.00 11.38 
D 4-(dipropylamino)butyronitrile 169.29 2.10 -0.28 28.23 12 29.40 25.45 -26.05 11.12 
E N,N-dibutyl-N'-methyl-1,3-propanediamine 202.38 2.69 -1.74 21.05 14 24.06 26.51 -27.89 11.00 
F N-isopropyl-1,5-dimethylhexylamine (Metron S) 172.33 3.62 0.49 16.61 12 10.55 24.91 -25.21 10.88 
G (+)-S,S-Ethambutol 205.32 -0.08 -2.25 69.10 14 128.51 25.83 -27.68 10.72 
H Serinol 92.12 -2.02 -3.76 68.10 6 248.77 18.53 -18.57 10.20 
I 5-[(2-Hydroxyethyl)(propyl)amino]-1-pentanol 190.30 0.86 -1.85 44.90 13 72.31 23.8 -24.38 10.12 
J Triisopropanolamine 192.28 -0.49 -2.50 65.13 13 138.59 21.81 -22.15 9.28 
K N,N-bis(2-hydroxypropyl)ethanolamine  178.25 -0.92 -2.64 65.13 12 183.76 19.57 -19.88 8.55 
L Triethanolamine 149.19 -1.11 -2.96 64.00 10 149.00 17.76 -18.22 8.24 
 Bis-tris 210.25 -3.27 -4.04 105.59 14 891.45 13.39 -14.88 5.56 
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4.2.4 Structural insights into binding of bis-tris and H3K36me3 analogs to 
DNMT3B PWWP domain 
Crystallographic complexes were obtained to gain structural insight into the binding mode of 
new identified compounds to DNTM3B PWWP domain. These complexes (Figs. 4 and 5) 
revealed the canonical anti-parallel β-barrel-like fold that we retrieved for other PWWP 
domains (Wen et al., 2014). However, the different complexes highlighted a conformational 
flexibility of the binding site and this effect is really marked compared to the apo-structure 
(PDB code: 3FLG) (Fig. 6). Upon binding of ligands, the closure of the binding site is initiated 
by conformational change of the Phe236 side-chain (displacement of the phenyl ring centroid 
of ~11 Å) accompanied by backbone rearrangements. This change reveals a flexibility of the 
loop situated between the β1 and β2 strand. Flexibility of the Phe236 is also observed when 
comparing different complexes. The complex formed with the triisopropylamine (Fig. 5j), one 
of the most crowded amine compound, showed the larger aromatic cavity with Phe236-ring 
centroid displacement of 1.65 Å compared to the 6-dipropylamino-1-hexanol complex (the 
smallest cavity) (Fig. 5a). This conformational adaptation reveals the importance to this 
induced-fit mechanism to enhance recognition of analogs. 
In all complexes, the analogs have similar binding modes to DNMT3B PWWP domain. All 
structures were refined between 1.6 and 2.6 Å and the statistics are summarised in Table S2. 
Complexes with bis-tris analogs show that these compounds mimic scaffold of H3K36me3 
epigenetic mark as exemplified by choline. This compound (Fig. 5c) engages van der Waals 
and electrostatic interactions as observed for H3K36me3 peptide and makes an additional 
hydrogen bond interaction with Asp266. Interestingly, the supplementation of choline in mice 
induced a reduction of hypermethylation in the hippocampus and prefrontal cortex after 
alcohol exposure (Otero et al., 2012) and a deficiency of choline alters brain development 
(Niculescu et al., 2006). Choline is a methyl group donor like folate, methionine, and vitamin 
B12 and its deficiency is associated with carcinoma in rats (Newberne and Rogers, 1986). 
These results show that choline impacts the epigenome depending on the cellular context 
and our solved structure may explain partially the link with the regulation of DNA methylation. 
Furthermore, we identified the FDA-approved drug ethambutol (Fig. 5g) (EMB) used in 
tritherapy (rifampicin, isoniazid, ethambutol) against Mycobacterium tuberculosis (Mtb). 
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Ethambutol inhibits arabinosyl transferase and prevents the cell-wall biosynthesis of Mtb. 
However, its anti-cancer activity has to be demonstrated. The antihistamine agent, Metron S 
(Fig. 5f), was also identified.  
 
Figure 4. Structure of the DNMT3B PWWP domain. (a) Structural overview of the DNMT3B PWWP 
domain structure with the superposition of H3K36me3 peptide (yellow) and bis-tris compound (pink). 
The PWWP domain contains an anti-parallel β-barrel-like fold (green) with a short 310 helix (gray) and 
a helix bundle of α-helices (blue). (b) Zoom on the aromatic cage of DNMT3B PWWP domain. The main 
residues involved in the interaction with bis-tris and H3K36me3 analogs (Fig. 5) are labeled and shown 
in stick representation. 
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Figure 5. Molecular binding mode of identified ligands in the binding site of DNMT3B PWWP domain. 
(A-L) Detailed view of crystallographic complexes obtained at 1.6-2.6 Å resolution. These small 
molecules bind at PPI interfaces. In the top figure, binding site of PWWP domain binding site is depicted 
as a transparent white surface and a 2Fo-Fc electron density map was contoured at 1.0 σ for each 
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ligand. The ligands are well defined in the electron density (blue mesh).  The bis-tris analogs are shown 
in pink stick model and H3K36me3 analogs in orange stick model. For the bottom figure, molecular 
interactions are shown in dotted lines with the following color codes: blue for water hydrogen bond, 
orange for π-cation interaction, green for conventional hydrogen bond, purple for π-sigma interaction, 
light pink for π-alkyl interaction and pink for π-π T-shaped interaction. DNMT3B PWWP domain is 
represented as line ribbon with interacting residues in grey stick representation.  
 
Figure 6. Superimposition of the apo structure of PWWP domain (green) and 6-dipropylamino-1-
hexanol (kaki), triisopropanolamine (pink) ligand complexes.  
4.2.5 Pharmacophore model generation and pharmacophore-based virtual 
screening 
In order to increase the chemical diversity and identify new ligands with high binding affinity 
towards DNTM3B PWWP domain, pharmacophore generation and pharmacophore-based 
search were performed. The pharmacophore model (Fig. 7b) was created with LigandScout 
(Wolber and Langer, 2005) using the solved structures of complexes with both analogs of bis-
tris and H3K36me3 peptide. Pharmacophore identified from each complex were merged into 
one model (Fig. 7a). The final model contains two positive-ionic centers, two lipophilic parts, 
four hydrogen bond acceptors and five hydrogen bond donors (Fig. 7b). The resulting 
pharmacophore model was screened against ZINC database which contains over 35 million 
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compounds. ZINCPharmer software (http://zincpharmer.csb.pitt.edu) was used for the 
pharmacophore research. The hits identified were subjected to ADME-Tox prediction using FAF-
Drugs3 (Lagorce et al., 2015) prior to docking simulations. 
 
Figure 7. Pharmacophore model generation of DNMT3B PWWP ligands. Pharmacophore sites are 
colored red for H-bond acceptors, green for H-bond donors, blue for positively ionizable groups and 
yellow for hydrophobic groups. (a) Aligned ligands from crystallographic complexes with 
pharmacophore features. (b) Pharmacophore model generation based on common chemical features. 
Excluded volumes (ligand-inaccessible) of residues forming the binding site are represented as gray 
spheres. 
4.2.6 Binding mode analysis of new hits 
 Compounds that fit the pharmacophore model (61 compounds) were further docked into 
the binding site of DNMT3B PWWP domain to gain insights into their binding mode. These 
compounds share some structural chemical similarities with small difference in physical 
properties as the logP and the solubility (Fig. 8 and Table 2). 
Table 2. Physicochemical descriptors and normalized scores of virtual screening hits. logD at pH 
7.4 were calculated for both compounds using MarvinSketch v.15.3.2 (ChemAxon Kft., 
Budapest, Hungary, www.chemaxon.com). 
ID 
Name  
(ZINC database) 
MW 
(g.mol-1) 
logP logD 
tPSA 
(Å²) 
Heavy 
Atoms 
(N) 
Solub. 
pH 7.4 
(mg/ml) 
ΔG 
(kcal/mol) 
Normalized 
Score 
(ChemScore/
N 1/3) 
A ZINC69436570 316.45 1.65 -3.29 70 23 30.36 -31.53 10.30 
B ZINC72429462 322.48 0.41 -3.03 80 23 29.78 -30.02 10.25 
C ZINC77263678 397.46 -0.68 -0.36 120 29 45.58 -33.40 10.01 
D ZINC38689942 362.37 2.10 1.17 103 27 11.46 -31.53 9.84 
E ZINC73562089 350.51 2.15 -0.68 61 25 26.08 -28.14 9.35 
F ZINC86715539 370.50 1.74 -1.77 84 27 21.01 -27.99 9.22 
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Figure 8. Identified hits obtained after pharmacophore model generation and pharmacophore-
based virtual screening. The six best ranked compounds after simulations docking are represented. 
 A detailed binding mode analysis of the three best compounds (Fig. 9) presenting novel 
chemical features is described in detail (ZINC IDs:  ZINC69436570 (2-[4-[[(3-phenyl-1H-
pyrazol-4-yl)methylamino]methyl]-1-piperidyl]ethanol), ZINC72429462 ([(2S)-1-[2-[(2-
methyl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl)amino]ethyl]-2-piperidyl]meth) 
and ZINC77263678 (N-[[(2R,3S,4R)-4-[bis(1H-imidazol-2-ylmethyl)amino]-3-hydroxy-
tetrahydrofuran-2-yl]methyl]benzamide).  
Their simulated modes of binding are quite similar as both phenyl group of ZINC69436570 
and ZINC77263678 forming T-shaped π–π interactions with all aromatic residues Phe236, 
Trp239 and Trp263 from the binding site (Fig. 9a and c). The methoxy group carried by the 
piperidyl moety of ZINC69436570 and ZINC72429462 compounds interacts by hydrogen bond 
with the carbonyl group of the backbone with an additional interaction with the Asp266 for 
ZINC69436570 compound (Fig. 9a and b). Additionally, pyrazol group of ZINC69436570 
engaged hydrogen bonding network with residues Trp263, Phe269 and Ser270. Two salt 
bridges are also observed between both positively charged amine groups and the residue 
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Asp266. This compound exhibited a binding energy of -31.53 kcal.mol-1. For the 
ZINC72429462 (Fig. 9b), the methyl 2-Pyrimidine interacts by parallel π-π stacking interaction 
with residue Trp239 and T-shaped π–π interaction with residue Phe236. The positively 
charged amine of the azepin group forms a pi-cation interaction with residue Trp263. In 
addition to the previously described interactions, ZINC77263678 (Fig. 9c) forms multiple 
hydrogen bonds with residues Trp263, Phe296 and Ser270. This compound has the lowest 
binding energy (-33.40 kcal.mol-1). In fine, these complexes form intermolecular interfaces of 
high shape complementarity.  
 
Figure 9. Binding modes of identified potential PPIs to DNMT3B PWWP domain from the 
pharmacophore-based virtual screening. a) ZINC69436570; b) ZINC72429462; c) ZINC77263678. 
Compounds are shown in green stick representation and DNMT3B PWWP domain is represented as 
line ribbon with interacting residues in grey stick representation. 
4.3 Conclusion 
The research of small drug-like molecules modulating protein-protein interactions of 
epigenetic “readers” is quite recent. Here we developed a workflow to identify new ligands 
for the DNMT3B PWWP domain. The similarity-based virtual screening approach gives 
multiple hits after virtual screening and allowed us to obtain complexes with DNMT3B PWWP 
domain. All the complexes structures led to the construction of a pharmacophore model for 
the discovery of novel and potential inhibitors by virtual screening. This conducts to the 
identification of the structural requirements for binding of ligands to DNMT3B PWWP domain 
and a first step for the development of protein-protein interaction inhibitors. The small 
molecules identified may modulate protein-protein interactions between DNMT3B PWWP 
domain and H3K36me3 epigenetic mark and downregulate expression of oncogenes (e.g., 
ITPKA) and oncoprotein-regulated genes (e.g., c-Myc). 
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4.4 Materials and methods 
4.4.1 ADMET prediction 
 The compounds were exported in standard structure-data file (SDFile; SDF) after similarity 
research with Tanimoto coefficient (threshold = 0.6) (Fig. S1). Prior to in silico screening, 
ADME-Tox (absorption, distribution, metabolism, excretion and Toxicity) properties of 
compounds identified from similarity research and the pharmacophore screening were 
predicted and studied using FAF-Drugs2 (Lagorce et al., 2008b) and FAF-Drugs3 (Free ADME-
Tox Filtering Tool) (Lagorce et al., 2015). Pre-defined filters “Drug-Like Soft” and “Lead-Like 
Soft” were used (Table S1) to select the best candidates for further evaluation as PPI 
inhibitors. 
4.4.2 Molecular docking 
Ligand preparation  
 SDF file containing chemical description of molecules was imported into Discovery Studio 
3.5 and converted into 3D representations. Ligands were prepared by using the “Prepare 
Ligands” tool in Discovery Studio protocols. The pH was set to 7.4 to calculate the degree of 
ionization of compounds and the other parameters were turned to “False”. A minimization 
procedure was applied to the molecules with MMFF (Merck molecular force field) force field 
(Halgren, 1996) and the conjugate gradient algorithm with a convergence criteria of 0.01 
kcal.mol-1.Å-1. 
Protein preparation 
 Crystallographic structure of DNMT3B PWWP domain (PDB code: 3QKJ) in complex with 
bis-tris was used. The three dimensional structure was visualized with Discovery Studio 4.0. 
(Visualizer, 2013). Conserved water molecule HOH-362 from chain A was kept in the binding 
pocket and the bis-tris ligand was extracted. In order to explore all the binding poses into 
DNMT3B PWWP domain, the binding site was defined as a sphere of 13 Å radius centered on 
the bis-tris molecule (Fig. S2). Protein was prepared for docking by using the “Prepare 
Protein” tool in Discovery Studio protocols. This procedure permits to adjust the pH to 7.4 in 
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order to generate protonation states of proper residues, add missing hydrogens, fixe the 
missing side chains and assign atom types (corrected connectivity and bond orders) by 
applying CHARMm (Chemistry at HARvard Macromolecular mechanics) force field (version 
c36b2) (Brooks et al., 1983). 
Docking Simulations 
 Number of genetic algorithm (GA) iterations was changed to 100 and 20 docking poses 
were generated for every ligand using GOLD Suite software (v5.2.2, CCDC, Cambridge, UK) 
and scored with ChemPLP (Korb et al., 2009) scoring function. ChemPLP is one of the best 
scoring functions at both pose prediction and virtual screening performance of GOLD (top 
ranked success rate = 81%). It contains the Chemscore hydrogen bonding term and different 
linear potentials to model van der Waals and repulsive terms. Rescoring of docking poses was 
performed using ChemScore scoring function. The option “receptor depth scaling” was 
checked to increase score for hydrogen bonds located deep into the binding site.  Prior to this 
stage, a local optimization was carried out to minimize the docked ligand into the binding site. 
In each cluster of twenty random conformations generated, the top ranked binding poses 
were selected for visual inspection and analysed to select the most representative 
conformation with the highest score. As a final step, normalization of docking scores 
(ChemScore) was performed by dividing energy score for each ligand by the cube root of the 
number of non-hydrogen atoms, N1/3. 
4.4.3 Overexpression and purification of human DNMT3B PWWP domain 
 Overexpression of human DNMT3B PWWP domain was done in E. coli strain Rosetta™ 2 
(DE3) competent cells (Novagen®) containing the plasmid obtained from Addgene (plasmid 
32044, C. Arrowsmith). The protein was produced and purified as previously described 
(Rondelet et al., 2016; Wu et al., 2011).  
4.4.4 Crystallization  
 Purified PWWP domain of DNMT3B was used for crystallization trials. Co-crystallization 
trials were performed using the Hampton Research Crystal Screen kits 1–2 and the sitting-
drop vapor-diffusion method in 96-well plates at room temperature. Drops consisted of 1 μl 
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of DNMT3B PWWP domain at 22 mg/ml – ligand (1:2 M ratio) plus 1 μl of reservoir solution 
equilibrated against a reservoir volume of 50 μl. Complex crystals of DNMT3B PWWP domain 
and 5-[(2-Hydroxyethyl)(propyl)amino]-1-pentanol were grown against a reservoir consisting 
of  0.1 M HEPES sodium pH 7.5, 2% v/v Polyethylene glycol 400, 2.0 M Ammonium sulfate 
(Hampton Research Crystal Screen 1 No. 39). 
 To obtain crystals for soaking, conditions were adapted from previous research (Wu et al., 
2011) using sitting drop vapour-diffusion method at room temperature. Sitting drop was 
prepared by mixing 2 μl of the protein solution (22 mg/mL) with 2 μl of the reservoir solution 
containing 0.1 M Mes (pH 5.7 to 6.7), 0.2 M Li2SO4, and 23 to 33% PEG 3350 in a 24-well plate. 
4.4.5 Crystal soaking 
 For crystal soaking trials, DNMT3B PWWP domain crystals were introduced into a 2 µl 
fresh drop of soaking solution containing 0.1 M Mes (pH 5.7 to 6.7), 0.2 M Li2SO4, 23 to 33% 
PEG 3350 and 25mM ligand for 10-30 min before being flash-cooled in liquid nitrogen. 
4.4.6 Structure determination 
 Single crystals and data sets were collected at SOLEIL Synchrotron, Gif-sur-Yvette, France 
on beamline PROXIMA 1 (PX1) and PROXIMA 2 (PX2-A) using PILATUS 6M detector at a 
wavelength of 0.97857 Å for PX1 and an ADSC Q315r detector at a wavelength of 0.9801 Å 
for PX2-A. The data were processed using XDS/XSCALE (Kabsch, 2010). A summary of the data-
collection and refinement statistics is presented in Table S2. Initial phases were calculated by 
molecular replacement using the program PHASER in PHENIX (Adams et al., 2010 and McCoy 
et al., 2007) with experimental reflection data set (Fo) and the search model (Fc) solved at 
2.0 Å resolution (PDB code: 3QKJ) (Wu et al., 2011). The complex was built using 
the Coot program (Emsley et al., 2010) and refined with the program PHENIX (Adams et al., 
2010). Figures were drawn using both Pymol (DeLano, 2002) and Discovery Studio (BIOVIA, 
2015). 
 
 
                                   Protein-protein inhibitors of the DNMT3B PWWP-H3K36me3 complex | 4 
139 
 
 
4.4.7 Generation of pharmacophore model and Pharmacophore-based virtual 
screening  
 The 3D pharmacophore model was built using LigandScout v.4.09.2 (Wolber and Langer, 
2005). Crystal structures of protein-ligand complexes solved in this study were used to 
generate different pharmacophore models. Features pharmacophore identified were merged 
into a single pharmacophore model. The pharmacophore model was used for virtual 
screening against the ZINC database using the free pharmacophore search software 
ZINCPharmer (Koes and Camacho, 2012). Some unrepresentative features (not located in the 
same spatial position) were deleted to increase identified hits. The final hits from screening 
were filtered using FAF-Drugs3. 
4.4.8 Structure-Based Virtual Screening 
 Structure-based virtual screening was carried out using compounds identified from 
pharmacophore virtual screening. As previously described, GOLD Suite software (v5.2.2, 
CCDC, Cambridge, UK) and poses were scored with ChemPLP (Korb et al., 2009) scoring 
function. Rescoring of docking poses was performed using ChemScore scoring function. The 
top ranked binding poses were selected for visual inspection and analysis to select the most 
representative conformation with the highest score. Finally, normalization of docking scores 
(ChemScore) was performed by dividing energy score for each ligand by the cube root of the 
number of non-hydrogen atoms, N1/3. 
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4.6 Supplementary Data 
  
Supplementary Figure S1: Tanimoto coefficient. (a) Intersection C between two sets (A and B) defined 
by Tanimoto coefficient (b) to measure molecular similarity. Tanimoto coefficient, also called the 
Jaccard coefficient (Otani et al., 2009) is used to determine the degree of similarity between two 
structures made of binary bits, each bit representing the absence (0) or the presence (1) from a list of 
structure fragments and/or particular features (Jurkowska et al., 2008). Consider two molecules A and 
B defined each by a 2D structure fingerprint, with C the intersection of the fingerprints sets with the 
same bits as 1, then the Tanimoto coefficient is defined by equation (b). In this equation, Na and Nb 
represent the number of present features (digit 1) in each structure A and B, and Nc represents the 
common features to fingerprints A and B. So, T quantifies the fraction of features common to A and B 
to the total number of features of A or B. The Tanimoto coefficient gives values between 0 (dissimilar) 
and 1 (similar). So the higher the Tanimoto value, the closer the target structures are to the query 
structure. A Tanimoto coefficient higher than 0.85 indicates that two molecules may have similar 
activities (Chen et al., 2004). 
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Supplementary Figure S2: PWWP domain of human DNA (cytosine-5)-methyltransferase 3B in complex 
with a bis-tris molecule. (a) Binding site defined as a sphere of 13 Å radius centered on the bis-tris 
molecule In order to explore all the binding poses into the DNMT3B PWWP domain. (b) Superimposition 
of the co-crystallized pose (pink) of bis-tris (PDB code: 3QKJ) and the top ranked pose (orange) based 
on chemPLP function score.  
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Supplementary Table S1: Physico-chemical property filters developed in FAF-Drugs3. Orally 
administered drugs should have good oral bioavailability in order to be effective. The pioneering 
research by Lipinski et al. led to the well-known "Rule of Five" for selecting drug-like molecules (Lipinski, 
2000). According to the "Rule of Five", a drug-like molecule should have no more than one of the 
following violations: No more than 5 hydrogen bond donors No more than 10 hydrogen bond acceptors 
Molecular weight no more than 500 LogP no more than 5 (Polar surface area <150 Å2). 
 
  Rule of 3   Rule of 5     Drug-Like Soft    Lead-Like Soft   
MW  ≤ 300 (≤ 500) 100 - 600 150 - 400 
logP  -3 to 3 (≤ 5) -3 to 6 -3 to 4 
HBA  ≤ 3 (≤ 10) ≤ 12 ≤ 7 
HBD ≤ 3 (≤ 5) ≤ 5 ≤ 4 
HBonds  - - - - 
tPSA (Å2) ≤ 60 - ≤ 180 ≤ 160 
Rotatable Bonds  ≤ 3 - ≤ 11 ≤ 9 
Rigid Bonds  - - ≤ 30 ≤ 30 
Rings - - ≤ 6 ≤ 4 
Max Size System Ring  - - ≤ 18 ≤ 18 
Carbons  - - 3 - 35 3 - 35 
HeteroAtoms  - - 1 - 15 1 - 15 
H/C Ratio  - - 0.1 to 1.1 0.1 to 1.1 
Charges  - - ≤ 3 ≤ 3 
Total Charge  - - -2 to 2 -2 to 2 
RO5 Violations  - 2 - - 
Stereo Centers  - - - ≤ 2 
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Supplementary Table S2: Data Collection and Refinement Statistics for the twelve ligands (Table1)-
DNMT3B PWWP complexes. 
 A B C 
Data collection    
Space group P 32 2 1 P 32 2 1 P 32 2 1 
Cell dimensions    
   a, b, c (Å) 73.55 73.55 155.30 74.68 74.68 157.58 74.27 74.27 158.2 
,,() 90 90 120 90 90 120 90 90 120 
Resolution (Å) 40.37 - 2.07 
   (2.21 - 2.07) * 
49.97 - 2.54 
(2.72 - 2.54)  
40.78 - 2.40  
(2.55 - 2.40)  
Rsym or Rmerge (%) 5.2 (65.8) 5.3 (64.3) 4.7 (89.7) 
I /I 21.37 (2.90) 23.12 (3.46) 27.78 (1.85) 
Completeness (%) 99.66 (97.19) 99.63 (99.04) 99.92 (99.20) 
Redundancy 7.3 (7.3) 9.8 (9.7) 9.3 (7.2) 
    
Refinement    
Resolution (Å) 40.17  - 2.07 
(2.15  - 2.07) 
40.77  - 2.57 
(2.66  - 2.57) 
40.78  - 2.40  
(2.49  - 2.40) 
No. reflections 30107 16831 20415 
Rwork / Rfree (%) 20.71/24.35 19.79/23.29 20.66/24.40 
No. atoms    
    Protein 2087 2104 2060 
    Ligand/ion 78 43 59 
    Water 183 45 70 
Overall B-factor 38.50 56.50 57.20 
    Ligand 36.01 63.22 58.02 
Occupancy (ligand) 0.9 0.8 0.9 
R.m.s. deviations    
    Bond lengths (Å) 0.008 0.011 0.009 
    Bond angles () 1.10 1.21 1.23 
Clashscore 7.1 7.1 8.7 
Ramachandran plot     
   Favored regions (%) 96 96 96 
   Allowed regions (%) 3.2 3.2 3.2 
   Outlier regions (%) 0.8 0.8 0.8 
 *Values in parentheses are for highest-resolution shell 
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 D E F 
Data collection    
Space group P 32 2 1 P 32 2 1 P 32 2 1 
Cell dimensions    
   a, b, c (Å) 74.26 74.26 159.1 74.61 74.61 156.51 74.63 74.63 156.67 
,,() 90 90 120 90 90 120 90 90 120 
Resolution (Å) 40.92 - 2.40 
(2.54 - 2.40) 
40.59 - 2.45 
(2.59 - 2.45) 
40.62 - 2.03 
(2.15 - 2.03) 
Rsym or Rmerge (%) 4.1 (88.6) 8.2 (65.2) 4.2 (87.1) 
I /I 29.24 (2.48) 19.64 (1.93) 26.62 (1.98) 
Completeness (%) 99.91 (99.25) 99.72 (97.14) 99.87 (98.79) 
Redundancy 9.7 (9.8) 9.7 (9.3) 9.8 (9.9) 
    
Refinement    
Resolution (Å) 40.92  - 2.40  
(2.48  - 2.40) 
40.59  - 2.45  
(2.53  - 2.45) 
40.62  - 2.03  
(2.10  - 2.03) 
No. reflections 20558 19248 33473 
Rwork / Rfree (%) 19.44/24.35 19.96/23.93 20.13/24.05 
No. atoms    
    Protein 2128 2070 2142 
    Ligand/ion 69 58 64 
    Water 73 61 104 
Overall B-factor 51.40 45.90 50.70 
    Ligand 39.83 47.93 63.12 
Occupancy (ligand) 0.9 0.8 0.9 
R.m.s. deviations    
    Bond lengths (Å) 0.009 0.008 0.008 
    Bond angles () 1.97 1.25 1.17 
Clashscore 7.7 9.1 5.8 
Ramachandran plot     
   Favored regions (%) 96 96 97 
   Allowed regions (%) 3.2 3.6 2.2 
   Outlier regions (%) 0.8 0.4 0.8 
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 G H I 
Data collection    
Space group P 32 2 1 P 32 2 1 P 32 2 1 
Cell dimensions    
   a, b, c (Å) 74.20 74.20 155.80  74.63 74.63 156.57 73.50 73.50 159.96 
,,() 90 90 120 90 90 120 90 90 120 
Resolution (Å) 40.36 - 2.30  
(2.43 - 2.30) 
40.60 - 2.71 
(2.83 - 2.71) 
49.88 - 1.70  
(1.81 - 1.70) 
Rsym or Rmerge (%) 7.8 (87.3) 9.1 (75.3) 3.4 (65.6) 
I /I 26.96 (3.65) 16.97 (3.54) 25.73 (2.28) 
Completeness (%) 99.95 (99.96) 99.79 (97.91) 99.96 (99.98) 
Redundancy 9.6 (9.4) 9.8 (10.1) 6.6 (6.5) 
    
Refinement    
Resolution (Å) 40.39  - 2.30  
(2.38  - 2.30) 
40.6  - 2.71  
(2.79  - 2.71) 
40.87  - 1.70  
(1.76  - 1.70) 
No. reflections 22766 18134 55899 
Rwork / Rfree (%) 19.61/23.79 20.06/24.73 19.35/21.32 
No. atoms    
    Protein 2104 2072 2223 
    Ligand/ion 43 52 51 
    Water 171 48 340 
Overall B-factor 35.90 38.00 41.50 
    Ligand 48.13 42.23 49.87 
Occupancy (ligand) 0.9 1.0 0.9 
R.m.s. deviations    
    Bond lengths (Å) 0.008 0.008 0.007 
    Bond angles () 1.13 1.20 1.09 
Clashscore 8.3 9.9 5.8 
Ramachandran plot    
   Favored regions (%) 95 96 97 
   Allowed regions (%) 4.2 3.2 2.3 
   Outlier regions (%) 0.8 0.8 0.7 
 
 
 
 
 
 
 
 
 
 
 
 
                                  Protein-protein inhibitors of the DNMT3B PWWP-H3K36me3 complex | 4 
 
151 
 
 J K L 
Data collection    
Space group P 32 2 1 P 32 2 1 P 32 2 1 
Cell dimensions    
   a, b, c (Å) 74.26 74.26 158.19 74.93 74.93 157.47 74.87 74.87 157.63 
,,() 90 90 120 90 90 120 90 90 120 
Resolution (Å) 40.77 - 2.27  
(2.41 - 2.27) 
40.81 - 2.30  
(2.44 - 2.30) 
40.82 - 2.50  
(2.65 - 2.50) 
Rsym or Rmerge (%) 3.5 (66.1) 5.0 (89.3) 6.0 (57.8) 
I /I 37.57 (2.80) 24.72 (1.66) 24.21 (1.85) 
Completeness (%) 99.91 (99.06) 99.49 (94.91) 99.92 (99.61) 
Redundancy 12.6 (10.9) 9.3 (7.2) 9.8 (9.9) 
    
Refinement    
Resolution (Å) 40.78  - 2.27  
(2.35  - 2.27) 
40.81  - 2.30  
(2.38  - 2.30) 
33.68  - 2.50  
(2.59  - 2.50) 
No. reflections 24069 23390 18364 
Rwork / Rfree (%) 22.68/26.81 19.51/24.77 19.59/22.80 
No. atoms    
    Protein 2102 2128 2118 
    Ligand/ion 33 49 45 
    Water 115 60 30 
Overall B-factor 55.00 60.50 63.70 
    Ligand 64.42 70.49 75.11 
Occupancy (ligand) 1.0 1.0 0.9 
R.m.s. deviations    
    Bond lengths (Å) 0.012 0.014 0.014 
    Bond angles () 1.33 1.39 1.28 
Clashscore 17.3 7.0 6.3 
Ramachandran plot    
   Favored regions (%) 92 97 96 
   Allowed regions (%) 6.4 2.2 3.6 
   Outlier regions (%) 1.6 0.8 0.4 
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General conclusions 
DNA methylation is an important epigenetic modification involved in gene expression 
regulation in normal cells. This modification occurs on cytosine residues of CpG dinucleotides 
and is catalyzed by DNA methyltransferases (DNMTs). In cancer, DNA methylation 
deregulation leads to tumorigenesis and tumor maintenance. Thereby, gene body methylation 
promotes activation of genes up-regulated by oncoproteins, and hypermethylation status of 
tumor suppressor genes promoters leads to their inactivation. As DNA methylation is a 
reversible process, epi-drugs targeting DNMTs are promising anticancer agents to reverse the 
deregulated methylome to stop cancer proliferation. To develop more specialized and 
personalized treatments for cancer, selective inhibition of DNMTs is required. Indeed, this 
methylome deregulation depends on DNMT isoforms overexpression in a cell type-specific 
manner or, inter alia, post-translational modification of histones to recruit DNMTs to 
particular genomic regions.  
The objectives of this thesis were to: i) investigate the mode of action of current non-nucleoside 
targeting the C-terminal catalytic domain of DNMTs; ii) understand mechanism of H3K36me3 
nucleosome recognition by DNMT3s; and iii) develop protein-protein interaction inhibitors of 
the PWWP DNMT3B-H3K36me3 complex to downregulate expression of oncogenes and 
oncoprotein-regulated genes.  
   In the first part, we focused our research on maleimide derivatives of RG108 (Fig. 1) 
(RG108-1 and RG119-1) as covalent inhibitors. These compounds show differences in 
selectivity and potency towards DNMTs. Enzymatic assays revealed that RG108-1 is selective 
for DNMT3A with an IC50 value of 27 µM (IC50DNMT1 value in the millimolar range). RG119-1 
exhibited better activity against both DNMT3A and DNMT1 with IC50 values of 3.1 µM and 45 
µM, respectively. This difference of activity towards DNMT1 was reflected in the cytotoxic 
assays on mesothelioma cell lines. Indeed, these cells lines overexpress preferentially DNMT1 
and RG119-1 shows a potent inhibition in the low micromolar range (TC50H28= 6.2 µM; 
TC50M14K= 5.4 µM) compared to RG108-1 (TC50 values in the millimolar range).  
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Figure 1. Chemical structures of the non-nucleoside DNA methylation inhibitor RG108 and its 
maleimide derivatives. 
In order to understand the difference of selectivity between RG108-1 and RG119-1, 
differential scanning fluorimetry assays and molecular docking were performed on DNMT1. 
The stability of DNMT1 is more pronounced in presence of DNA and RG119-1 with a thermal 
shift of ~2.8°C and, as expected, RG108-1 does not stabilize DNMT1 in any form. This ternary 
system was retained for non-covalent and covalent docking simulations into DNMT1 (Fig. 2). 
From non-covalent docking studies, indole ring of RG119-1 occupies a hydrophobic pocket 
and is involved in π-π T-shaped interactions with Phe1148 residue and π-sulfur interactions 
with Met1172 residue (Fig. 2). The maleimide ring is preferentially oriented to the substrate 
cytosine pocket containing the catalytic cysteine via a moderate hydrogen bond interaction 
with Gln1230 residue. Based on this conformation, a covalent docking was performed by 
fixing a covalent link between ligands (succinimide group group) and the catalytic cysteine. 
The indole group of RG119-1 maintains the aromatic interaction with Phe1148 and makes an 
additional strong hydrogen-bonding interaction with Glu1171 (DA-B = 2.5 Å). Another strong 
hydrogen-bonding between maleimide ring and the protonated Glu1269 (DA-B = 2.6 Å) is newly 
formed.  
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Figure 2. Binding mode of RG119-1 into mouse DNMT1. (a) Non-covalent docking of RG119-1 into 
mouse DNMT1. (b) Covalent docking of RG108-1 and RG119-1 into bacterial M.HhaI and mouse 
DNMT1. Ligands and amino acid residues of the binding site are rendered as stick models, while the 
rest of the protein backbone is displayed as line ribbon. DNA backbone is displayed as purple tube 
model. 5-Fluorocytosine, removed prior to docking simulations, was added for final visualization. 
In this same study, crystallization assays have been conducted to the crystal structure of 
the M.HhaI apoenzyme (Fig. 3). This structure reveals that the SAM cofactor does not affect the 
cofactor binding site conformation of M.HhaI and that RG119-1 is able to displace this strong 
association between the cofactor and M.HhaI suggesting a competition mechanism of RG119-1 as 
suggested by our docking results. For RG108-1, the difference of selectivity compared to RG119-
1 could arise from the fact that the maleimide ring is not stabilized inside the catalytic domain, 
and the compound is blocked by non-covalent interactions which prevent covalent reaction 
with the catalytic cysteine. Even if a covalent bond is formed, the compound seems not 
strongly stabilized inside the binding pocket.  
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Figure 3. Superposition of binary complex M.HhaI-SAM cofactor (orange) (PDB code: 2HMY) with 
the apoenzyme (blue). Amino acid residues of the binding site are rendered as stick models while rest 
of the protein backbone is displayed as line ribbon. SAM cofactor is rendered as green stick model. (a) 
Slight backbone displacement for residues Glu40, Trp41, Asp60, and Ile 61 (from 0.8 Å to 1.5 Å) and (b) 
conformational side-chain rearrangements for residues Phe18 and Trp41 when cofactor binds to 
M.HhaI.  
For a decade, efforts to discover non-nucleoside inhibitors that act directly on DNMTs is 
currently slowed by the lack of structural information of DNMTs, the low selectivity for 
DNMTs, the lack of information about their mechanism of inhibition and the low inhibitory 
activity in cells (Erdmann et al., 2015). These non-nucleoside compounds are proposed as novel 
alternative for epigenetic cancer therapy compared to the approved nucleoside analogs 
Vidaza® and Dacogen® which present a significant toxicity (Christman, 2002; Issa and 
Kantarjian, 2009; Jones and Taylor, 1980; Wijermans et al., 2008). In the present work, we 
showed that our series of compounds present IC50 in the low micromolar, a selectivity towards 
DNMTs isoform and, from crystallography and modeling, we were able in part to rationalize 
the mode of action of these compounds. However, a series of experiments has to be 
addressed to go further. In order to obtain crystal structures of complexes with these 
inhibitors, different isoforms of DNMTs can be considered. Conditions to achieve this can be 
based on the newly crystal structure of DNMT1 (Zhang et al., 2015). To investigate more 
thoroughly the mechanism of action of these compounds, determination of the different 
catalytic constant have to be addressed to determine the nature of the covalent bond. Finally, 
study of their effect on specific tumor suppressor genes reactivation has also to be addressed.  
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In the following part, we proposed a new therapeutic strategy against specific cancers based 
on the inhibition of protein-protein interactions involved during gene body methylation. This 
feature of DNA methylation mediates activation of oncogenes (e.g., ITPKA) and genes up-
regulated (e.g., c-Myc) and is related with a specific distribution of histone H3K36me3 within 
the genome in a particular cell phase. This permissive epigenetic mark, H3K36me3, recruits 
DNMT3B to gene bodies via its PWWP domain.  
Chapter 3 deals with the structural basis for recognition of the histone mark H3K36me3 
by human de novo DNA methyltransferases 3A and 3B in a nucleosomal context. For this, 
structure of DNMT3B PWWP domain in complex with the epigenetic mark H3K36me3 (H332–
38K36me3) was solved (Fig. 4a and b). This complex revealed an induced fit of the protein 
which enhances the recognition of the peptide by π-cation interactions in addition to van der 
Waals and electrostatic interactions which contribute to a specific association of DNMT3B 
PWWP domain with H3K36me3 peptide. A key strong hydrogen-bonding interaction for the 
recognition of this epigenetic mark involved the CO main chain group of trimethylated Lys36 
with a conserved water molecule stabilized by the oxygen atom of the lateral chain of Ser270. 
This is consistent with the observation that the mutation (S270P) in the ICF 
(Immunodeficiency, Centromeric instability and Facial abnormalities) syndrome conducts to 
the lack of methyltransferase recognition and activity on nucleosomal substrates. The 
proposed model of DNMT3A in complex with the H3K36me3 peptide (H332–38K36me3) 
provides a similar binding mode (Fig. 4c). 
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Figure 4. Structures of DNMT3s PWWP domain in complex with H3K36me3 peptide. (a) Solid ribbon 
representation of the crystal structure of the complex between the DNMT3B PWWP domain and the 
H3K36me3 peptide (H332–38K36me3). (b) Crystal structure of DNMT3B PWWP domain (grey stick 
representation) in complex with H3K36me3 peptide (yellow stick representation). Selected 
intermolecular interactions are represented. (c) Molecular modeling of interactions between the 
DNMT3A PWWP domain (orange stick representation) and H3K36me3 peptide (yellow stick 
representation). 
From the model generated for the DNMT3A and DNMT3B PWWP domains in complex 
with the nucleosome core (Fig. 5), we conclude that the selectivity of DNMT3A and DNMT3B 
for the H3K36me3-NCP (nucleosome core particle) is mediated by interactions of the PWWP 
domain through the aromatic cage for H3K36me3 recognition and the basic surface which 
could bind two DNA duplexes of the nucleosome. 
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Figure 5. PWWP domains in complex with H3K36me3-NCP. PWWP domains surface colored by 
electrostatic potential of the residues (red: negatively charged area and blue: positively charged area). 
The black circle represents the zone of interaction between the aromatic cage of DNMT3s PWWP 
domains and the epigenetic mark H3K36me3.  
Finally, we reconstructed the complete structure of DNMT3A (PWWP-ADD-CD domains) 
and determined the structural model of DNMT3A-DNMT3L heterotetramer in complex with 
H3K36me3-modified dinucleosome. This model provides structural information about DNA 
methylation on the linker DNA region of nucleosomes and the de novo DNA methylation 
patterns in agreement with the findings of the literature (Fig. 6). 
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Figure 6. Proposed mechanism for recognition of nucleosome and DNA methylation by DNMT3A. (a) 
Sequential recognition mechanism of DNMT3A for nucleosome and methylation activation with H3 
tail: 1-Nucleosome recognition by PWWP domain through interaction with methylated histone H3 tail 
(H3K36me3). 2-Histone H3 tail (H3K4me0) allosterically activates DNMT3A through binding with ADD 
domain. ADD domain of DNMT3A interacts with the catalytic domain and inhibits its activity by 
preventing it to interact with DNA. (b) Periodicity in de novo methylation patterns of ∼10-bp between 
two CpG sites. (The model is available online: http://dx.doi.org/10.1016/j.jsb.2016.03.013) 
One of the most difficult tasks for the future will be to understand the difference of 
methylation activity between DNMT3A and DNMT3B. Structure determination of these 
enzyme with nucleosome could answer this question. However, such crystallographic 
complexes remain challenging to obtain. In the PDB (Protein Data Bank), only two protein in 
complex with a nucleosome core particle were deposited since 2013 (PDB code: 5E5A 
(chromatin-tethering domain of Human cytomegalovirus IE1 protein) and 4LD9 (BAH domain 
of Sir3)). The model proposed in this thesis could help to set up a procedure for obtaining 
such complexes with H3K36me3-modified dinucleosome. 
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In the last chapter, we explored potent protein-protein interaction inhibitors of our previous 
solved crystal structure complex between DNMT3B PWWP domain and the tissue-specific 
cancer post-translational modification of histone 3, H3K36me3.  
Ten years ago, protein-protein interactions emerged as a new class of therapeutic targets. 
Nowadays, identification of residues responsible of the binding affinity (hot spot) in a focus 
region in protein-protein interactions have permitted to develop small-inhibitors for dozens 
of protein-protein interactions (Arkin et al., 2014). In our case, the hot spot identified in the 
aromatic cage of DNMT3B PWWP domain is a novel druggable site for the development of 
small molecules (Fig. 7). These potential inhibitors are designed in order to downregulate c-
Myc-regulated genes and oncogenes promoted by gene body methylation. For this, we 
performed first a similarity-based virtual screening using the bis-tris molecule, identified from 
a complex with DNMT3B PWWP domain (PDB code: 3QKJ), and H3K36me3 epigenetic mark 
as both chemical references. 
 
Figure 7. Superimposition of complex structures of PWWP-H3K36me3 (PDB code: 5CIU) and PWWP-
bis-tris (PDB code: 3QKJ) of DNMT3B. Bis-tris molecule (pink) is bound at the same position as the 
trimethyl-ammonium group of epigenetic mark H3K36me3. 
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Among the twenty top ranked ligands, twelve led to a crystal complex with the DNMT3B 
PWWP domain. These crystallographic complexes gave structural insight into the binding 
mode including the conformational flexibility of the binding site. Interestingly, the identified 
choline showed, in a previous study, a reduction of hypermethylation in hippocampus and 
prefrontal cortex after alcohol exposure and is possibly linked with its capacity to inhibit the 
H3K36me3-DNMT3B PWWP interactions. Furthermore, we identified the FDA-approved drug 
ethambutol used in tritherapy against Mycobacterium tuberculosis and the antihistamine 
agent Metron S. Based twelve crystallographic complexes, we constructed a pharmacophore 
model (Fig. 8) and performed a pharmacophore-based virtual screening against ZINC 
database.  
 
Figure 8. Pharmacophore model generation of DNMT3B PWWP ligands. Pharmacophore sites are 
colored red for H-bond acceptors, green for H-bond donors, blue for positively ionizable groups and 
yellow for hydrophobic groups. (a) Aligned ligands from crystallographic complexes with 
pharmacophore features. (b) Pharmacophore model generation based on common chemical features. 
Excluded volumes (ligand-inaccessible) of residues forming the binding site are represented as gray 
spheres. 
Finally, molecular docking simulations were carried out into DNMT3B PWWP domain with 
compounds (Fig. 9) that fit the pharmacophore model to gain insights into the binding mode 
to identify and explore chemical diversity for development of protein-protein interaction 
inhibitors with high binding affinity towards DNMT3B PWWP domain. These complexes show 
intermolecular interfaces of high shape complementarity. 
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Figure 9. Identified hits obtained after pharmacophore model generation and pharmacophore-
based virtual screening. The six best ranked compounds after simulations docking are represented. 
One of the direct perspectives of chapter 4 is to obtain structures of complexes between 
the newly identified hits (Fig. 9) and the DNMT3B PWWP domain to get insight in the binding 
recognition. Determination of the binding constant and thermodynamics constants 
(isothermal titration calorimetry experiments) will provide important information on the 
affinity of these compounds for DNMT3B PWWP domain. To determine if molecules are able 
to inhibit the protein-protein interaction between DNMT3B PWWP domain and H3K36me3, 
HTRF (Homogenous Time Resolved fluorescence) experiment based on FRET (Fluorescence 
Resonance Energy Transfer) technology can be set up as for the BRD4-acetylated lysine 
system (Degorce et al., 2009; Duffy et al., 2015). Nowadays, several inhibitors of 
bromodomains used in cancer and inflammation are in clinical trials, such as I-BET762 (Glaxo 
Smith-Klein), CPI-0610 (Constellation) and OTX15 (OncEthix) which are based on the JQ1 
scaffold (see chap. 1 section 7.1) (Fig. 10) (Filippakopoulos and Knapp, 2014; Arkin et al., 
2014). The same strategy to design protein-protein inhibitors of the DNMT3B PWWP-
H3K36me3 complex could lead to drugs able to downregulate oncogenes. 
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Figure 10. Small-molecule inhibitors of BRD4 bromodomain. Clinical compounds (I-BET762, 
CPI-0610 and OTX15) are shown below JQ1.  
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General Perspectives  
In addition to the direct perspectives of each chapter provided in the above concluding 
section, some perspectives are proposed here. These are based on the combinatorial readout 
of histone H3 modifications by de novo methyltransferases (DNMT3A/3B) to enhance 
inhibition of these regulators for cancer therapy.  
To be targeted to a specific genomic region in a particular cellular context, the combination 
of permissive epigenetic marks H3K4me0 and H3K36me3 are needed to activate and permit 
methylation of the genome. To understand the structural mechanism of these recognition 
events, the structure of DNMT3A ADD domain in complex with H3K4me0 and DNMT3B PWWP 
domain in complex with H3K36me3 were solved (see introduction Figs. 6 and 7).  
However, structures of the full DNMT3A and DNMT3B enzymes have still to be addressed 
and, especially in this combinatorial readout system. These structural information will be 
useful in determining conformation and molecular mechanisms underlying these events. 
Indeed, specific protein-protein inhibitors can be developed by targeting either ADD domain 
or PWWP domain. Dual inhibition therapy could, therefore, produce a significant synergistic 
inhibitory effect towards aberrant DNMT3s activity. Moreover, physiological conformation of 
DNMT3s will highlight the relative position between hotspots in ADD and PWWP domains. An 
inhibitor targeting both domains could be developed, for example, by cross linking of 
identified protein-protein inhibitors of each domain.  
Finally, small-molecule inhibitors of epigenetic regulators in combination with personal 
epigenome analysis could lead to a more efficiency and personalized cancer treatment. 
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